

## CURRICULUM VITAE

Goran Bo Gustaf Klintmalm, M.D., Ph.D., F.A.C.S.

June 2006

### EDUCATION

Karolinska Institute, Stockholm, Sweden Med. Kand (=B.Sc.)	Sep 1969-Jun 1971
Karolinska Institute, Stockholm, Sweden Doctor of Medicine	Aug 1971-Jan 1975
Karolinska Institute, Stockholm, Sweden Ph.D. Thesis: "Cyclosporine A Nephrotoxicity in human transplant patients. Clinical pharmacological and morphological findings."	Sep 1984

### POSTDOCTORAL EDUCATION

Sabbatsberg Hospital, Stockholm, Sweden Department of Anesthesiology Rotating Internship	Jun 1973-Aug 1973
Soder Hospital, Stockholm, Sweden Department of Anesthesiology Rotating Internship	Jun 1974-Aug 1974
St. Eriks Hospital, Stockholm, Sweden Department of Surgery Rotating Internship	Feb 1975-Jul 1975

St. Eriks Hospital, Stockholm, Sweden Department of Internal Medicine Rotating Internship	Aug 1975-Jan 1976
Beckomberga Hospital, Stockholm, Sweden Department of Psychiatry Rotating Internship	Feb 1976-Apr 1976
Tumba Hospital, Stockholm, Sweden General Practice Rotating Internship	May 1976-Jul 1976
Karolinska Institute, Huddinge Hospital, Stockholm, Sweden Department of Surgery, Chair: K. Frankson Residency in Surgery	Sep 1976-Aug 1979
University of Colorado, Health Science Center, Denver, Colorado Department of Surgery, Chair: T. Starzl Division of Transplantation, Chair: T. Starzl Fellowship in Transplantation Surgery	Aug 1979-Dec 1980
University of Pittsburgh, Medical School, Pittsburgh, Pennsylvania Department of Surgery, Chair: H. Bahnson Division of Transplantation, Chief: T. Starzl Fellowship in Transplantation Surgery	Jan 1981 – June 1981
Karolinska Institute, Huddinge Hospital, Stockholm, Sweden Department of Surgery, Chair: D. Hallberg Division of Transplantation, Chief: C. Groth Fellowship in Transplantation Surgery	Aug 1981-April 1983
Karolinska Institute, Huddinge Hospital, Stockholm, Sweden Department of Anesthesiology Part of Residency in Surgery	Jan 1984-Aug 1984

## LICENSURE

Pennsylvania, 1981, No. MD-039022-L

Texas, 1985, No. G7835

E.C.F.M.G., 1977, Identification No. 292-280-5 - not eligible for Board certification

American College of Surgeons, Fellow, 1991, Identification No. 3017696-4

## CURRENT POSITIONS

Director, Transplantation Services, Baylor University Medical Center, Dallas, Texas	1985-present
Chairman and Chief, Baylor Regional Transplant Institute	1995-present
Director, Dallas Liver Transplant Program, joint program at Baylor University Medical Center, Children's Medical Center of Dallas and University of Texas Southwestern Medical Center, Dallas, Texas	1995-present

## ACADEMIC APPOINTMENTS

Visiting Assistant Professor Department of Surgery, Division of Transplantation University of Pittsburgh Medical School Pittsburgh, Pennsylvania	Jun 1981-Jun 1982
Acting Associate Professor Department of Transplantation Surgery Karolinska Institute Huddinge Hospital Stockholm, Sweden	May 1983-Jan 1984
Research Sabbatical Department of Transplantation Surgery Karolinska Institute Huddinge Hospital Stockholm, Sweden	Jul 1984-Dec 1984
Visiting Associate Professor Department of Surgery, Division of Transplantation Surgery University of Pittsburgh Medical School Pittsburgh, Pennsylvania	Jan 1985 to present
Attending Staff Baylor University Medical Center Dallas, Texas	Apr 1985 to present

Courtesy Staff Department of Surgery Children's Hospital of Pittsburgh Pittsburgh, Pennsylvania	Feb 1986 to present
Associate Professor, Graduate Faculty Baylor University Institute of Biomedical Studies Waco, Texas	Jan 1990 to present
Associate Attending Staff Division of Pediatric Surgery Children's Medical Center of Dallas Dallas, Texas	1995 to present
Clinical Professor of Surgery Division of Surgery University of Texas Southwestern Medical Center Dallas, Texas	1995 to present
Sponsored Attending Staff Department of Surgery Methodist Hospitals of Dallas Dallas, Texas	1997 to 2003

**LIVER TRANSPLANT CLINICAL FELLOW TRAINEES**

Arthur Moore, MD Deceased	Mar 1985-Aug 1985
Andreas Tzakis, MD <u>Current Position:</u> Director of Liver Transplantation, Professor of Surgery University of Miami School of Medicine, Miami, Florida	Jul 1985-Aug 1985
Jose Nery, MD <u>Current Position:</u> Assistant Professor of Clinical Surgery University of Miami School of Medicine, Miami, Florida	May 1986-Dec 1987
Robert Goldstein, MD <u>Current Position:</u> Surgical Director, Transplantation Services Baylor Regional Transplant Institute, Dallas, Texas Clinical Association Professor of Surgery UTSMCD	Jul 1987-Jun 1988
Steven Poplawski, MD <u>Current Position:</u> Director of Liver Transplantation	Jul 1987-Jul 1989

Carolina Medical Center, Charlotte, North Carolina

- Joseph Cofer, MD Jul 1988-Jun 1990  
Current Position:  
University of Tennessee, Chattanooga, Tennessee
- Harvey Solomon, MD Jul 1989-Jun 1991  
Current Position: Assistant Professor of Surgery  
St. Louis University Hospital, St. Louis, Missouri
- Eytan Mor, MD Jul 1989-Jun 1991  
Current Position: Associate Professor of Surgery and Transplantation  
Chaim Sheba Medical Center, Tel-Aviv University, Tel Hashomer, Israel
- Michael Holman, MD Jul 1990-Jun 1991  
Current Position: Co-Director, Central Pennsylvania Transplant Associates, Inc.  
PinnacleHealth Hospitals at Harrisburg, Harrisburg, Pennsylvania
- John Gibbs, MD Jul 1990-Jun 1992  
Current Position: Chief, Upper GI Service  
Roswell Park Cancer Institute, Department of Surgical Oncology, Buffalo, New York
- Marlon Levy, MD Jul 1991-Jun 1992  
Current Position: Surgical Director, Transplant Surgeon  
Baylor Regional Transplant Institute, Ft. Worth, Texas  
Clinical Assistant Professor of Surgery  
UTSMCD
- Robert McMillan, MD Jul 1991-Jun 1992  
Current Position: Director of Transplantation, Assistant Professor,  
Division of Transplantation  
Louisiana State University Medical Center, Shreveport, Louisiana
- Lars Backman, MD, PhD Jul 1991-Jun 1993  
Current Position: Director of Liver Transplantation, Associate Professor of Surgery  
Sahlgrenska Hospital, University of Gothenburg, Sweden
- Dale Distant, MD Jul 1992-Jun 1993  
Current Position: Assistant Professor of Surgery and Transplant Surgeon  
State University of New York Health Science Center, Brooklyn, New York
- Tom Renard, MD Jul 1992-Jun 1993

Current Position: Pediatric Surgeon  
Dallas, Texas

Marwan Abouljoud, MD Jul 1993 - Jun 1994  
Current Position: Director of Liver Transplantation  
Henry Ford Hospital, Detroit, Michigan

David Mulligan, MD Jul 1993 - Jun 1995  
Current Position: Chair of the Division of Transplant Surgery  
Mayo Clinic Hospital, Phoenix, Arizona

Stig B. Holmberg, MD Jul 1994 - Apr 1995  
Current Position: Chief of Surgical Oncology, Department of Surgery  
Molndal Hospital, Sweden

Osman Abbasoglu, MD, PhD Jul 1995 - Jun 1997  
Current Position: Assistant Professor, School of Medicine,  
Hacettepe University, Ankara, Turkey

Rohan Jeyarajah, MD Jul 1996 - Jun 1997  
Current Position: Assistant Professor, Department of Surgery,  
University of Texas Southwestern Medical Center at Dallas

Giuliano Testa, MD Jul 1996 - Jun 1998  
Current Position: Allgemein Chirurgie und Transplantation  
Universita Tsklinikum

Samuel Obiekwe, MD Jul 1997 - Jun 1998  
Current Position: Fellow in Biliary Surgery,  
Memorial Sloan-Kettering Cancer Center, New York City, New York

Ghapjoong Jung, MD Aug 1998 - Jul 2000  
Current Position: Chairman, Department of General Surgery,  
Dong-A University Hospital, Pusan, South Korea

Shigeru Marubashi, MD Apr 1999 - Mar 2001  
Current Position: Student, Department of Surgery 2,  
Osaka University Graduate School of Medicine, Osaka, Japan

Edmund Sanchez, MD Jul 1999 - Jun 2001  
Current Position: Transplant Surgeon  
Baylor Regional Transplant Institute, Dallas, Texas

Brian Gogel, MD Jul 2000 - Jun 2001  
Current Position: General Surgeon

Medical City Dallas Hospital, Dallas, Texas

Nicholas Onaca, MD Jul 2001 – Dec 2002  
Current Position: Transplant Surgeon  
Chaim Sheba Medical Center, Tel-Aviv University, Tel Hashomer, Israel

Mark Thomas, MD Jul 2001 – Jun 2003  
Current Position: Transplant Surgeon  
University of Cincinnati, Cincinnati, Ohio

Vandad Raofi, MD Jul 2002 – Jul 2003  
Current Position: Unknown  
Atlanta, Georgia

Takehisa Ueno, MD Jul 2002 – Jul 2004  
Current Position: Unknown  
University of Miami School of Medicine, Miami, Florida

Patrick Martin, MD Feb 2003 – Feb 2005  
Current Position: Transplant Surgeon  
Leipzig, Germany

Toru Ikegami, MD Jan 2004 – Jan 2006  
Current Position: Transplant Surgeon  
Japan

Current Fellows

Tadahiro Uemura, MD Jul 2004 – Present  
Gomathy Narasimhan, MD Jul 2004 – Present

## HOSPITAL MEDICAL COMMITTEES

Surgical Advisory Committee Baylor University Medical Center	1988 to present
Cancer Center Executive Committee Baylor University Medical Center	1990 to present
Member of Board of Directors Baylor Health Care Services Foundation Baylor University Medical Center	1991 to present
Transplant Review Committee Baylor University Medical Center	1991 to present
Medical Board Baylor University Medical Center	1992 to present
Data Management Committee Baylor University Medical Center	1992 to present
Board of Directors of Baylor Research Institute Baylor University Medical Center	1997 to present
Administrative and Steering Committee Baylor Liver and Pancreas Disease Center Baylor University Medical Center	1998 to present

## NATIONAL MEDICAL COMMITTEES

Member UNOS Liver Subcommittee	1991-1993
Member UNOS Membership and Professional Standards Committee	1992 to 1994
Member Education Committee American Society of Transplant Surgeons	1991 to 1994
Member Local Arrangements Committee American Society of Transplant Surgeons	1994 to 1995



Member FK506 Publications Committee	1992 to 1995
Councillor UNOS Region 4	1994 to 1996
Member UNOS Board of Directors	1994 to 1996
Member UNOS Regional Review Board for Region 4	1997 to present
Member National Association of Medical Examiners ASTS Government and Scientific Liaison Committee	1997 to present
Member Medical Advisory Committee of the Southwest Transplant Alliance	1997 to present
Member ASA Membership Committee American Surgical Association	1997 to present
Member Board of Directors of the Southwest Transplant Alliance	1998 to 2006
Member Medical Advisory Committee Blood Care Dallas, Texas	1992 to present
Member Travelers Insurance Company Solid Organ Transplant Physician Panel	1992 to present
Member Medical Advisory Committee National Kidney Foundation	1994 to present
Member Advisory Membership Committee American Medical Association	1996-2000

Spokesperson American Association for the Study of liver Diseases	1999
Member-At-Large Executive Council American Hepato-Pancreato-Biliary Association	1999-2001
Member Ad Hoc Committee on Public Policy American Society of Transplant Surgeons	1998
Expert Panelist Panel to Study Organ Procurement and Transplantation Network Policies and Final Rule American Society of Transplant Surgeons	1998
Member Advisory Committee on Issues American Society of Transplant Surgeons	1999
Member Subcommittee on Liver Allocation American Society of Transplant Surgeons	2000
Member UNOS Medical Examiner and Coroner Task Force United Network for Organ Sharing	1999 to present
Member ASTS Executive Council American Society of Transplant Surgeons	1999 to present
Member Compensation Committee Southwest Transplant Alliance	1999 to present
Member ASTS Nominations Committee American Society of Transplant Surgeons	2001-2003
Member HCC Working Group for the Liver Committee United Network for Organ Sharing	2002

Treasurer	
American Society of Transplant Surgeons	2003-2006
<b><u>MEDICAL AND SURGICAL SOCIETY MEMBERSHIPS</u></b>	
Swedish Society of Medicine	1976
Swedish Medical Association	1976
Swedish Surgical Association	1976
Swedish Transplantation Society	1982
Scandinavian Transplantation Society	1982
European Society of Organ Transplantation	1983
Transplantation Society	1984
American Society of Transplant Surgeons	1985
American Medical Association	1985
Southern Medical Association	1985
Texas Medical Association	1985
Dallas County Medical Association	1985
Association for Academic Surgery	1985
Pan American Medical Association	1985
Member of Council on Transplantation of Organs	
International Liver Transplantation Society	1985
Royal Society of Medicine (Great Britain)	1985 - 2004
Society of University Surgeons	1987
Texas Transplantation Society	1987
International Surgical Society	1987
American Council on Transplantation	1988

American Society of Transplant Physicians	1989
Academy of Surgical Research	1989
American Association for the Study of Liver Diseases	1990
Society for Surgery of the Alimentary Tract	1991
American College of Surgeons, Fellow	1991
American Surgical Association	1993
Xenotransplantation Association	1998
International Xenotransplantation Association	1999

### **TEXTBOOK CONTRIBUTIONS**

<u>Clinical Transplants 1990</u> , edited by Paul I. Terasaki Chapter: "Liver Transplantation in 1990: A Dallas Perspective"	1990
<u>The Handbook of Transplantation Management</u> , edited by Leonard Makowka Chapter: "The Organ Transplanted Patient: Immunological Concepts and Immunosuppression"	1991
<u>Transplantation of the Liver</u> , edited by Willis Maddrey Chapter: "Liver Transplantation in Patients with Tumors"	1995
<u>Principles of Drug Development in Transplantation &amp; Autoimmunity</u> , edited by Ronald Lieberman and Asoke Mukherjee Chapter: "Tacrolimus Immunoprophylaxis and Rescue Therapy in Liver Transplantation"	1996
<u>Transplantation of the Liver, First Edition</u> edited by Ronald W. Busuttil and Goran B. Klintmalm (author of 6 chapters)	1996
The Recipient Hepatectomy and Grafting <i>Goran B. Klintmalm, Ronald W. Busuttil</i>	
Combined Liver-Kidney Transplantation <i>Goran B. Klintmalm, Ronald W. Busuttil</i>	
Postoperative Management: Adults <i>Marlon F. Levy, Goran B. Klintmalm</i>	

Induction and Maintenance of Immunosuppression  
*Goran B. Klintmalm*

Preoperative Predictors of Outcome in Liver Transplantation:  
Models for Defining High-Risk Transplant Recipients  
*Eytan Mor, Goran B. Klintmalm*

Long-Term Functional Recovery and Quality of Life  
*Marlon F. Levy, Goran B. Klintmalm*

Liver Transplantation, edited by Russell Wiesner 1999  
Chapter: "Long-Term Results of Liver Transplantation in  
Patients with Hepatocellular Cancer and Bile Duct Cancer"  
Chapter: "Recipient Operation"

Transplantation: Principles of Clinical Practice, 1999  
edited by Leo Ginns, Benedict Cosimi and Peter Morris  
Chapter 7: "Pharmacologic Agents - Tacrolimus"

Organ Procurement and Preservation, 1999  
edited by Goran Klintmalm and Marlon Levy

Immunosuppression in Transplantation 1999  
edited by Leo C. Ginns, A. Benedict Cosimi and Peter J. Morris  
Chapter 4: "Tacrolimus"

Atlas of Liver Transplantation 2002  
Edited by Ernest P. Molmenti and Goran B. Klintmalm

Transplantation of the Liver, Second Edition 2005  
Edited by Ronald W. Busuttil and Goran B. Klintmalm (and author of 9 chapters)

Transplantation for Primary Hepatic Malignancy  
*Mavin J. Stone, J. Mark Fulmer, Goran B. Klintmalm*

Transplantation for Budd-Chiari Syndrome  
*Marvin J. Stone, J. Mark Fulmer, Goran B. Klintmalm*

The Recipient Hepatectomy and Grafting  
*Goran B. Klintmalm, Ronald W. Busuttil*

Combined Liver-Kidney Transplantation  
*Edmund Q. Sanchez, Goran B. Klintmalm*

Postoperative Intensive Care Unit Management: Adult Liver Transplant Recipients  
*Henry B. Randall, Goran B. Klintmalm*

Postoperative Management Beyond the Intensive Care Unit: Adults  
*Edmund Q. Sanchez, Goran B. Klintmalm*

Induction and Maintenance of Immunosuppression  
*Srinath Chinnakotla, Goran B. Klintmalm*

Outcome Predictors in Liver Transplantation  
*Rafik M. Ghobrial, Goran B. Klintmalm*

Long-Term Functional Recovery and Quality of Life: Childhood, Adulthood, Employment,  
Pregnancy, and Family Planning  
*Marlon F. Levy, Terianne Cowling, Goran B. Klintmalm*

### **EDITORIAL BOARD APPOINTMENTS**

<u>Transplant Journal of Organ and Tissue Transplantation</u> (Editorial Board), Madrid, Spain	1989
<u>Transplantation Proceedings</u> (Clinical Board)	1991
<u>Journal of Investigative Surgery</u> (Editorial Board)	1991
<u>Transplantation Science</u> (Editorial Board)	1991
<u>Hepatology</u> (Ad Hoc Reviewer)	
<u>Transplantation</u> (Editorial Board)	1993-1999
<u>Transplantation International</u> (Ad Hoc Reviewer)	
<u>Recent Developments in Transplantation Medicine</u> (Editorial Board)	1993
<u>Liver Transplantation and Surgery</u> (Editorial Board)	1994 - 1999
<u>American Journal of Gastroenterology</u> (Ad Hoc Reviewer)	1994
<u>Clinical Transplantation</u> (Editorial Board)	1997
<u>Graft</u> (Editorial Board)	1998-2004
<u>Liver Transplantation and Surgery</u> (Associate Editor)	1999-2004
<u>American Journal of Transplantation</u> (Associate Editor)	2003-present
<u>Liver Transplantation and Surgery</u> (Editorial Board)	2005-2010

## VISITING PROFESSORSHIPS AND LECTURESHIPS

Seminar on Current Gastroenterology Portland, Oregon Keynote Lecturer	Apr 1989
Mendez Pelayo International University Santander, Spain Visiting Professor of Surgery and Seminar on Hepatic Transplantation	Sep 1989
American Association for the Study of Liver Diseases Liver Transplant Roundtable, Chicago, Illinois Invited Lecturer	Oct 1989
University of Pennsylvania Liver Transplant Symposium Philadelphia, Pennsylvania Visiting Professor of Surgery and Keynote Speaker	Feb 1990
University of Texas Medical Branch Galveston, Texas Visiting Professor, Department of Surgery	Oct 1990
University of Oxford John Radcliffe Hospital, Headington, Oxford, United Kingdom Invited Lecturer	Nov 1990
Central Surgical Association Indianapolis, Indiana Invited Discussant	Mar 1991
Gastrological Society of Mexico Guadalajara, Mexico Guest Faculty	May 1991
Closed Roundtable on Immunosuppression and Lymphoproliferative Diseases Cincinnati, Ohio Invited Lecturer	Jun 1991
International Surgical Week Stockholm, Sweden Invited Presenter	Aug 1991

Winter Nephrology Symposium Vail, Colorado Invited Presenter	Feb 1992
International Liver Transplantation Society Minneapolis, Minnesota Invited Presenter	May 1992
Scott and White Medical Center Eleventh Annual Internal Medicine Review South Padre Island, Texas Invited Lecturer	Aug 1992
XIV International Congress of the Transplantation Society Paris, France Invited Presenter	Aug 1992
The Texas Society for Gastroenterology and Endoscopy Dallas, Texas Invited Lecturer	Sep 1992
Rikhospitalit National Hospital Oslo, Norway Visiting Professor	Oct 1992
Congress of General Surgeons of Mexico Acapulco, Mexico Invited Lecturer	Nov 1992
Department of Health and Human Services Center for Drug Evaluation and Research Staff College, Rockville, Maryland Invited Lecturer	May 1993
American Society of Transplant Surgeons Postgraduate Course, Houston, Texas Invited Lecturer	May 1993
St. Louis University Hospital St. Louis, Missouri Visiting Professor	Aug 1993
American Association for the Study of Liver Diseases Single Topic Symposium, Reston, Virginia Invited Lecturer	Nov 1994



University of Nebraska Medical Center Omaha, Nebraska Visiting Professor	Feb 1995
American Association for the Study of Liver Diseases Single Topic Symposium, Chicago, Illinois Invited Lecturer	Mar 1995
American Association for the Study of Liver Diseases Digestive Disease Week, San Diego, California Invited Lecturer	May 1995
Society of Surgical Chairmen Washington, D.C. Invited Lecturer	Oct 1995
University of Miami School of Medicine Miami, Florida Visiting Professor	Feb 1996
University of California at San Francisco San Francisco, California Visiting Professor	May 1996
Stanford University Stanford, California Visiting Professor	May 1996
Oregon Health Sciences University Portland, Oregon Visiting Professor	Sep 1996
University of Miami School of Medicine Miami, Florida Visiting Professor	May 1998
University of Southwestern Medical School Dallas, Texas Invited Lecturer	Nov 1998
University of California at Los Angeles Los Angeles, California Invited Lecturer	Jan 1999

Baylor-Stockholm School of Economics Conference on Health Care Policy Stockholm, Sweden Invited Presenter	May 2001
Roche National Liver Transplant Advisory Board Dallas, Texas Invited Lecturer	Feb 2002
SCVIR 27 <sup>th</sup> Annual Meeting Baltimore, Maryland Invited Lecturer	April 2002
University of Chicago Chicago, Illinois Visiting Professor	Nov 2002
Tulsa Liver Transplant Support Group Lecture Tulsa, Oklahoma Invited Lecturer	Nov 2002
UNOS Consensus Conference Miami, Florida Invited Presenter	Jan 2003
URN Conference Scottsdale, Arizona Invited Presenter	April 2003
Johns Hopkins University Baltimore, Maryland Visiting Professor	Feb 2004
University of Cincinnati Cincinnati, Ohio Visiting Professor	April 2004
University of Tennessee Memphis, Tennessee Visiting Professor	May 2004
Integris Baptist Medical Center Oklahoma City, Oklahoma Visiting Professor	July 2004

Carl Gustav Groth Lecture 2004  
Stockholm, Sweden  
Invited Guest Lecturer

November 2004

University of Pennsylvania  
Philadelphia, PA  
Visiting Professor

December 2004

The Cleveland Clinic  
Cleveland, OH  
Visiting Professor

January 2005

## NATIONAL RESEARCH PROJECTS

Principal Investigator National Institute of Health Liver Transplant Database Baylor University Medical Center Dallas, Texas Grant #NIH-NIDDK-88-3	1987 - 1989
Principal Investigator, FDA-approved studies on Fujisawa FK506: Study #FPC-FK506-7 Study #FPC-FK506-9 Study #FPC-FK506-036 Study #FPC-FK506-037 Study #FPC-FK506-039 Study #FPC-FK506-0045	1990 - 1992 1990 - 1994 1992 - 1994 1992 - 1997 1992 - 1994 1992 - 1994
Principal Investigator, FDA-approved studies on Roche RS-61443: Study #2378 Study #1803 Study #2646	1994 - 1998 1991 - 1997 1996 - present
Principle Investigator, FDA-approved study on Sandoz Neoral Study #OLN-354	1994 - 1998
Principal Investigator, FDA-approved studies with Wyeth-Ayerst Research on Sirolimus Study #0468E1-211-US Study #0468E1-306-US	1997 - 1999 1998 - present
Investigator, FDA-approved studies on Roche RS-61443: Study #1812 Study #1858 Study #1866 Study #1868 Study #1880 Study #1912 Study #2172 Study #2400 Study #2682 Study #2734	1990 - 1991 1992 - 1994 1992 - 1997 1992 - 1996 1992 - 1996 1992 - 1998 1986 - 1997 1995 - 1998 1996 1996 - 1997
Investigator, FDA-approved study on UpJohn Prostaglandin E1	1993 - 1995
Investigator, FDA-approved study on Amgen Filgrastin	

Study #940140	1994 - 1996
Investigator, FDA-approved study on Bristol Myers Squibb Deoxyspergualin Study #IM 137-014	1995 - 1996
Investigator, FDA-approved study on Baxter Anti CD45	1994 - 1995
Investigator, FDA-approved study with Nextran on Transgenic Pig Livers Study #96-02	1997 - 2000
Investigator, FDA-approved post-marketing studies with Fujisawa Study #10-95-006	1996- present
Study #20-96-003	1996- present
Investigator, FDA-approved study with Wyeth-Ayerst Research on Sirolimus Study #0468E1-212-US	1997 - present
Advisory Board for Clinical Development of FTY 720 with Novartis	1998
Investigator, FDA-approved study with Novartis on RAD001 Study #CRAD001 B251	1998- present
Investigator, FDA-approved study with Cohesion Technology on Co-Stasis Hemostatis Device Study #HEM-97-3.0	1998 - 1999
Investigator, FDA-approved study with Radiotherapeutics Corporation on LaVeen Needle Electrode. Study #Radio Frequency Ablation	1998-present
Investigator, FDA-approved study with Wyeth-Ayerst on VPA-985 Study #0892A1-203-US	1998- present
Investigator, FDA-approved study with Abbott on Abbott Cyclosporine Study #M99-033	1999-present
Investigator, FDA-approved study with Roche on Zenapax in Kidney Pancreas Transplants Study #ZEN049	1999-present
Principal Investigator, FDA-approved study with NovoNordisk on Factor VIIa (rFVIIa/Novo Seven) Study #F7Liver-1252	1999-present

Investigator, FDA-approved study with Wyeth-Ayerst on Sirolimus with Reduced versus Standard Cyclosporine Study #0468E1-100154	1999–present
Co-Investigator, Models for Optimal Liver Transplant Outcomes	2001– present
Principal Investigator, FDA-approved study with Wyeth-Ayerst on Conventional dose Tacrolimus plus steroids vs. reduced dose Tacrolimus plus Sirolimus and steroids in liver transplant recipients Study #0468H1-220-US	2002–present
Principal Investigator, FDA-approved study with Novartis to compare Neoral with C-2h Monitoring to Tacrolimus with Trough Monitoring in DeNovo Liver Transplant Recipients Study #COLO400	2002–present
Co-Principal Investigator, FDA-approved study with Novartis to compare The effect of two Neoral C-2h maintenance targets, beyond two months Post transplant on renal function in the context of an immunosuppressive Regimen consisting of Myfortic, Simulect, and steroids Study #Myfortic/ERL080 (002-010)	2002–2003
Sub-Investigator, FDA-approved study with Wyeth-Ayerst of Prograf + Rapamune + Corticosteroids compared to Cyclosporine Microemulsion Capsules, USP (Modified) + Rapamune + Corticosteroids in high risk Renal allograft Study #002-216	2002-2003
Principal Investigator, FDA-approved Baylor led multicenter study to Compare the efficacy & safety among three treatment regimens in patients Receiving a liver transplant for endstage liver disease caused by chronic Hep C Study #002-039 (Main)	2002–present
Sub-Investigator, FDA-approved study with SangStat on Thymoglobulin Versus OKT3 for treatment of steroid resistant acute cellular rejection in Liver transplantation Study #002-075	2002–present
Principal Investigator, FDA-approved study with Wyeth-Ayerst on Conversion from Tacrolimus to Sirolimus versus continued use of Tacrolimus in established liver allograft recipients on maintenance therapy Study #0468H1-313-US (002-091)	2002–present

Principal Investigator, FDA-approved Baylor led study on operational Tolerance induction in liver transplant recipients through a preconditioning Regimen including Thymoglobulin and Tacrolimus monotherapy with gene Chip monitoring Study #002-109	2002-present
Sub-Investigator, FDA-approved study with Fujisawa on Micafungin versus Placebo as Preemptive Antifungal Therapy in patients in the Intensive Care Unit at high risk for developing fungal infection Study #002-126	2002-present
Principal Investigator, FDA-approved pilot trial of operation tolerance Induction in liver transplant recipients through a preconditioning regimen Including Thymoglobulin and Tacrolimus monotherapy with gene chip Monitoring Study #002-157	2002-present
Principal Investigator, FDA-approved multicenter study with Fujisawa to Assess the pharmacokinetics, long-term safety & tolerability of Tacrolimus In stable liver transplant patients converted from a Prograf based Immunosuppression regimen to a modified release Tacrolimus based Immunosuppression Study #002-233	2002-present
Principal Investigator, FDA-approved Zenapax Pharmacokinetic Substudy Study #002-039 (Sub-study)	2003-present
Principal Investigator, FDA-approved Univ of Penn led study on Mycophenolic Acid Pharmacokinetics following Liver Transplantation Substudy to Protocol ZEN159: A Study to Assess the Efficacy & Safety of Zenapax in Combination with CellCept, Tacrolimus & Corticosteroids In Patients Undergoing Liver Transplantation Study #003-014 (Main)	2003-present
Principal Investigator, FDA-approved substudy on Mycophenolic Acid Pharmacokinetics following Liver Transplantation Study #003-014 (Sub-study)	2003-present
Sub-Investigator, FDA-approved study with Novartis to Evaluate the Efficacy & Safety of FTY720 Combined with Reduced-Dose or Full-Dose Neoral & Corticosteroids vs. MMF/CellCept Combined with Full-Dose Neoral & Corticosteroids, in de novo Adult Renal Transplant Recipients	

Study # FTY720 0125 (003-016)	2003-2004
Principal Investigator, FDA-approved Mayo sponsored study on models For patient management & resource allocation for liver transplantation Study #003-074	2003-present
Sub-Investigator, FDA-approved study with Fujisawa to Assess the Safety & Efficacy of Prograf (Tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF & Neoral (Cyclosporine)/MMF in de novo kidney transplant Study #003-076	2003-present
Principal Investigator, FDA-approved Baylor sponsored study on Donor T-Lymphocyte Chimerism in liver transplant patients (The persistence of Donor Blood Cells in patients who have received a liver transplant) Study #003-127	2003-present
Principal Investigator, FDA-approved study with Idun Pharmaceuticals on Safety, Tolerability & Efficacy of a Caspase Inhibitor, IDN-6556, in patients Undergoing Orthotopic Liver Transplantation (OLT) Study #003-142	2003-present
Sub-Investigator, FDA-approved comparison study with Odyssey on the Effectiveness of Custodiol HTK Solution with Viaspan UW Solution in the In-Situ Perfusion, Storage, and Transplantation of Cadaveric-Donor Kidneys & Livers Study # 003-207	2003-present

### **CLINICAL AREAS OF INTEREST**

Liver Transplantation  
Kidney Transplantation  
Small Bowel Transplantation  
Hepatobiliary Surgery  
Immunosuppression

### **RESEARCH AREAS OF SPECIAL INTEREST**

Immunosuppression  
Organ Preservation



**GORAN B. KLINTMALM, M.D., PH.D., F.A.C.S.**  
**LIST OF PUBLICATIONS**

**PEER REVIEWED JOURNALS**

1. Tillegard A, **Klintmalm G**, Malmborg AS, Wiman LG, and Back E. Pneumoni hos njurtransplanterade patienter - kan bronkoskopi ge upplysningar om orsaken? *Svensk Kirurgi* 36(2):58-60, 1978.
2. **Klintmalm G**, Tillegard A, and Magnusson G. Patienter som kraver antiepileptika - en hogriskgrupp vid njurtransplantation. *Svensk Kirurgi* 36(2):61-62, 1978.
3. **Klintmalm G**, Berg B, Lundgren G, Ljungdahl I, Magnusson G, Tillegard A, Groth CG, and Franksson C. 500 njurtransplantationer i Stockholm. *Svensk Kirurgi* 37(1):130-133, 1979.
4. **Klintmalm G**, Astrom H, Bergenwald L, Cronestrand R, von Euler C, and Juhlin-Dannfelt A. Blodflodet i a. carotis interna vid varierande blodvolym och PCO<sub>2</sub> under operation for carotisstenos. *Svensk Kirurgi* 37(1):138-139, 1979.
5. Berg B, Groth CG, **Klintmalm G**, Lundgren G, Ringden O, and Moller E: Betydelsen av HLA-A, -B och -Dr typning for resultatet efter njurtransplantation i Stockholm. *Svensk Kirurgi* 37(2):139-142, 1979.
6. Lundgren G, Cronestrand R, Groth CG, **Klintmalm G**, and Ost L. Artarstenoser i transplanterade njurar. *Svensk Kirurgi* 37(2):147-148, 1979.
7. Berg B, Groth CG, **Klintmalm G**, Lundgren G, and Moller E. The implications of HLA-DR match for the outcome of cadaveric renal transplantation. *Scand J Urol Nephrol* (Suppl) 54:29-31, 1980.
8. Starzl TE, Weil III R, Iwatsuki S, **Klintmalm G**, Schroter GPJ, Koep LJ, Iwaki Y, Terasaki PI, and Porter KA. The use of cyclosporine A and prednisone in cadaver kidney transplantation. *Surg Gynecol Obstet*, July, 151:17-26, 1980.
9. Dahlborn M, Cronestrand R, **Klintmalm G**, and Sundelius S. Blood inflow and coagulation in vascular catheters. Comparison of the effect of polysaccharide solutions, saline and contrast medium. *Acta Radiol Diagn* 21 (Fasc. 6):715-720, 1980.
10. **Klintmalm G**, Iwatsuki S, and Starzl TE. Nephrotoxicity of cyclosporine A in liver and kidney transplant patients. *Lancet* 1(28 Feb):470-471, 1981.
11. Starzl TE, Iwatsuki S, **Klintmalm G**, Schroter GPJ, Weil III R, Koep LJ, and Porter KA: Liver transplantation, 1980, with particular reference to cyclosporine-A. *Trans Proc* 13, (1) (March):281-285, 1981.

12. Iwatsuki S, Iwaki Y, Kano T, **Klintmalm G**, Koep LJ, Weil R, and Starzl TE. Successful liver transplantation from crossmatch-positive donors. *Trans Proc* 13, (1): 1981.
13. **Klintmalm G**, Iwatsuki S, Kano T, Iwaki Y, Terasaki PI, Schroter G, Koep L, Weil R, and Starzl TE. Determinants of effectiveness of thoracic duct drainage for primary cadaver kidney transplantation. *Trans Proc*, 13, (1) (March): 537-538, 1981.
14. Starzl TE: Iwatsuki S, **Klintmalm GBG**, Porter KA, and Fernandez-Bueno C. Human organ transplantation under cyclosporine A and steroids. Transplantation and Clinical Immunology, Vol 13, Proc 13 Internat. Course, Lyon, France, June 15-17, *Excerpta Medica*:53-59, 1981.
15. Starzl TE, **Klintmalm GBG**, Iwatsuki S, and Fernandez-Bueno C. Past and future prospects of orthoptic liver transplantation. *Arch Surg* 116:1342-1343, October 1981.
16. **Klintmalm GBG**, Iwatsuki S, and Starzl TE. Abstract: Nephrotoxicity of cyclosporine A in liver and kidney transplant patients. In: International Synopses, Ed. R. Kessler, Princeton, NJ, USA, *Urology Digest* Dec: 7-8, 1981.
17. Starzl TE, **Klintmalm GBG**, Iwatsuki S, and Weil III R. Late follow-up after thoracic duct drainage in cadaveric renal transplantation. *Surg Gynecol Obstet* 153:377-382, 1981.
18. **Klintmalm GBG**, Iwatsuki S, and Starzl TE: Cyclosporine A hepatotoxicity in 66 renal allograft recipients. *Transplantation* 32(6):488-489, 1981.
19. Klingensmith III WC, Whitney WP, Spitzer VM, **Klintmalm GBG**, Koep LM, and Kuni CC. Effect of complete biliary-tract obstruction on serial hepatobiliary imaging in an experimental model: concise communication. *J Nucl Med* 22:866-868, 1981.
20. Starzl TE, **Klintmalm GBG**, Weil III R, Porter KA, Iwatsuki S, Schroter GP, Fernandez-Bueno C, and MacHugh N. Cyclosporine A and steroid therapy in 66 cadaver kidney recipients. *Surg Gynecol Obstet* 153:486-494, 1981.
21. Starzl TE, **Klintmalm GBG**, Porter KA, Iwatsuki S, and Schroter GPJ. Liver transplantation with use of cyclosporine A and prednisone. *New Engl J Med* 305:266-269, 1981.
22. **Klintmalm GBG**, Starzl TE, Groth CG, Iwatsuki S, Ringden O, Lundgren G, Magnusson G, and Collste H. Cyclosporine A, ett nytt immunosuppressivum vid hjart-, lever och njurtransplantation. *Svensk Kirurgi* 19:225, 1981.

23. **Klintmalm GBG**, Klingensmith III WC, Iwatsuki S, Schroter GPJ, and Starzl TE.  $^{99m}\text{Tc}$ -DTPA and  $^{131}\text{I}$ -Hippuran findings in liver transplant recipients treated with cyclosporine A. *Radiology* 142:199-202, January, 1982.
24. **Klintmalm GBG**, Starzl TE, Iwatsuki S, and Hakala T. Cyclosporine A and kidney transplantation: present status of a partially randomized trial. *Trans Proc*, 14(1)(March):98-99, 1982.
25. Ringden, O, Collste H, **Klintmalm G**, Lundgren G, Magnusson G, Wilczek H, and Groth CG. Cyclosporine A in high-risk renal transplant recipients and in recipients with azathioprine intolerance. *Trans Proc*, 14, (1) (March):100-102, 1982.
26. **Klintmalm G**, Astrom H, Bergenwald L, Cronstrand R, von Euler C, and Juhlin-Dannfelt A. Intra-operative variations in carotid artery blood flow and cardiac output: the effects of changes in blood volume and carbon dioxide during surgery under neurolept anesthesia. *Acta Chir Scand* 148:121-125, 1982.
27. Starzl TE, **Klintmalm GBG**, and Iwatsuki S. The true one-handed tie. *Surg Gynecol Obstet* 154(6):576, 1982.
28. Ringden O, Persson U, Johansson G, Gahrton G, Groth CG, **Klintmalm G**, Lundgren G, Lonnqvist B, and Moller E. Correlation between increase in serum-IgE levels and clinical signs of acute graft-versus-host disease. *Experimental Hematology* Vol. 10, Suppl 10:94-95, 1982.
29. Groth CG, Collste H, Lundgren G, Wilczek H, **Klintmalm G**, Ringden O, Gunnarsson R, and Ostman J. Successful outcome of segmental human pancreatic transplantation with enteric exocrine diversion after modifications in technique. *Lancet* 2:522-524, 1982.
30. Groth CG, Berg B, Collste H, Fehrman I, **Klintmalm G**, Lundgren G, Magnusson G, Ringden O, Wilczek H, and Ost L. Njurtransplantation. In: Transplantationskirurgi idag, CG Groth (red), *Svenska Lakaresallskapets Handlingar Hygiea* 91(4):7-23, 1982.
31. **Klintmalm G**. Hjärt-och levertransplantation. In: Transplantationskirurgi idag, CG Groth (red), *Svenska Lakaresallskapets Handlingar Hygiea* 91(4):37-44, 1982.
32. Iwatsuki S, **Klintmalm GBG**, and Starzl TE. Total hepatectomy and liver replacement (orthotopic liver transplantation) for primary hepatic malignancy. *World J Surg* 6: 1982.
33. **Klintmalm G**. Cyclosporine A (Sandimmune®) - ett nytt immunosuppressivum. *Forskning och Praktik* 7:97-101, 1982.

34. **Klintmalm G**, Bergstrand A, Ringden O, Wasserman J, Collste H, Lundgren G, Wilczek, and Groth CG. Graft biopsy for the differentiation between nephrotoxicity and rejection in cyclosporine-A-treated renal transplant recipients. *Trans Proc* 15(1) (March): 493-496, 1983.
35. Ringden O, Ost L, **Klintmalm G**, Tillegard A, Fehrman I, Wilczek H, Groth CG: Improved outcome in renal transplant recipients above 55 years of age treated with cyclosporine and low doses of steroids. *Trans Proc* 15(4) (Suppl 1) (December): 1983.
36. **Klintmalm G**, Ringden O, and Groth CG: Clinical and laboratory signs in nephrotoxicity and rejection in cyclosporine-treated renal allograft recipients. *Trans Proc* 15(4) (Suppl 1 December):2815-2820, 1983.
37. **Klintmalm GB** and Husberg BS: Etablering av ett levertransplantationscentrum i USA - erfarenhetsredovisning (med svenska ogon). *Lakartidningen* 84:1353-1355, 1983.
38. Starzl TE, Rosenthal JT, Hakala TR, Iwatsuki S, Shaw JB, and **Klintmalm GB**: Steps in immunosuppression for renal transplantation. *Kidney International* 23(Suppl. 14),S-60 1983.
39. Ringden O, Baryd I, Johansson B, Bolme P, Gahrton G, Groth CG, **Klintmalm G**, Lundgren G, and Lonnqvist B: Increased mortality in bone marrow transplant recipients accidentally receiving an increased dose rate of total body irradiation. *Experimental Hematology* 11:131-133, 1983.
40. **Klintmalm G**: Cyclosporin A. *Njurfunk* 2:14-15, 1983.
41. Gunnarsson R, **Klintmalm G**, Lundgren G, Wilczek H, Ostman J, and Groth CG: Deterioration in glucose metabolism in pancreatic transplant recipients given cyclosporine. *Lancet* 2:571-572, 1983.
42. **Klintmalm G** and Groth CG: Levertransplantation - utvecklingen gar framat. *Lakartidningen*, 80(NR 42):3901, 1983.
43. **Klintmalm G**: Cyklosporin - immunhammare med vidgad anvandning. *Lakartidningen*, 80(9 NR 47):4530-4531, 1983.
44. **Klintmalm G** and Lundgren G: Can pre-transplant blood transfusions and DR-matching be omitted in cyclosporine-A treated renal transplant patients? *Scandinatransplant Report*:24-26, 1983.
45. **Klintmalm GBG**, Cronstrand R, Wennmalm A, Lundgren G, Groth CG: Human Renal Allograft Blood Flow, Oxygen Extraction, and Prostaglandin Release: Their Bearing on Graft Function. *Surgery* 95(4)(April):427-432, 1984.

46. Gunnarsson R, **Klintmalm G**, Lundgren G, Tyden G, Wilczek H, Ostman J, and Groth CG. Deterioration in glucose metabolism in pancreatic transplant recipients after conversion from azathioprine to cyclosporine. *Trans Proc* 16(3) (June):709-712, 1984.
47. Groth CG, Lundgren G, Wilczek H, **Klintmalm G**, Tyden G, Gunnarsson R, and Ostman J. Segmental pancreatic transplantation with duct ligation or enteric diversion: technical aspects. *Trans Proc*, 16(3) (June):724-728, 1984.
48. Lundgren G, Wilczek H, **Klintmalm G**, Tyden G, and Groth CG: Procurement and preservation of human pancreatic grafts. *Trans Proc* 16(3) (June):681-683, 1984.
49. **Klintmalm G**, Althoff P, Appleby G, and Segerbrandt E: Renal function in a newborn baby delivered of a renal transplant patient taking cyclosporine. *Transplantation* August: 198-199, 1984.
50. **Klintmalm G**, Sawe J, von Bahr C, Ringden O, Lundgren G, Wilczek H, Tyden G, and Groth CG: Optimal cyclosporine plasma levels decline with time of therapy. *Transplant Proc*, 16(5) (October):1208-1211, 1984.
51. Tyden G, Lundgren G, Wilczek H, **Klintmalm G**, Ost L, Gunnarsson R, Ostman J, and Groth CG: Recent experience with pancreatic transplantation at huddinge hospital. *Trans Proc* 16(5) (October):1270-1273, 1984.
52. Svenson K, Holmdahl R, Klareskog L, Wibell L, Sjoberg O, **Klintmalm G**, and Bostrom H: Cyclosporine A (CyA) treatment in a case of relapsing polychondritis. *Scand J Rheumatol*, 1984.
53. **Klintmalm G**: The first international congress on cyclosporine - en rapport fran Houston. *Forskning och Praktik* 16:65-69, 1984.
54. Groth CG, Tyden G, Lundgren G, Wilczek H, **Klintmalm G**, Ost L, Gunnarsson R, and Ostman J: Segmental pancreatic transplantation with enteric exocrine diversion. *World J Surg* 8:257-261, 1984.
55. **Klintmalm G** and Sawe J: High dose methylprednisolone increases plasma cyclosporine levels in renal transplant recipients. *Lancet* 1:731, 1984.
56. Ringden O, Myrenfors P, **Klintmalm G**, Tyden G, and Ost L: Nephrotoxicity by cotrimoxazole and cyclosporine in transplanted patients. *Lancet* 1:1016-1017, 1984.
57. **Klintmalm G**, Bowman S, Sundelin B, and Wilczek H: Morphological changes in renal allografts after 12-46 months of cyclosporine therapy: beneficial effect of lower doses early after transplantation. *Lancet* 2:950-954, 1984.

58. **Klintmalm G**: Monitoring of cyclosporine/sandimmune levels and the use of renal biopsies in the care of renal transplanted patients. *Excerpta Medica, Amsterdam*, 1984.
59. Bohman S, **Klintmalm G**, Ringden O, Sundelin B, and Wilczek H: Interstitial fibrosis in human kidney grafts after 12 to 46 months of cyclosporine therapy. *Trans Proc*, 17(1) (February):1168-1171, 1985.
60. **Klintmalm G**, Brynger H, Flatmark A, Frodin L, Husberg B, Thorsby E, and Groth CG: The blood transfusion, DR matching, and mixed lymphocyte culture effects are not seen in cyclosporine-treated renal transplant recipients. *Trans Proc* 17(1) (February):1026-1031, 1985.
61. Iwatsuki S, Esquivel CO, **Klintmalm GBG**, Gordon RD, Shaw BW, and Starzl TE: Nephrotoxicity of cyclosporine in liver transplantation. *Trans Proc* 17(4) (Suppl August):191-195, 1985.
62. **Klintmalm G**, Lonnqvist B, Oberg B, Gahrton G, Lernestedt J, Lundgren G, Ringden O, Robert K, Wahren B, and Groth CG: Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients. *Scand J Infect Dis* 17:157-163, 1985.
63. **Klintmalm G**, Sawe J, Ringden O, and von Bahr C: Cyclosporine plasma levels in renal transplant patients - association with renal toxicity and allograft rejection. *Transplantation* 39(2):132-137, 1985.
64. Ost L, **Klintmalm G**, and Ringden O: Mutual interaction between prednisolone and cyclosporine in renal transplant patients. *Trans Proc* 17:1252-1255, 1985.
65. **Klintmalm G** and Moore AE: Organization of a new liver transplant center. *Seminars on Liver Disease* 5(4):412-417, 1985.
66. Lundgren G, Albrechtsen D, Flatmark A, Gabel H, **Klintmalm G**, Persson H, Groth CG, Brynger H, Frodin L, Husberg B, Maurer W, and Thorsby E: HLA-matching and pretransplant blood transfusions in cadaveric renal transplantation--a changing picture with cyclosporine. *Lancet* July 12:66-69, 1986.
67. Lundgren G, Albrechtsen D, Brynger H, Flatmark A, Frodin L, Gabel H, Husberg B, **Klintmalm G**, Maurer W, Persson H, Thorsby E, and Groth CG: Role of blood transfusions and HLA matching in cyclosporine-treated renal transplant recipients: a scandinavian multicenter study. *Trans Proc* 18(5) (October):1248-1255, 1986.
68. Friskopp J and **Klintmalm G**: Gingival enlargement. A comparison between cyclosporine and azathioprine treated renal allograft recipients. *Swed Dent J* 10:85-92, 1986.

69. Ringden O, Lonnqvist B, Paulin T, Ahlmen J, **Klintmalm G**, Wahren B, and Lernestedt JO: Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. *Journal of Antimicrobial Chemotherapy* 17:373-387, 1986.
70. **Klintmalm GBG**: Renal toxicity of cyclosporin, clinical studies. *Contr Nephrol*, 51: 1986.
71. Iwatsuki S, Starzl TE, van Thiel D, Gordon RD, Esquivel CO, Tzakis A, **Klintmalm G**, and Schade R: Liver transplantation for primary sclerosing cholangitis. *Am. Assoc. for Study of Liver Diseases*, 1986.
72. Starzl TE, Tzakis A, Makowka L, Fung J, **Klintmalm G**, Todo S, Gordon R, and Griffin M: Combined liver and kidney transplantation: with particular reference to positive cytotoxic crossmatches. *Kidney International*, 31(1) (January):218, 1987.
73. Paulsen AW, Valek TR, Blessing WS, Johnson DD, Parks RI, Pyron JT, Ramsay M, Simpson BR, Swygert T, Walling P, and **Klintmalm G**: Hemodynamics during liver transplantation with veno-venous bypass. *Trans Proc*, 19(1) (February):2417, 1987.
74. Bryan CF, Newman JT, Nery J, Husberg B, **Klintmalm GB**, and Stone MJ: Quantitative and functional profile of the immune system after liver transplantation. *Trans Proc*, (October):4340-4344, 1987.
75. **Klintmalm G**: Development of chronic renal cyclosporine-A toxicity. *Nephrologie*, 8:131-133, 1987.
76. Esquivel CO, **Klintmalm G**, Iwatsuki S, Makowka L, Gordon RD, Tzakis A, and Starzl TE: Liver transplantation in patients with patent splenorenal shunts. *Surgery* 101(4):430, 1987.
77. Olson LM, Roden J, Nery J, Husberg B, and **Klintmalm G**: Liver transplantation at baylor university medical center: the first eighteen months. *Lakartidningen* 84(16):1351, 1987.
78. Detre KM and LTD Investigators: The NIDDK liver transplantation database. *Clin Trans*, 6:33-42, 1987.
79. Roden J, **Klintmalm GB**, Husberg BS, Nery J, and Olson LM: Cerebrospinal fluid inflammation during OKT3 therapy. *Lancet*: 272, 1987.
80. Fung J, Makowka L, Tzakis A, **Klintmalm G**, Duquesnoy R, Gordon R, Todo S, Griffin M, and Starzl T: Combined liver-kidney transplantation: analysis of

- patients with preformed lymphocytotoxic antibodies. *Trans Proc* 20(1) (Suppl 1) (February): 1988.
81. Iwatsuki S, Starzl TE, Todo S, Gordon RD, Esquivel CO, Tzakis AG, Makowka L, Marsh JW, Koneru B, Stieber A, **Klintmalm G**, and Husberg G: Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. *Trans Proc* 20(1) (Suppl 1) (February):498-504, 1988.
  82. Goldstein RM, Olson LM, **Klintmalm GBG**, Husberg BS, Nery JR, Gonwa TA, Roden JS, and Polter DE: Decreased mortality associated with orthotopic liver transplantation. *Trans Proc* 20(1) (Suppl 1) (February):505-507, 1988.
  83. Gonwa TA, **Klintmalm GB**, Husberg BS, Olson L, Nery J, and Roden J: Liver transplantation in patients with preexisting acute and chronic renal failure. *Trans Proc* 20(1) (Suppl 1) (February):561-563, 1988.
  84. **Klintmalm GB**, Olson LM, Nery JR, Husberg BS, and Paulsen WA: Treatment of hepatic artery thrombosis after liver transplantation with immediate vascular reconstruction: a report of three cases. *Trans Proc* 20(1) (Suppl 1) (February): 610-612, 1988.
  85. **Klintmalm GBG**, Olson LM, Paulsen AW, Whitten CW, and Husberg BS: Hepatic arterial thrombosis after liver transplantation: intraoperative electromagnetic blood flow evaluation. *Trans Proc* 20(1) (Suppl 1) (February):616-618, 1988.
  86. Greene CL, Fehrman I, Tillery GW, Husberg BS, and **Klintmalm GB**: Transplant aspiration cytology detects entities other than acute cellular rejection in liver allografts. *Trans Proc* 20(1) (Suppl 1) (February):692-694, 1988.
  87. Olson LM, **Klintmalm GB**, Husberg BS, Nery JR, Whitten CW, Paulsen AW, and McClure R: Superoxide dismutase improves organ preservation in liver transplantation. *Trans Proc* 20(1) (Suppl 1) (February):961-964, 1988.
  88. Nery J, **Klintmalm G**, Olson L, Neely S, Rippert L, Gonwa T, and Husberg B: Incidence and outcome of acute rejection in liver transplantation. *Trans Proc* 20(3) (Suppl) (June):375-377, 1988.
  89. Gonwa TA, Poplawski SC, Husberg BS, Nery JR, and **Klintmalm GB**: Cyclosporine nephrotoxicity in orthotopic liver transplantation. *Trans Proc*, 20(3) (Suppl 3) (June):401-404, 1988.
  90. Wilczek H, Bohman SO, **Klintmalm G**, and Groth CG: Five years serial renal graft biopsy study in cyclosporine-treated patients. *Trans Proc*, 20(3) (Suppl 3) (June): 812-815, 1988.



91. Markus BH, Duquesnoy RJ, Gordon RD, Fung JJ, Vanek M, **Klintmalm G**, Bryan C, and Starzl TE: Histocompatibility and liver transplant outcome: does HLA exert a dualistic effect? *Transplantation* 46(3) (Sept): 372-377, 1988.
92. **Klintmalm GBG**: The liver donor: special considerations. *Trans Proc* 20(5) (Suppl 7)(October): 9-11, 1988.
93. Iwatsuki S, Starzl TE, Todo S, Gordon R, Tzakis A, Marsh JW, Makowka L, Koneru B, Stieber A, **Klintmalm G**, Husberg BS, and Van Thiel D: Liver transplantation in the treatment of bleeding esophageal varices. *Surgery* 104(4) October:697-705, 1988.
94. Gonwa TA, Nery JR, Husberg BS, and **Klintmalm GB**: Simultaneous liver and renal transplantation in man. *Transplantation* 46(5) (November):690-693, 1988.
95. Paulsen AW, Whitten CW, Ramsay MAE, Swygert T, and **Klintmalm G**: Patients presenting for hepatic transplantation: comparison of typical and low cardiac index groups. *Anesth Analg* 67:S1- S266, 1988.
96. Lindholm A, Pousette A, Carlstrom K, and **Klintmalm G**: Cyclosporine-associated hypertrichosis is not related to sex hormone levels following renal transplantation. *Nephro* 50:199-204, 1988.
97. Makowka L, Sher L, Kahn D, Tzakis AG, Todo S, Marsh JW, Stieber A, Koneru B, **Klintmalm GBG**, Staschak SM, Iwatsuki S, Gordon RD, Van Thiel D, and Starzl TE: Which liver-disease patients need a transplant? *Diagnosis* 10(6):62-79, 1988.
98. **Klintmalm GBG** and Nery JR: Prevention, diagnosis, and treatment of rejection in the adult hepatic transplant patient. *Clin Trans* 25-227, 1988.
99. Poplawski S, Gonwa TA, Greene C, Husberg BS, and **Klintmalm G**: Interstitial nephritis secondary to OKT3 administration. *Clin Trans* 2:341-343, 1988.
100. Marino IR, Todo S, Tzakis AG, **Klintmalm G**, Kelleher M, Iwatsuki S, Starzl TE, and Esquivel CO: Treatment of hepatic epithelioid hemangioendothelioma with liver transplantation. *Cancer* 62(10):2079-2084, 1988.
101. Brajtbord D, Parks RI, Ramsay MA, Paulsen AW, Valek TR, Swygert TH, and **Klintmalm GB**: management of acute elevation of intracranial pressure during hepatic transplantation. *Anesthesiology* 70(1):139-141, 1989.
102. Mai M, Nery J, Sutker W, Husberg B, **Klintmalm G**, and Gonwa T: DHPG (Gancyclovir) improves survival in CMV pneumonia. *Trans Proc* 21(1)(February):2263-2265, 1989.

103. Nikaein A, **Klintmalm G**, Husberg B, and Stone MJ: Limiting dilution analysis: a new approach to identify the status of allograft recipients. *Trans Proc* 21(1) (February):2286-2289, 1989.
104. Zachariah NY, Nikaein A, Gonwa T, Alivizatos P, **Klintmalm G**, and Husberg B: Neoptrin: a biochemical marker in the process of organ transplantation. *Trans Proc* 21(1) (February):2294-2296, 1989.
105. Poplawski S, Gonwa T, Goldstein R, Husberg B, and **Klintmalm G**: Long term nephrotoxicity in liver transplantation. *Trans Proc* 21(1)(February):2469-2471, 1989.
106. Gonwa TA, Poplawski S, Paulsen W, Brajtbord D, Goldstein R, Husberg B, and **Klintmalm G**: Pathogenesis and outcome of hepatorenal syndrome in patients undergoing orthotopic liver transplant. *Transplantation* 47(2)(February):395-397, 1989.
107. Gilbert SC, **Klintmalm G**, Menter A, and Silverman A: Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis: a word of caution in light of the expanding use of this "steroid-sparing" agent. *JAMA* (March) 1989.
108. Markus BH, Dickson ER, Grambsch PM, Fleming TR, Mazzaferro V, **Klintmalm GBG**, Wiesner RH, Van Thiel DH, and Starzl TE: Efficacy of liver transplantation in patients with primary biliary cirrhosis. *New Eng J Med* 320(26) (June 29):1709-1713, 1989.
109. Stone MJ, **Klintmalm G**, Polter D, Husberg B, and Egorin MJ: Neoadjuvant chemotherapy and orthotopic liver transplantation for hepatocellular carcinoma. *Transplantation* 47(2) (August):344-347, 1989.
110. Gilbert SC, Emmett M, Menter A, Silverman A, and **Klintmalm G**: Cyclosporine therapy for psoriasis: serum creatinine measurements are an unreliable predictor of decreased renal function. *Journal of the Am Academy of Derm* 21(3) (Pt. 1):470-474, 1989.
111. **Klintmalm GBG**, Nery JR, Husberg BS, Gonwa TA, and Tillery GW: Rejection in liver transplantation. *Hepatology* 10(6):978-985, 1989.
112. Poplawski SC, Gonwa TA, Goldstein RM, Husberg BS, and **Klintmalm GB**: Renal dysfunction following orthotopic liver transplantation. *Clin Trans* 94-100, 1989.
113. Takaoka F, Brown MR, Paulsen W, Ramsay MAE, and **Klintmalm GB**: Adult respiratory distress syndrome following orthotopic liver transplantation. *Clin Trans* 3:294-299, 1989.

114. Sayage LH, Gonwa TA, Goldstein RM, Husberg BS, and **Klintmalm GB**: Cytomegalovirus infection in orthotopic liver transplantation. *Trans Int* 2:96-101, 1989.
115. Sayage LH, Husberg BS, **Klintmalm GB**, Goldstein RM, and Gonwa TA: Vascular complications in adult liver transplant patients. Value of post-operative doppler ultrasound screening and the surgical management of hepatic arterial thrombosis. *Clin Trans* 3:344-348, 1989.
116. Paulsen AW, Whitten CW, Ramsay MAE, and **Klintmalm GB**: Considerations for anesthetic management during veno-venous bypass in adult hepatic transplantation. *Anesth Analg* 68:489-496, 1989.
117. Osther K and **Klintmalm G**: The quick western blot, a novel transportable 50-minute HIV-1 antibody test. *Transplantation* 47(5):834-838, 1989.
118. **Klintmalm GB**, Alivizatos PA, Husberg BS, Howard TK, Small AB, Goldstein RM, and Cofer JM: Hepatic transplantation in a patient with mesoatrial shunt and occlusion of the inferior vena cava. *Surgery* 107(2):220-223, 1990.
119. Gilbert SC, **Klintmalm G**, Menter A, and Silverman A. Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis. A word of caution in light of the expanding use of this 'steroid-sparing' agent. *Arch Intern Med* 150(4): 889-91, 1990.
120. **Klintmalm GB** and Stone MJ: Liver transplantation for malignancy. *Transplantation Reviews* 4(1):52-58, 1990.
121. Mora NP, **Klintmalm GB**, Cofer JB, Poplawski SS, Goldstein RM, Gonwa TA, and Husberg BS: Results after liver retransplantation (RETx): a comparative study between "elective" vs "nonelective" RETx. *Trans Proc* 22(4) (August):1509-1511, 1990.
122. Goldstein RM, Secrest CL, **Klintmalm GB**, and Husberg BS: Problematic vascular reconstruction in liver transplantation. Part I. Arterial. *Surgery* 107(5):540-543, 1990.
123. Kirsch JP, Howard TK, **Klintmalm GB**, Husberg BS, and Goldstein RM: Problematic vascular reconstruction in liver transplantation. Part II. Portovenous conduits. *Surgery* 107(5):544-548, 1990.
124. Howard TK, **Klintmalm GBG**, Cofer JB, Husberg BS, Goldstein RM, and Gonwa TA: The influence of preservation injury on rejection in the hepatic transplant recipient. *Transplantation* 49(1):103-107, 1990.

125. Takaoka F, Brown MR, Ramsay MAE, Paulsen AW, Brajtbord D, and **Klintmalm GB**: Intraoperative evaluation of eurocollins and university of wisconsin preservation solutions in patients undergoing hepatic transplantation. *Transplantation* 49(3):544 1990.
126. Sayage L, Gunby R, Gonwa T, Husberg B, Goldstein R, and **Klintmalm G**: Cytomegalovirus endometritis after liver transplantation. *Transplantation* 49(4):815-817, 1990.
127. Senzer NN, Stone MJ, **Klintmalm GB**, and Polter D: Adjuvant radiochemotherapy following orthotopic liver transplantation for bile duct cancer. *Transplantation* 50(6): 1045-1047, 1990.
128. Cofer JB, **Klintmalm GB**, Howard TK, Morris CV, Husberg BS, Goldstein RM, and Gonwa TA: A comparison of UW with eurocollins preservation solution in liver transplantation. *Transplantation* 49(6):1088-1093, 1990.
129. Cofer JB, Morris CA, Sutker WL, Husberg BS, Goldstein RM, Gonwa TA, and **Klintmalm GB**: A randomized double-blind study of the effect of prophylactic immune globulin on the incidence and severity of CMV infection in the liver transplant recipient. *Trans Proc* 23(1) (February):1525-1527, 1991.
130. Mora NP, Cofer JB, Solomon H, Goldstein RM, Gonwa TA, Husberg BS, and **Klintmalm GB**: Analysis of severe infections (INF) after 180 consecutive liver transplants: the impact of amphotericin B prophylaxis for reducing the incidence and severity of fungal infections. *Trans Proc* 23(1) (February):1528-1530, 1991.
131. Husberg BS, Goldstein RM, **Klintmalm GB**, Gonwa T, Ramsay M, Cofer J, Solomon H, and Watemberg I: A totally failing liver may be more harmful than no liver at all: three cases of total hepatic devascularization in preparation for emergency liver transplantation. *Trans Proc* 23(1) (February):1533-1535, 1991.
132. Gunning TC, Brown MR, Swygert TH, Goldstein R, Husberg BS, **Klintmalm GB**, DiBona G, Paulsen AW, Ramsay MAE, and Gonwa TA: Perioperative renal function in patients undergoing orthotopic liver transplantation. *Transplantation* 51(2) (February):422-427, 1991.
133. Gonwa TA, Morris CA, Goldstein RM, Husberg BS, and **Klintmalm GB**: Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome--experience in 300 patients. *Transplantation* 51(2) (February):428-430, 1991.
134. Cofer JB, Morris CA, Sutker WL, Husberg BS, Goldstein RM, Gonwa TA, and **Klintmalm GB**: Immunotherapy with intravenous immunoglobulins. "the effect of

- prophylactic immune globulin on cytomegalovirus infection in liver transplants." 229-235, Academic Press Ltd., 1991.
135. Gonwa TA, Morris CA, Mai ML, Husberg BS, Goldstein RG, and **Klintmalm GB**: Race and liver transplantation. *Arch Surg* 126:1141-1143, 1991.
  136. Mora NP, **Klintmalm GB**, Cofer JB, Solomon H, Goldstein RM, Gonwa TA, and Husberg BS. Results after liver transplantation in a group of 50 regrafted patients: two different concepts of elective versus emergency retransplantation. *Trans Int* 1991.
  137. **Klintmalm GB**: Rejection therapies. *Digestive Diseases and Sciences* 36(10)(October):1431-1433, 1991.
  138. McDiarmid SV, **Klintmalm G**, and Busuttil RW: FK506 rescue therapy in liver transplantation: outcome and complications. *Trans Proc* 23(6)(December):2996, 1991.
  139. Demetris AJ, Belle S, Hart J, Lewin K, Ludwig J, Snover D, Tillery GW, and Detre K. The liver transplantation database (LTD) investigators: intraobserver and interobserver variation in the histopathological assessment of liver allograft rejection. *Hepatology* 1991.
  140. Gonwa TA, Husberg B, **Klintmalm GB**, Goldstein RM, Capehart JE, Miller AH, Johnston SB, and Alivizatos PA. Simultaneous cardiac and renal transplantation: a report of three cases and review of the literature. *Journal of Heart Transplantation II* (1) (Part 1) (January/February) 1992.
  141. Mor E, **Klintmalm GB**, Gonwa TA, Solomon H, Holman MJ, Gibbs JF, Watemberg I, Goldstein RM, and Husberg, BS: Use of marginal donors for liver transplantation: A retrospective study of 365 liver donors. *Transplantation* 53:383-386, 1992.
  142. Mor E, Solomon H, Gibbs J, Holman M, Goldstein R, Husberg B, Gonwa T, and **G Klintmalm**: Acute cellular rejection following liver transplantation: clinical pathologic features and effect on outcome. *Sem in Liv Dis* 12(1) (February):28-40, 1992.
  143. Gibbs J, Holman M, Diamond N, Goldstein R, Husberg B, and **Klintmalm G**: The evolving management of complicated biliary strictures. *Trans Science* 2(1)(March):7-11, 1992.
  144. Collins R, Cooper B, Nikaein A, **Klintmalm G**, and Fay J: Graft-versus-host disease in a liver transplant recipient. *Ann of Int Med* 116:391-392, 1992.

145. Cofer J, **Klintmalm G**, Morris C, Solomon H, Watemberg I, Husberg B, and Jennings L: A prospective randomized trial between eurocollins and university of Wisconsin solutions as the initial flush in hepatic allograft procurement. *Transplantation* 53(5): 1992.
146. Howard T, **Klintmalm G**, Stone M, Cofer J, Husberg B, Goldstein R, and Gonwa T: Lymphoproliferative disorder masquerading as rejection in liver transplant recipients -- an early aggressive tumor with atypical presentation. *Transplantation* 53(5):1145, 1992.
147. Shaked A, Goldstein R, **Klintmalm G**, Drazan K, Husberg B, and Busuttill R: Portosystemic shunt versus orthotopic liver transplantation for the budd-chiari syndrome. *Surg Gyn & Obs* 174(6):453-459, 1992.
148. Paulsen AW and **Klintmalm GB**: Measurement of human hepatic blood flow during transplant. *Hepatology*, 16(1):100-111, 1992.
149. **Klintmalm GB**: De Novo lymphoma after liver transplantation. *Clin Trans* 6(3)(Part)(June): 272-274, 1992.
150. Mora N, Gonwa T, Goldstein R, Husberg B, and **Klintmalm G**: Risk of postoperative infection after liver transplantation: a univariate and stepwise logistic regression analysis of risk factors in 150 consecutive patients. *Clin Trans* 46: 443-449, 1992.
151. Mor E, Gonwa T, Husberg B, Goldstein R, and **Klintmalm G**: Late-onset acute rejection in orthotopic liver transplantation - associated risk factors and outcome. *Transplantation* 54(5):821-824, 1992.
152. Sollinger H, Belzer F, Deierhoi M, Diethelm A, Gonwa T, Kauffman R, **Klintmalm G**, McDiarmid S, Roberts J, Rosenthal J, and Tomlanovich S: RS-61443 (mycophenolate mofetil): a multicenter study for refractory kidney transplant rejection. *Annals of Surgery* 216(4):513-519, 1992.
153. Stone M, **Klintmalm G**, Polter D, Husberg B, Mennel R, Ramsay M, Flemens E, and Goldstein R: Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients. *Gastroenterology*, 104:196-202, 1993.
154. Abouljoud M, Mulligan D, and **Klintmalm GB**. Baylor update: outcome analysis in liver transplantation. *Clin Transpl*: 161-73, 1993.
155. Collins RH Jr, Anastasi J, Terstappen LW, Nikaein A, Feng J, Fay JW, **Klintmalm G**, and Stone MJ. Brief report: donor-derived long-term multilineage hematopoiesis in a liver-transplant recipient. *N Engl J Med* 28(11): 762-5, 1993.

156. Solomon H, Gonwa T, Mor E, Holman M, Gibbs J, Watemberg I, Netto G, Goldstein R, Husberg B, and **Klintmalm G**: OKT3 rescue for steroid-resistant rejection in adult liver transplantation. *Transplantation* 55(1):87-91, 1993.
157. Holman M, Gonwa T, Cooper B, Husberg B, Goldstein R, Gibbs J, and **Klintmalm G**: FK506-associated thrombotic thrombocytopenic purpura. *Transplantation* 55(1):205-206, 1993.
158. **Klintmalm G**, Goldstein R, Gonwa T, Wiesner R, Krom R, Shaw B, Stratta R, Ascher N, Roberts J, Lake J, Busuttil R, McDiarmid S, Esquivel C, Nakazato P, Marsh J, Woodie E, Kalayoglu M, D'Alessandro A, Pirsch J, Miller C, Schwartz M, Lewis W, Monaco A, Jenkins R, Emond J, Thistlethwaite J, Whittington P, Steinmuller D, Fitzsimmons W, and Lawrence I: The use of prograf (FK506) as rescue therapy for refractory rejection after liver transplantation. *Trans Proc* 25(1):679-688, 1993.
159. **Klintmalm G**, Goldstein R, Gonwa T, Wiesner R, Krom R, Shaw B, Stratta R, Ascher N, Roberts J, Lake J, Busuttil R, McDiarmid S, Esquivel C, Nakazato P, Marsh J, Woodie E, Kalayoglu, D'Alessandro A, Pirsch J, Miller C, Schwartz M, Lewis W, Monaco A, Jenkins R, Emond J, Thistlethwaite J, Whittington P, Steinmuller D, Fitzsimmons W, and Lawrence I: Use of FK506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. *Trans Proc* 25(1):635-637, 1993.
160. **Klintmalm G**, Goldstein R, Gonwa T, Wiesner R, Krom R, Shaw B, Stratta R, Ascher N, Roberts J, Lake J, Busuttil R, McDiarmid S, Esquivel C, Nakazato P, Marsh J, Woodie E, Kalayoglu, D'Alessandro A, Pirsch J, Miller C, Schwartz M, Lewis W, Monaco A, Jenkins R, Emond J, Thistlethwaite J, Whittington P, Steinmuller D, Fitzsimmons W, and Lawrence I: Prognostic factors for successful conversion from cyclosporine to FK506-based immunosuppressive therapy for refractory rejection after liver transplantation. *Trans Proc* 25(1):641-643, 1993.
161. Levy M, Backman L, Husberg B, Goldstein R, McMillan R, Gibbs J, Gonwa T, Holman M, and **Klintmalm G**: De Novo malignancy following liver transplantation: a single-center study. *Trans Proc* 25(1):1397-1399, 1993.
162. Mor E, Jennings L, Gonwa TA, Holman MJ, Gibbs JF, Solomon H, Goldstein RM, Husberg BS, Watemberg IA, and **Klintmalm GBG**. The impact of operative bleeding on outcome in liver transplantation. *Surg, Gyn & Ob* 176:219-227, 1993.
163. **Klintmalm G**, Bell M, Husberg B, Holman M, Goldstein R, Ramsay M, and Polter D: Liver transplant in complete situs inversus: a case report. *Surgery* 114(1):102-106, 1993.

164. Backman L, Gibbs J, Levy M, McMillan R, Holman M, Husberg B, Goldstein R, Gonwa T, and **Klintmalm G**: Causes of late graft loss after liver transplantation. *Transplantation* 55(5):1078-1082, 1993.
165. McDiarmid S, **Klintmalm G**, and Busuttill R: FK506 conversion for intractable rejection of the liver allograft. *Trans Int* 6:305-312, 1993.
166. Han KH, Hollinger FB, Noonan CA, Solomon H, **Klintmalm GB**, Genta RM, and Yoffe B. Southern-blot analysis and simultaneous in situ detection of hepatitis B virus-associated DNA and antigens in patients with end-stage liver disease. *Hepatology* 18(5): 1032-8, 1993.
167. Goldstein R, Stone M, Tillery G, Senzer N, Levy M, Husberg B, Gonwa T, and **Klintmalm G**: Is liver transplantation indicated for cholangiocarcinoma? *American Journal of Surgery* 166:768-772, 1993.
168. Husberg B, Genyk Y, and **Klintmalm G**: A new rat model for studies of the ischemic injury after transplantation of fatty livers: improvement after postoperative administration of prostaglandin (PGE<sub>1</sub>). *Transplantation* 57:457-482, 1994.
169. Nikaein A, Collins R, **Klintmalm G**, Poole T, Fay J, and Stone M: Immunologic monitoring of graft-versus-host-disease following orthotopic liver transplantation. *Transplantation* 57:637-640, 1994.
170. Backman L, Nicar M, Levy M, Distant D, Eisenstein C, Renard T, Goldstein R, Husberg B, Gonwa T, and **Klintmalm G**: FK506 trough levels in whole blood and plasma in liver transplant-recipients: Correlation with clinical events and side effects. *Transplantation* 57:519-525, 1994.
171. **Klintmalm G**: A review of FK506: A new immunosuppressant agent for the prevention and rescue of graft rejection. *Transplantation Reviews* 8(2):53-63, 1994.
172. **Klintmalm G**: FK506: An update. *Clin Trans* 8:207-210, 1994.
173. **Klintmalm G** and Stone M: The results of liver transplantation with adjuvant chemotherapy for hepatobiliary surgery. *J Hepato-Biliary-Pancreatic Surg* 2:141-144, 1994.
174. Nikaein A, Backman L, Jennings L, Levy M, Goldstein R, Gonwa T, Stone M, and **Klintmalm G**: HLA compatibility and liver transplant outcome: Improved patient survival by HLA and crossmatching. *Transplantation* 58(7):786-792, 1994.
175. Busuttill R, McDiarmid S, **Klintmalm G**, Goldstein R, Miller C, Schwartz M, Shaw B, Roberts J, Herbert M, Esquivel C, Nakazato P, Wiesner R, Krom R, Kalayoglu M,



- D'Alessandro A, Marsh J, Peters M, Burdick J, Klein A, Lewis W, Jenkins R, Thistlethwaite J, Emond J, Jusko W, D'Ambrosio R, Buell D, and Fitzsimmons W: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. *N Eng J Med* 331:1110-1115, 1994.
176. Abouljoud M, Levy M, Rees C, Diamond N, Lee S, Mulligan D, Goldstein R, Husberg B, Gonwa T, and **Klintmalm G**: A comparison of treatment with transjugular intrahepatic portosystemic shunt or distal splenorenal shunt in the management of variceal bleeding prior to liver transplantation. *Transplantation* 59(2):226-229, 1994.
177. Gonwa T, **Klintmalm G**, Jennings L, Goldstein R, and Husberg B: The impact of pre-transplant renal function on survival following liver transplantation. *Transplantation* 59(3):361-365, 1994.
178. Mor E, Tillery W, Solomon H, Netto G, Watenberg I, and **Klintmalm GB**. The predictive value of hepatocyte glycogen content on liver allograft biopsy. Correlation with early graft function. *Transplantation* 59(1):141-3, 1995.
179. **Klintmalm G**: Who should receive the allograft: The transplant center or the recipient? *Liver Transplantation and Surgery* 1(1):55-58, 1995.
180. Gonwa TA, **Klintmalm GB**, Levy M, Jennings LS, Goldstein RM, and Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. *Transplantation* 59(3):361-365, 1995.
181. Levy M, Jennings L, Abouljoud M, Mulligan D, Goldstein R, Husberg B, Gonwa T, and **Klintmalm G**: Quality of life improvements at one, two and five years after liver transplantation. *Transplantation* 59(4):515-518, 1995.
182. Jusko WJ, Piekoszewski W, **Klintmalm GB**, Shaefer MS, Hebert MF, Piergies AA, Lee CC, Schechter P, and Mekki QA. Pharmacokinetics of tacrolimus in liver transplant patients. *Clin Pharmacol Ther* 57(3):281-90, 1995.
183. Diamond N, Lee S, Niblett R, Rees C, and **Klintmalm G**: Metallic stents for the treatment of intrahepatic biliary strictures after liver transplantation. *Journal of Vascular and Interventional Radiology* 6:755-761, 1995.
184. Scholz T, Backman L, Mathisen O, Buo L, Karlsrud T, Johansen H, Bergan A, **Klintmalm G**, and Aasen A: Activation of the plasma contact system and hemodynamic changes after graft revascularization in liver transplantation. *Transplantation* 60(1):36, 1995.

185. Mulligan D, Gentry L, Dombrausky L, **Klintmalm G**, and Nikaein A: Monitoring of allograft recipients for the development of HLA-specific antibodies: elimination of OKT3 as a complicating factor. *Clin Trans*: 438-441, 1995.
186. Mulligan DC and **Klintmalm GB**: Should liver transplantation be performed for hepatitis B? *Clin Trans* 9(3, Part II):246-248, 1995.
187. **Klintmalm G** and Gonwa T: Nephrotoxicity associated with cyclosporine and FK506. *Liver Transplantation and Surgery*, 1(5): 11-19, 1995.
188. Holman M, Harrison D, Stewart A, Stone M, Goldstein R, Husbert B, and **Klintmalm G**. Neoadjuvant chemotherapy and orthotopic liver transplantation for hepatocellular carcinoma. *N J Med* 92(8): 519-22, 1995.
189. Collins RH Jr and **Klintmalm GB**. Aplastic anemia after liver transplantation. *Hepatology* 22(3):1011-2, 1995.
190. Lake JR, Gorman KJ, Esquivel CO, Wiesner RH, **Klintmalm GB**, Miller CM, Shaw BW, and Gordon JA. The impact of immunosuppressive regimens on the cost of liver transplantation – results from the US FK 506 multicenter trial. *Transplantation* 60(10):1089-95, 1995.
191. Tong AW, Su D, Mues G, Tillery GW, Goldstein R, **Klintmalm G**, and Stone MJ: Chemosensitization of human hepatocellular carcinoma cells with cyclosporin A in post-liver transplant patient plasma. *Clin Cancer Research* 2:531-539, 1996.
192. Busuttill RW, **Klintmalm GB**, Lake JR, Miller CM, and Porayko M. General guidelines for the use of tacrolimus in adult liver transplant patients. *Transplantation* 61(5):845-7, 1996.
193. **Klintmalm GB**: Clinical use of FK506 in liver transplantation. *Trans Proc* 28(2):974-976, 1996.
194. Miller M, Crippin J, and **Klintmalm GB**: End stage liver disease in a 13-year old secondary to hepatitis C and hemochromatosis. *American Journal of Gastroenterology* 91:7, 1427-1429, 1996.
195. Gerhardt T, Goldstein R, Urschel H, Tripp L, Levy M, Husberg G, Jennings L, Gonwa T, and **Klintmalm G**: Alcohol use following liver transplantation for alcoholic cirrhosis. *Transplantation*, 62(8): 1060-1063, 1996.
196. Kazachkov Y, Khaoustov V, Yoffe B, Solomon H, **Klintmalm GBG**, and E Tabor: p53 abnormalities in hepatocellular carcinoma from United States patients: analysis of all 11 exons. *Carcinogenesis* Vol. 17 No.10 pp. 2207-2212, 1996.

197. Brooks BK, Levy MF, Jennings LW, Abbasogulu O, Vodapally M, Goldstein RM, Husberg BS, Gonwa TA, and **Klntmalm GB**: Influence of donor and recipient gender on the outcome of liver transplantation. *Transplantation* 62:1784-1787, 1996.
198. Peltekian KM, Makowka L, Williams R, Blendis LM, Levy GA, and the Prostaglandins in Liver Transplantation Research Group: Prostaglandins in liver failure and transplantation: regeneration, immunomodulation and cytoprotection. *Liver Transplantation and Surgery* 2(3):171-184, 1996.
199. Collins R, Sackler M, Pitcher C, Waldrop S, **Klntmalm G**, Jenkins R, and Picker L: Immune reconstitution with donor-derived memory/effector T cells after orthotopic liver transplantation. *Experimental Hematology* 25:147-159, 1997.
200. Abbasoglu O, Levy M, Vodapally M, Goldstein R, Husberg B, Gonwa T, and **Klntmalm G**: Hepatic artery stenosis after liver transplantation--incidence, presentation, treatment, and long term outcome. *Transplantation* 63(2):250-255, 1997.
201. Fabia R, Travis DL, Levy MF, Husberg BS, Goldstein RM, and **Klntmalm GB**: Effect of pentoxifylline on porcine hepatic ischemia and reperfusion injury. *Surgery* 121(5):520-525, 1997.
202. Ramsay M, Simpson B, Nguyen A, Ramsay K, East C, and **Klntmalm G**: Severe pulmonary hypertension in liver transplant candidates. *Liver Transplantation and Surgery* 3(5):494-500, 1997.
203. Ramsay MAE, Schmidt A, Hein HAT, Nguyen A, Lynch K, East CA, Ramsay KJ, and **Klntmalm GBG**: Nitric oxide does not reverse pulmonary hypertension associated with end-stage liver disease: a preliminary report. *Hepatology* 25(3):524-527, 1997.
204. Ricci P, Therneau TM, Malinchoc M, Benson JT, Petz JL, **Klntmalm GB**, Crippin JS, Wiesner RH, Steers JL, Rakela J, Starzl TE, and Dickson ER. A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease. *Hepatology* 25(3):672-677, 1997.
205. The U.S. Multicenter Liver Study Group (Sher LS, Cosenza CA, Michel J, Makowka L, Miller CM, Schwartz ME, Busuttill R, McDiarmid S, Burdick JF, Klein AS, Esquivel C, **Klntmalm G**, Levy M, Roberts JP, Lake JR, Kalayoglu M, D'Alessandro AM, Gordon RD, Stieber AC, Shaw BW Jr, Thistlethwaite JR, Whittington P, Wiesner RH, Porayko M, Bynon JS, Eckhoff DE, Freeman RB, Rohrer RJ, Lewis WD, Marsh JW, Peters M, Powelson J, and Cosimi AB). Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation. *Transplantation* 1997; 64:258-63.

206. Jeyarajah DR and **Klintmalm GB**: Is liver transplantation indicated for cholangiocarcinoma? *J Hepato-Biliary-Pancreatic Surg* 1-4, 1997.
207. Jeyarajah DR, McBride M, **Klintmalm GB**, and Gonwa TA. Combined liver-kidney transplantation: what are the indications? *Transplantation* 64(8):1091-1096, 1997.
208. Pelosi F, **Klintmalm GBG**, Simon WS, and Roberts WC. Liver transplantation after coronary bypass grafting. *Am J Cardiol* 79(10):1405-1407, 1997
209. Abbasoglu O, Levy MF, Brkic BB, Testa G, Jeyarajah DR, Goldstein RM, Husberg BS, Gonwa TA, and **Klintmalm GB**. Ten years of liver transplantation. *Transplantation* 64(12):1801-1807, 1997.
210. Jeyarajah DR, Gonwa TA, McBride M, Testa G, Abbasoglu O, Husberg BS, Levy MF, Goldstein RM, and **Klintmalm GB**. Hepatorenal syndrome: combined liver kidney transplants versus isolated liver. *Transplantation* 64(12):1760-1765, 1997.
211. Testa G and **Klintmalm GB**. Liver transplantation for primary and metastatic liver cancers. *Annals of Transplantation* 2(4):19-21, 1997.
212. Kaspar MD, Ramsay AE, Shuey CB, Levy MF, and **Klintmalm GGB**. Severe pulmonary hypertension and amelioration of hepatopulmonary syndrome after liver transplantation: case report. *Liver Transplantation and Surgery* 4(2):177-179, 1998.
213. Fabia R, Levy MF, Crippin J, Tillery W, Netto GJ, Aguanno J, Dysert P, Goldstein RM, Husberg, Gonwa TA, and **Klintmalm GB**. De Novo hepatitis B infection after liver transplantation: source of disease, incidence, and impact. *Liver Transplantation and Surgery* 4(2):119-127, 1998.
214. Prabhakar G, Testa G, Abbasoglu O, Jeyarajah DR, Goldstein RM, Levy MF, Husberg BS, Gonwa TA, and **Klintmalm GB**. The safety of cardiac operations in the liver transplant recipient. *Ann Thorac Surg* 65:1060-1064, 1998.
215. Testa G, Goldstein RM, Netto G, Abbasoglu O, Brooks BK, Levy MF, Husberg BS, Gonwa TA, and **Klintmalm GB**. Long-term outcome of patients transplanted with livers from hepatitis C-positive donors. *Transplantation* 65(7):925-929, 1998.
216. Testa G, Goldstein RM, Toughanipour A, Abbasoglu O, Jeyarajah DR, Levy M, Husberg BS, Gonwa TA, and **Klintmalm GB**. Guidelines for surgical procedures after liver transplantation. *Ann Surg* 227(4):590-599, 1998.
217. Kim WR, Wiesner RH, Therneau TM, Poterucha JJ, Porayko MK, Evans RW, **Klintmalm GB**, Crippin JS, Krom RA, and Dickson ER. Optimal timing of liver transplantation for primary biliary cirrhosis. *Hepatology* 28(1):33-38, 1998.

218. The U.S. FK506 Study Group (**Klintmalm GB**, Goldstein R, Miller CM, Schwartz, Shaw BW, Roberts JP, Hebert MF, Esquivel CO, Nakazato P, Krom RAF, Kalayoglu M, D'Alessandro AM, Marsh JW, Peters MG, Burdick J, Klein A, Lewis WD, Jenkins R, Thistlethwaite JR, Edmond JC, Gadgil S, and Facklam DP). A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation. *Transplantation* 66:493-499, 1998.
219. Jeyarajah DR, Gonwa TA, Testa G, Abbasoglu O, Goldstein R, Husberg BS, Levy MF, and **Klintmalm GB**. Liver and kidney transplantation for polycystic disease. *Transplantation* 66(4):529-544, 1998.
220. Fabia R, Levy MF, Testa G, Obiekwe S, Goldstein RM, Husberg BS, Gonwa TA, and **Klintmalm GB**. Colon carcinoma in patients undergoing liver transplantation. *Am J Surg* 176:265-269, 1998.
221. **Klintmalm GB**. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. *Ann Surg* 228(4):479-490, 1998.
222. **Klintmalm GB**. Why immunology? *BUMC Proceedings* 11(4):207-208, 1998.
223. Kazachkov Y, Yoffe B, Khaoustov VI, Solomon H, **Klintmalm GBG**, and Tabor E. Microsatellite instability in human hepatocellular carcinoma: relationship to p53 abnormalities. *Liver* 18:156-161, 1998.
224. Abbasoglu O, Goldstein RM, Vodapally MS, Jennings LW, Levy MF, Husberg BS, and **Klintmalm GB**. Liver transplantation in hyponatremic patients with emphasis on central pontine myelinolysis. *Clin Trans* 12:263-269, 1998.
225. Jeyarajah DR, Netto GJ, Lee SP, Testa G, Abbasoglu O, Husberg BS, Levy MF, Goldstein RM, Gonwa TA, Tillery GW, Crippin JS, and **Klintmalm GB**. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process? *Transplantation* 66(10):1300-1306, 1998.
226. Prabhakar G, Testa G, Abbasoglu O, Jeyarajah DR, Goldstein RM, Levy MF, Husberg BS, Gonwa TA, and **Klintmalm GB**. The safety of cardiac operations in the liver transplant recipient. *Annals of Thoracic Surgery* 65:1060-1064, 1998.
227. Travis DL, Fabia R, Netto GG, Husberg BS, Goldstein RM, **Klintmalm GB**, and Levy MF. Protection by cyclosporine A against normothermic liver ischemia-reperfusion in pigs. *Journal of Surgical Research* 75(2):116-126, 1998.
228. Abbasoglu O, Levy MF, Testa G, Obiekwe S, Brkic BS, Jennings LW, Goldstein RM, Husberg BS, Gonwa TA, and **Klintmalm GB**. Does intraoperative hepatic artery

- flow predict arterial complications after liver transplantation? *Transplantation* 66(5):598-601, 1998.
229. Gross CR, Malinchoc M, Kim WR, Evans RW, Wiesner TH, Petz JL, Crippin JS, **Klintmalm GB**, Levy MF, Ricci P, Therneau TM, and Dickson ER. Quality of life before and after liver transplantation for cholestatic liver disease. *Hepatology* 29(2):356-64, 1999.
  230. Ramsay MAE, Spikes C, East CA, Lynch K, Hein HAT, Ramsay KJ, and **Klintmalm GBG**. The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol. *Anesthesiology: Case Report*. 90(1):299-301, 1999.
  231. Markmann JF, Gornbein J, Markowitz JS, Levy MF, **Klintmalm GB**, Yersiz H, Morrissey M, Drazan K, Farmer DG, Ghobrial RM, Goss J, Seu P, Martin P, Goldstein LI, and Busuttil RW. A simple model to estimate survival after retransplantation of the liver. *Transplantation* 67(3):422-430, 1999.
  232. Scholz T, Gallimore MJ, Backman L, Mathisen O, Bergan A, **Klintmalm GB**, and Aasen AO. Plasma proteolytic activity in liver transplant rejection. *Transpl Int* 12:100-107, 1999.
  233. Simpson RI, Ramsay MAE, Lynch K, Ramsay KJ, Tillmann Hein HA, Crippin JS, Sarles HE, Black RD, East CA, Escobar JM, Goldstein RM, Husberg BS, Levy MF, and **Klintmalm GBG**. Paradoxical role of inhaled nitric oxide in advanced liver disease. *BUMC Proceedings* 12(4):223-225, 1999.
  234. Kim WR, Wiesner RH, Poterucha JJ, Therneau TM, Malinchoc M, Benson JT, Crippin JS, **Klintmalm GBG**, Rakela J, Starzl TE, Krom RAF, Evans RW, and Dickson ER. Hepatic retransplantation in cholestatic liver disease: impact of the interval to retransplantation on survival and resource utilization. *Hepatology* 30(2):395-400, 1999.
  235. Klein, Andrew and the U.S. Multicenter FK506 Liver Study Group. Tacrolimus rescue in liver transplant patients with refractory rejection or intolerance or malabsorption of cyclosporine. *Liver Transplantation and Surgery* 5(6):502-508, 1999.
  236. Levy MF, Crippin J, Sutton S, Netto G, Jeff McCormack, Curiel T, Gold tein RM, Newman JT, Gonwa TA, Banchereau J, Diamond, LE, Byrne G, Logan J, and **Klintmalm GB**. Liver allotransplantation after extracorporeal hepatic support with transgenic (hCD55/hCD59) porcine livers: clinical results and lack of pig-to-human transmission of the porcine endogenous retrovirus. *Transplantation* 69(2):272-280, 2000.
  237. Tong MJ, Terrault NA, and **Klintmalm G**. Hepatitis B transplantation: special conditions. *Sem Liver Dis* 20 (Suppl. 1):25-28, 2000. (moderator)

238. Cowling T, Jennings LW, Jung GS, Goldstein RM, Molmenti E, Gonwa TA, **Klntmalm GB**, and Levy MF. Comparing quality of life following liver transplantation for Laennec's versus non-Laennec's patients. *Clin Trans* 14:115-120, 2000.
239. Molmenti EP, **Klntmalm GB**. Hepatitis C recurrence after liver transplantation. *Liver Transplantation* 6(4):413-414, 2000. (editorial)
240. Testa G, Crippin JS, Netto GJ, Goldstein RM, Jennings LW, Brkic BS, Brooks BK, Levy MF, Gonwa TA, and **Klntmalm GB**. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. *Liver Transplantation* 6(5):553-561, 2000.
241. Molmenti EP and **Klntmalm GB**. Cancer and liver transplantation. *Transplantation Reviews* 14(4): 183-198, 2000.
242. Levy MF, Somasundar PS, Jennings LW, Jung GJ, Molmenti EP, Fasola CG, Goldstein RM, Gonwa TA, and **Klntmalm GB**. The elderly liver transplant recipient: a call for caution. *Annals of Surgery* 233(1):107-113, 2001.
243. Levy MF, Greene L, Ramsay MAE, Jennings LW, Ramsay KJ, Meng J, Hein HAT, Goldstein RM, Husberg BS, Gonwa TA, and **Klntmalm GB**. Readmission to the ICU following liver transplantation. *Critical Care Medicine* 29(1):18-24, 2001.
244. Wiesner R, Rabkin J, **Klntmalm G**, McDiarmid S, Langnas A, Punch J, McMaster P, Kalayoglu M, Levy G, Freeman R, Bismuth H, Neuhaus P, Mamelok R, and Wang W. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. *Liver Transplantation* 7(5):442-450, 2001.
245. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, and **Klntmalm GB**. Renal replacement therapy and orthotopic liver transplantation: The role of continuous veno-venous hemodialysis. *Transplantation* 71(10):1424-1428, 2001.
246. Molmenti EP, Molmenti H, Marubashi S, Sanchez EQ, Gogel B, Goldstein RM, Levy MF, Fasola CG, Gonwa TA, and **Klntmalm GB**. Cannulations of the aorta in organ donors with aortic and caval injuries at the time of procurement. *Pediatr Transplantation* 5(5):378-380, 2001.
247. Molmenti EP, Nagata DE, Roden JS, Squires RH, Molmenti H, Fasola CG, Winick N, Tomlinson G, Lopez MJ, D'Amico L, Dyer HL, Savino AC, Sanchez EQ, Levy MF, Goldstein RG, Andersen JA, and **Klntmalm GB**. Posttransplant

- lymphoproliferative syndrome in the pediatric liver transplant population. *American Journal of Transplantation* 1(4):356-359, 2001.
248. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, and **Klintmalm GB**. End stage renal disease (ESRD) after orthotopic liver transplantation (OLT) using calcineurin based immunotherapy: risk of development and treatment. *Transplantation* 72(12):1934-1939, 2001.
  249. Molmenti EP, Molmenti H, Marubashi S, Sanchez EQ, Gogel BM, Goldstein RM, Levy ML, Fasola CG, Gonwa TA, and **Klintmalm GB**. Cannulation of the aorta in organ donors with Infrarenal Aortic Pathologies. *Digestive Diseases and Sciences* 46 (11):2457-2459, 2001.
  250. Scholz T, Solberg R, Okkenhaug C., Videm V, Gallimore MJ, Mathisen O, Pedersen T, Mollnes TE, Bergan A, Soreide O, **Klintmalm GB**, and Aasen AO. Veno-venous bypass in liver transplantation: heparin-coated perfusion circuits reduce the activation of humoral defense systems in an in vitro model. *Perfusion* 16(4), 285-292, 2001.
  251. **Klintmalm GB**. Marketing - what is it? *Graft* 4(6):421-423, 2001.
  252. Scholz T, Solberg R, Okkenhaug C, Videm V, Gallimore MJ, Mathisen O, Mollnes TE, Bergan A, Soreide O, **Klintmalm GB**, and Aasen AO. The significance of heparin-coated veno-venous bypass circuits in liver transplantation. *Perfusion* 17(1):45-50, 2002.
  253. Molmenti EP, Roodhouse TW, Molmenti H, Jaisway K, Jung GJ, Marubashi S, Sanchez EQ, Gogel B, Levy MF, Goldstein RM, Fasola CG, Elliott EE, Bursac N, Mulligan D, Gonwa TA, and **Klintmalm GB**. Thrombectomy for organized portal vein thrombosis at the time of liver transplantation. *Annals of Surgery* 235(2): 292-296, 2002.
  254. Molmenti EP, Levy MF, Molmenti H, Casey D, Fasola CG, Hamilton WM, Ghapjoong J, Marubashi S, Gogel BM, Goldstein RM, Gonwa TA, and **Klintmalm GB**. Correlation between intraoperative blood flows and hepatic artery strictures in liver transplantation. *Liver Transplantation* 8(2): 160-163, 2002.
  255. Sanchez EQ, Marubashi S, Jung G, Levy MF, Goldstein RM, Molmenti EP, Fasola CG, Gonwa TA, Jennings LW, Brooks BK, and **Klintmalm GB**. DeNovo tumors after liver transplantation: a single-institution experience. *Liver Transplantation* 8(3): 285-291, 2002.
  256. Gonwa TA, Mai ML, Melton LB, Levy MF, Goldstein RM, and **Klintmalm GB**. Immunosuppression for delayed or slow graft function in primary cadaveric



- renal transplantation: Use of low dose tacrolimus therapy with postoperative administration of anti-CD25 monoclonal antibody. *Clin Transplant* 16(2):144-149, 2002.
257. Molmenti EP, Netto GJ, Murray NG, Smith DM, Molmenti H, Crippin JS, Hoover TC, Jung GJ, Marubashi S, Sanchez EQ, Gogel B, Levy MF, Goldstein RM, Fasola CG, Gonwa TA, and **Klintmalm GB**. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. *Liver Transplantation* 8(6): 519-526, 2002.
258. Molmenti EP, Wilkinson K, Molmenti H, Roden JS, Squires RH, Fasola CG, Tomlinson G, Nagata DE, D'Amico L, Lopez MJ, Savino LM, Marubashi S, Sanchez ES, Goldstein RM, Levy MF, Andrews W, Andersen JA, and **Klintmalm GB**. Treatment of unresectable hepatoblastoma with liver transplantation in the pediatric population. *American Journal of Transplantation* 2: 535-538, 2002.
259. Fasola CG and **Klintmalm GB**. Letter to the Editor: Hepatitis C and mycopholate mofetil – a clarification. *Liver Transplantation* 8(4):411-413, 2002.
260. Molmenti EP and **Klintmalm GB**. Liver transplantation in association with hepatocellular carcinoma: an update of the international tumor registry. *Liver Transplantation* 8(9):736-748, 2002
261. Melear JM, Goldstein RM, Levy MF, Molmenti EP, Cooper B, Netto GJ, **Klintmalm GB**, and Stone MJ. Hematologic aspects of liver transplantation for budd-chiari syndrome with special reference to myeloproliferative disorders. *Transplantation* 74(8):1090-1095, 2002.
262. Molmenti EP, Smith DM, Molmenti H, Fasola CG, Aguanno JJ, Savino AC, Peterson TS, Barshes V, Levy MF, Goldstein RM, and **Klintmalm GB**. Unusually high incidence of positive HTLV I/II Results among young female organ donors in the peripartum period. *Digestive Diseases and Sciences* 47 (11):2383-2385, 2002.
263. Yoon D, Kueppers F, Genta RM, **Klintmalm GB**, Khaoustov VI, and Yoffe B. Role of alpha-1-antichymotrypsin deficiency in promoting cirrhosis in two siblings with heterozygous alpha-1-antitrypsin deficiency phenotype SZ. *Gut* 50(5):730-2, May 2002.
264. Onaca NN, Levy MF, Sanchez EQ, Chinnakotla S, Fasola CG, Thomas MJ, Weinstein JS, Murray NG, Goldstein RM, and **Klintmalm GB**. A correlation between the pretransplantation MELD score and mortality in the first two years after liver transplantation. *Liver Transplantation* 9(2):117-23, 2003.
265. Smith DM, Agura E, Netto G, Collins R, Levy M, Goldstein R, Christensen L, Baker J, Altrabulsi B, Osowski L, McCormack J, Fichtel L, Dawson DB, Domiati-Saad R,

- Stone M, and **Klntmalm G**. Liver transplant-associated graft-versus-host disease. *Transplantation* 75(1):118-126, 2003.
266. Molmenti EP, Molmenti H, Weinstein J, Elliott EE, Fasola CG, Orr D, Blum J, Savino D, Hamilton WM, Goldstein RM, Levy MF, and **Klntmalm GB**. Syndromic incidence of ovarian carcinoma after liver transplantation, with special reference to antecedent breast cancer. *Digestive Diseases and Sciences* 48 (1):187-189, 2003.
267. Sanchez EQ, Goldstein RM, **Klntmalm GB**, and Levy MF. Porcine hepatocytes for use in bioartificial liver support. *Verdauungskrankheiten* Jahrgang 21 (1):24-31, 2003.
268. Molmenti EP, Squires RH, Nagata D, Roden JS, Molmenti H, Fasola CG, Prestidge C, D'Amico L, Casey D, Sanchez EQ, Goldstein RM, Levy MF, Benser M, McPhail W, Andrews W, Andersen JA, and **Klntmalm GB**. Liver transplantation for cholestasis associated with cystic fibrosis in the pediatric population. *Pediatr Transplantation* 7(2):93-97, 2003.
269. Onaca NN, Levy MF, Netto, GJ, Thomas MJ, Sanchez EQ, Chinnakotla S, Fasola CG, Weinstein JS, Murray N, Goldstein RM, and **Klntmalm GB**. Pretransplant MELD score as a predictor of outcome after liver transplantation for chronic hepatitis C. *Am J Transplant* 3(5):626-630, 2003.
270. Onaca N, Goldstein RM, Levy MF, and **Klntmalm GB**. Baylor Regional Transplant Institute: an update on liver, kidney, and pancreas transplantation. *BUMC Proceedings* 16:297-301, 2003.
271. Onaca N, Goldstein RM, and **Klntmalm GB**. Xanthomas disappear rapidly after liver transplantation for familial hypercholesterolemia. *Liver Transplantation* 9(12): 1334-5, 2003.
272. Gonwa TA, Mai ML, and **Klntmalm GB**. Chronic renal failure after transplantation of a nonrenal organ. *N Engl J Med* 349(26): 2563-2565, 2003.
273. Sanchez EQ, Levy MF, Goldstein RM, Fasola CG, Tillery GW, Netto GJ, Watkins DL, Weinstein JS, Murray NG, Byers D, Christensen LL, and **Klntmalm GB**. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. *Transplantation* 76(11): 1583-1588, 2003.
274. Cowling T, Jennings LW, Sanchez EQ, Goldstein RM, Chinnakotla S, **Klntmalm GB**, and Levy MF. Societal reintegration after liver transplantation: findings in alcohol-related and nonalcohol-related transplant recipients. *Annals of Surgery* 239(1): 93-98, 2004.

275. Cowling T, Jennings LW, Goldstein RM, Sanchez EQ, Chinnakotla S, **Klintmalm GB**, and Levy MF. Liver transplantation and health-related quality of life: scoring differences between men and women. *Liver Transplantation* 10(1):88-96, 2004.
276. Kefalas CH, Murray NGB, Aguanno JJ, Docker WD, Weinstein JS, Anderson K, and **Klintmalm GB**. Pseudohypocalcemia after magnetic resonance imaging with gadolinium in patients with cirrhosis. *Liver Transplantation* 10(1): 136-140, 2004.
277. Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, and **Klintmalm GB**. Estimation of glomerular filtration rates before and after orthotopic liver transplantation; evaluation of current equations. *Liver Transplantation* 10(2):301-309, 2004.
278. Guirl MJ, Goldstein RM, Levy MF, **Klintmalm GB**, and Weinstein JS. Two stage total hepatectomy and liver transplantation for acute deterioration of chronic liver disease: a new bridge to transplantation. *Liver Transplantation* 10(4): 564-70, 2004.
279. Martin P, Busuttil RW, Goldstein RM, Crippin JS, **Klintmalm GB**, Fitzsimmons WE, and Uleman C. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. *Liver Transpl* 10(10): 1258-1262, 2004.
280. Levy G, Villamil F, Samuel D, Sanjuan F, Grazi G, Wu Y, Marotta P, Boillot O, Muelbacher F, **Klintmalm G**, and LIS2T Study Group. Results of LIS2T, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus C0 monitoring in de novo liver transplantation. *Transplantation* 77(11):1632-8, 2004.
281. Arenas JI, Gallegos-Orozco JF, Laskus T, Wilkinson J, Khatib Am, Fasola C, Adair D, Radowski M, Kibler KV, Nowicki M, Douglas D, Williams J, Netto G, Mulligan D, **Klintmalm G**, Rakela J, and Vargas HE. Hepatitis C virus quasispecies dynamics predict fibrosis progression after liver transplantation. *J of Infect Dis* 189(11): 2037-46, 2004
282. Onaca N, **Klintmalm GB**, and Levy MF. Pancreatic islet cell transplantation: a treatment strategy for type I diabetes mellitus. *Nutrition in Clinical Practice* 19(2):154-164, 2004.
283. Brown RS, Rush SH, Rosen HR, Langnas AN, **Klintmalm GB**, Hanto DW, and Punch JD. Liver and intestine transplantation. *American Journal of Transplantation* 4(9): 81-92, 2004.

284. Peters TG, Spinola KN, West JC, Aeder MI, Danovitch GM, **Klintmalm GBG**, Gorman KJ, Gordon JA, Kincaid CH, and First MR. Differences in Patient and Transplant Professional Perceptions of Immunosuppression-Induced Cosmetic Side Effects. *Transplantation* 78(4): 537-543, 2004
285. Sanchez EQ, Gonwa TA, Levy MF, Goldstein RM, Mai MM, Hays SR, Melton LB, Saracino G, and **Klintmalm GB**. Pre and perioperative predictors of the need for renal replacement therapy (RRT) following orthotopic liver transplantation (OLT). *Transplantation* 78(7): 1048-1054, 2004.
286. Florman S, Alloway R, Kalayoglu M, Lake K, Bak T, Klein A, **Klintmalm G**, Busque S, Brandenhagen D, Lake J, Wisemandle K, Fitzsimmons W, and First MR. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. *Transplant Proc* 37(2):1211-1213, 2005.
287. Srinivasan A, Burton EC, Kuehnert MJ, Rupprecht C, Sutker WL, Ksiazek TG, Paddock CD, Guarner J, Shieh WJ, Goldsmith C, Hanlon CA, Zoretic J, Fischbach B, Niezgoda M, El-Feky WH, Orciari L, Sanchez EQ, Likos A, **Klintmalm GB**, Cardo D, LeDuc J, Chamberland ME, Jernigan DB, Zaki SR, and Rabies in Transplant Recipients Investigation Team. Transmission of rabies virus from an organ donor to four transplant recipients. *N Engl J Med* 352(11):1103-1111, 2005.
288. Lucey MR, Abdelmalek MF, Gagliardi R, Granger D, Holt C, Kam I, **Klintmalm G**, Langnas A, Shetty K, Tzakis A, and Woodle ES. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. *Am J Transplant* 5(5):1111-1119, 2005.
289. Cowling T, Jennings LW, Goldstein RM, Sanchez EQ, Chinnakotla S, Dawson S, III, Randall HB, **Klintmalm GB**, and Levy MF. MELD scores do not predict patient morbidity while on the liver transplant waiting list. *Transplantation Proceedings* 37:2174-2178, 2005.
290. Singh N, Lortholary O, Alexander BD, Gupta KL, John GT, Pursell K, Munoz P, **Klintmalm GB**, Stosor V, del Busto R, Limaye AP, Somani J, Lyon M, Houston S, House AA, Pruett TL, Orloff S, Humar A, Dowdy L, Garcia-Diaz J, Kalil AC, Fisher RA, Husain S, and Cryptococcal Collaborative Transplant Study Group. An immune reconstitution syndrome-like illness associated with *Cryptococcus neoformans* infection in organ transplant recipients. *Clin Infect Dis* 40(12):1756-1761, 2005.
291. Burton EC, Burns DK, Opatowsky MJ, El-Feky WH, Fischbach B, Melton L, Sanchez E, Randall H, Watkins DL, Chang J, and **Klintmalm G**. Rabies encephalomyelitis: clinical, neuroradiological, and pathological findings in 4 transplant recipients. *Arch Neurol* 62(6):873-882, 2005.

292. Planinsic RM, van der Meer J, Testa G, Grande L, Candela A, Porte RJ, Ghobrial RM, Isoniemi H, Schelde PB, Erhardttsen E, **Klntmalm G**, and Emre S. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. *Liver Transpl* 11(8):895-900, 2005.
293. Onaca N, Sanchez EQ, Melton LB, Netto GJ, Glastad KA, Martin PA, Ueno T, Levy MF, Goldstein RM, and **Klntmalm GB**. Cadaveric orthotopic auxiliary split liver transpanatation and kidney transplantation: an alternative for type 1 primary hyperoxaluria. *Transplantation* 80(3): 421-4, 2005.
294. Sanchez EQ, Martin AP, Kiegami T, Uemura T, Narasimhan G, Goldstein RM, Levy MF, Chinnakotla S, Dawson S, Randall HB, Saracino G, and **Klntmalm GB**. Sirolimus conversion after liver transplantation: improvement in measure glomerular filtration rate after 2 years. *Transplantation Proceedings* 37:4416-4423, 2005.
295. Uemura T, Sanchez EQ, Ikegami T, Watkins D, Narasimhan G, McKenna GJ, Chinnakotla S, Dawson S, III, Randall HB, Levy MF, Goldstein RM, and **Klntmalm GB**. Successful combined liver and kidney transplant for COACH syndrome and 5-yr follow-up. *Clin Transplant* 19:717-720, 2005.
296. Singh N, Lorthoary O, Alexander BD, Gupta KL, John GT, Pursell K, Munoz P, **Klntmalm GB**, Stosor V, delBusto R, Limaye AP, Somani J, Lyon M, Houston S, House AA, Pruett TL, Orloff S, Humar A, Dowdy L, Garcia-Diaz J, Fisher RA, Husain S, and the Cryptococcal Collaborative Transplant Study Group. Allograft loss in renal transplant recipients with Cryptococcus neoformans associated immune reconstitution syndrome. *Transplantation* 80(8): 1131-1133, Oct. 2005.
297. Singh N, Lorthoary O, Alexander BD, Gupta KL, John GT, Pursell K, Munoz P, **Klntmalm GB**, Stosor V, delBusto R, Limaye AP, Somani J, Lyon M, Houston S, House AA, Pruett TL, Orloff S, Humar A, Dowdy L, Garcia-Diaz J, Fisher RA, Husain S, and the Cryptococcal Collaborative Transplant Study Group. Antifungal management practices and evolution of infection in organ transplant recipients with Cryptococcus neoformans infection. *Transplantation* 80(8):1033-1039, Oct. 2005.
298. Domiati-Saad R, **Klntmalm GB**, Netto G, Agura ED, Chinnakotla S, and Smith DM. Acute graft versus host disease after liver transplantation: patterns of lymphocyte chimerism. *Am J Transplant* 5:2968-2973, 2005.
299. Washburn WK, Teperman LW, Heffron TG, Douglas DD, Gay S, Katz E, and **Klntmalm GB**. A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study. *Liver Transpl* 12(2), 2006.

300. Singh N, Limaye AJ, Forrest G, Safdar N, Munoz P, Pursell K, Houston S, Rosso F, Montoya JG, Patton P, Del Busto R, Aguado JM, Fisher RA, **Klntmalm GB**, Miller R, Wagener MM, Lewis RE, Kontoyiannis DP, and Husain S. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. *Transpl* 81(3), 2006.
301. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, Benson J, Therneau T, Kremers W, Wiesner R, Kamath P, and **Klntmalm G**. Evidence-based incorporation of serum sodium concentration into MELD. *Gastroenterology* – accepted for publication, 2006.
302. Ueno T, Jones G, Martin A, Ikegami T, Sanchez EQ, Chinnakotla S, Randall HB, Levy MF, Goldstein RM, and **Klntmalm GB**. Clinical outcomes from hepatic artery stenting in liver transplantation. *Liver Transplantation* 12:522-427, 2006.
303. Onaca N, Levy MF, Ueno T, Martin AP, Sanchez EQ, Chinnakotla S, Randall HB, Dawson S, Goldstein RM, Davis GL, and **Klntmalm GB**. An outcome comparison between primary liver transplantation and retransplantation based on the pretransplant MELD score. *Transplant International* 19:282-287, 2006.
304. Ueno T, Jones G, Martin A, Ikegami T, Sanchez EQ, Chinnakotla S, Randall HB, Levy MF, Goldstein RM, and **Klntmalm GB**. Clinical outcomes from hepatic artery stenting in liver transplantation. *Liver Transplantation* 12:422-427, 2006.
305. Smith DM, Agura ED, Levy MF, Melton LB, Domiati-Saad R, and **Klntmalm G**. Graft vs. host disease following kidney transplantation using a ‘0 HLA antigen mismatched’ donor. *Nephrol Dial Transplant* 2006.
306. Netto GJ, Altrabulsi B, Katabi N, Martin P, Burt K, Levy M, Sanchez E, Watkins DL, Jennings L, **Klntmalm G**, and Goldstein R. Radio frequency ablation of hepatocellular carcinoma prior to liver transplantation: a histologic and TUNEL study. *Liver International* 26:746-751, 2006.
307. Netto GJ, Colby T, Williams JW, Sharky F, Corless C, Lewin D, Petrovic L, Kanel G, Theise N, **Klntmalm G**, and the Hepatitis C 3 Trial Group. Interobserver agreement in hepatitis C grading and staging and Banff grading schema for acute cellular rejection: the “Hepatitis C 3” multi-institutional trial experience. *Archives of Pathology & Laboratory Medicine* – accepted for publication, 2006.

## NON-PEER REVIEWED JOURNALS

1. Starzl TE, Hakala TR, Iwatsuki S, Rosenthal TJ, Shaw Jr BW, **Klintmalm G**, and Porter KA: Cyclosporin A and steroid treatment in 104 cadaveric renal transplantations. 365-377. In: *Cyclosporin A: Proceedings of an International Conference on Cyclosporin A*, D.J.G. White, ed. Elsevier Biomedical Press, Oxford, 1982. 32:365-377, 1982.
2. Husberg BS and **Klintmalm GBG**: Rejection treatment with monoclonal OKT3 antibodies after renal transplantation - a case. *Texas Medicine* 82,(December):45-47, 1986.
3. Bryan CF, Newman JT, Tillquist RL, Husberg B, **Klintmalm GB**, and Stone MJ: Development of class I-directed lymphocytotoxic antibodies after liver transplantation. *Trans Proc*, 19(1) (February):2392-2393, 1987.
4. Husberg BS and **Klintmalm GB**: Establishing a center for liver transplantation at baylor university medical center--a two year perspective. *BUMC Proceedings*, 1(1):9-15, January, 1988.
5. Markus BH, Duquesnoy RJ, Gordon RD, Fung JJ, Vanek M, **Klintmalm G**, Bryan C, Van Thiel D, and Starzl TE: Association of HLA compatibility and decreased liver transplant survival. *Trans Proc* 20(1) (Suppl 1) (February): 43-44, 1988.
6. Husberg BS, Olson LM, Neely SJ, Nery JR, and **Klintmalm GB**: Prophylactic low-dose amphotericin B treatment prevents invasive candida infection in high-risk liver transplant patients. *Trans Proc* 20(1) (Suppl 1) (February):659-660, 1988.
7. Olson LM, **Klintmalm GB**, Husberg BS, and Nery J: Physiological aberrations diagnostic of hepatic graft nonfunction: a case report. *Trans Proc* 20(1) (Suppl 1) (February):667-668, 1988.
8. Fehrman I, Greene CL, Tillery W, **Klintmalm G**, and Husberg B: Liver transplant aspiration cytology as a clinical tool for diagnosing allograft rejection. *Trans Proc* 20(1) (Suppl 1) (February):685-686, 1988.
9. Greene CL, Fehrman I, Tillery GW, Husberg BS, and **Klintmalm GB**: Liver transplant aspiration cytology is a useful tool for identifying and monitoring allograft rejection. *Trans Proc* 20(1) (Suppl 1) (February):687-688, 1988.
10. Ramsay MAE, **Klintmalm G**, Brajtbord D, Swygert T, Valek TR, and Paulsen AW: Air embolism during liver transplantation. (Letter to the Editor) *Anesthesiology* 68:829-830, 1988.

11. Makowka L, Sher L, Kahn D, Tzakis AG, Todo S, Marsh JW, Stieber A, Koneru B, **Klintmalm GBG**, Staschak SM, Iwatsuki S, Gordon RD, Van Thiel D, and Starzl TE: *Liver transplantation: a guideline for patient evaluation*.
12. Tillery W, Demetris J, Watkins D, Goldstein R, Poplawski S, Husberg B, and **Klintmalm G**: Pathologic recognition of preservation injury in hepatic allografts with six months follow-up. *Trans Proc* 21(1) (February):1330-1331, 1989.
13. Edwards LC, Nikaein A, Bryan C, Gonwa T, **Klintmalm G**, Husberg B, White M, and Stone MJ: The predictive role of immunologic tests in liver transplant rejection. *Trans Proc* 21(1) (February):2282-2283, 1989.
14. Paulsen AW, Brajtbord D, **Klintmalm GB**, Ramsay MAE, Valek TR, and Swygert TH: Intraoperative measurements related to subsequent hepatic graft failure. *Trans Proc*, 21(1) (February):2337-2388, 1989.
15. Secrest CL, Goldstein RM, **Klintmalm GB**, Paulsen WA, Nery JR, Husberg BS, and Poplawski SC: Arterial grafts for revascularization of liver transplants. *Trans Proc* 21(1) (February):2345-2346, 1989.
16. Brajtbord D, Paulsen AW, Ramsay MAE, Swygert TH, Valek TR, Ramon VJ, Johnson DD, Parks RI, Pyron JT, Walling PT, and **Klintmalm GB**: Potential problems with autotransfusion during hepatic transplantation. *Trans Proc* 21(1) (February):2347-2348, 1989.
17. Paulsen AW, Valek TR, Ramsay M, Swygert T, and **Klintmalm G**: Determination of an adequate flush volume for removal of preservation fluid prior to revascularization of the donor liver. *Trans Proc* 21(1) (February):2349-2350, 1989.
18. Gonwa TA, Poplawski S, Paulsen W, Brajtbord D, Goldstein R, Husberg B, and **Klintmalm G**: Hepatorenal syndrome and orthotopic liver transplantation. *Trans Proc* 21(1) (February):2419-2420, 1989.
19. Husberg B and **Klintmalm G**: Portocaval shunt in preparation for emergency liver transplantation. *Transplantation* (Letters to Editor) 47(3):574, 1989.
20. **Klintmalm GB**: Rejection therapies; Presented at the AASLD Liver Transplant Roundtable, Chicago, Ed. Dr. David Van Thiel, October 27, 1989.
21. Persson NH, Brown M, Goldstein R, Husberg B, Paulsen A, Ramsay M, and **Klintmalm G**: Inferior mesenteric vein cannulation for veno-venous bypass during liver transplantation: alternative access in difficult hilar dissection. *Trans Proc* 22(1) (February):174, 1990.



22. Mora NP, **Klintmalm GB**, Poplawski SS, Cofer JB, Husberg BS, Gonwa TA, and Goldstein RM: Recurrence of hepatitis B after liver transplantation: does hepatitis-B-immunoglobulin modify the recurrent disease? *Trans Proc* 22(4) (August):1549-1550, 1990.
23. Goldstein R, Clark P, **Klintmalm G**, Husberg B, Gonwa T, and Stone M: Prevention of recurrent thrombosis following liver transplantation for budd-chiari syndrome associated with myeloproliferative disorders: treatment with hydroxyurea and aspirin. *Trans Proc* 23(1) (February):1559-1560, 1991.
24. Turrion VS, Mora NP, Cofer JB, Solomon H, Morris CA, Gonwa TA, Goldstein RM, Husberg BS, and **Klintmalm GB**: retrospective evaluation of liver transplantation for cirrhosis: a comparative study of 100 patients with or without previous porto-systemic shunt. *Trans Proc* 23(1) (February):1570-1571, 1991.
25. Goldstein RM, **Klintmalm GK**, Husberg BS, Gonwa TA, and Polter D: Liver transplantation: a review of the first 200 patients. *Trans Proc* 23(2)(April):1991.
26. Brown M, Gunning T, Roberts C, Swygert T, **Klintmalm GB**, Ramsay, MAE and Gonwa TA: biochemical markers of renal perfusion are preserved during liver transplantation with venovenous bypass. *Trans Proc* 23(3) (June):1980-1981, 1991.
27. Gibbs JF, Holman MJ, Travis DL, Genyk YS, **Klintmalm GB**, and Paulsen AW: Portal vein oxygenation in an isolated porcine liver perfusion model. Poster Presentation: Fellow's Conference on Transplantation Chicago, IL, November 1991.
28. Klintmalm G, guest editor of *Dallas Medical Journal*, Special Transplant Update Issue, December 1991.
29. Mora NP, **Klintmalm GB**, Solomon H, Goldstein R, Gonwa T, and Husberg B: Selective amphotericin B. prophylaxis in the reduction of fungal infections after liver transplant. *Trans Proc* 24(1)(February):154-155, 1992.
30. Mora NP, **Klintmalm GB**, Solomon H, Goldstein RM, Gonwa TA, and Husberg BS: Survival after liver transplantation in 300 consecutive patients: the influence of age, clinical status, and pretransplant disease. *Trans Proc* 24(1)(February):156-157, 1992.
31. Mora N, Husberg B, Gonwa T, Goldstein R, and **Klintmalm G**: The impact of the different severe infections on the outcome of liver transplantation. A study of 150 patients. *Trans Int* 5(Suppl 1): S209-S210. 1992.
32. Collins RH, Cooper C, Nikaein A, **Klintmalm G**, and Fay J: Letter to the Editor, *Annals of Internal Medicine* 117 (15 July):2, 1992.

33. **Klintmalm G:** Liver transplantation: issues in 1992. Presentation: 19th Annual Winter Nephrology Symposium, Beaver Creek, Colorado, February, 1992.
34. **Klintmalm G,** Ascher N, Busuttill R, Deierhoi M, Gonwa T, Kauffman R, McDiarmid S, Poplawski S, Sollinger H, and Roberts J: RS-61443 for treatment-resistant human liver rejection. *Trans Proc* 25(1):697, 1993.
35. Gibbs J, Husberg B, **Klintmalm G,** Backman L, Levy M, Goldstein R, Holman M, Gonwa T, and Morris C: Outcome analysis of FK506 therapy for acute and chronic rejection. *Trans Proc* 25(1):622-623, 1993.
36. Goldstein R, Tripp L, Clemons J, Husberg B, Gonwa T, Polter D, and **Klintmalm GB:** Liver transplantation for alcoholic cirrhosis -- do they mix? *Trans Proc* 25(1):1131-1132, 1993.
37. Stephens J, Goldstein R, Crippin J, Husberg B, Holman M, Gonwa T, and **Klintmalm GB.** Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients. *Trans Proc* 25(1):1122-1123, 1993.
38. Backman L, Gibbs J, Levy M, McMillan R, Holman M, Husberg B, Goldstein R, Gonwa T, and **Klintmalm G:** Late graft loss after liver transplantation: a study of 434 consecutive patients. *Trans Proc* 25(1):1111-1112, 1993.
39. Sollinger H, Belzer F, Deierhoi M, Diethelm A, Gonwa T, Kauffman R, **Klintmalm G,** McDiarmid S, Roberts J, Rosenthal J, and Tomlanovich: RS-61443: rescue therapy in refractory kidney transplant rejection. *Trans Proc* 25(1):698-699, 1993.
40. **Klintmalm G,** Ascher N, Busuttill R, Deierhoi M, Gonwa T, Kauffman R, McDiarmid S, Poplawski S, Sollinger H, and Roberts J: RS-61443 for treatment-resistant human liver rejection. *Trans Proc* 25(1):697, 1993.
41. **G.B. Klintmalm,** J.F. Gibbs, R. McMillan, L. Backman, M. Levy, R.M. Goldstein, B.S. Husberg, M.J. Holman and T.A. Gonwa. Rejection: FK 506 for rescue or maintenance. *Trans Proc* 25(2):1914-1915, 1993.
42. **Klintmalm G:** FK506 - an update. Presentation: Fourth American Society of Transplant Surgeons Post Graduate Course, Houston, Texas, May 22, 1993.
43. Gonwa T, Goldstein R, Holman M, Husberg B, and **Klintmalm G:** Orthotopic liver transplantation and renal function: Outcome of hepatorenal syndrome and trial of verapamil for renal protection in nonhepatorenal syndrome. *Trans Proc* 25(2): 1891-1892, 1993.

44. **Klintmalm G:** The business of transplantation: Contracts, negotiations, and preferred providers. *J Transplant Coordination* 3:147-149, 1993.
45. Backman L, Nicar M, Levy M, Distant D, Eisenstein C, Renard T, Goldstein R, Husberg B, Gonwa T, and **Klintmalm G:** Chronic nephrotoxicity of FK506 after liver transplantation. *Trans Proc* 26(3):1803, 1994.
46. Backman L, Nicar M, Levy M, Distant D, Eisenstein C, Renard T, Goldstein R, Husberg B, Gonwa T, and **Klintmalm G:** Whole blood and plasma levels of FK506 after liver transplantation: Correlation with toxicity. *Trans Proc* 26(3):1804, 1994.
47. Gross CR, Savik SK, Ascher NL, Gordon RD, **Klintmalm GB,** Payne W, Shaw BW, Strasburg K, Parker A, Wiesner RH, et al. Effect of cyclosporine dosing on creatinine levels in hepatic transplant recipients. *Transplant Proc* 26(5): 2686-90, 1994.
48. Dawidson I, Lu C, Ar'Rajab A, **Klintmalm G,** Dickerman R, Trevino G, Melone D, Wallace J, Remmich S, and Risser R: Perioperative albumin and verapamil improve early outcome after cadaver renal transplantation. *Trans Proc* 26(6):3100-3101, 1994.
49. **Klintmalm G:** Hepatoma and liver transplantation (a commentary). *Transplantation Science* 4(1):1-4, 1994.
50. Porayko MK, Gonwa TA, **Klintmalm GB,** and Wiesner RH. Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US multicenter trial. US Multicenter Liver Study Group. *Trans Proc* 27(1):1114-6, 1995.
51. Abouljoud M, Levy M, Goldstein R, Mulligan D, Husberg B, Gonwa T, Crippin J, and **Klintmalm G:** Hyperlipidemia after liver transplantation: A randomized trial of FK506 versus Cyclosporine a US multicenter trial. *Trans Proc* 27(1):1121-1123, 1995.
52. Backman L, **Klintmalm G,** and U.S. FK506 Multicenter Study Group: Whole blood and plasma levels of FK506 after liver transplantation: Results from the U.S. multicenter trial. *Trans Proc* 27(1):1124, 1995.
53. Nikaein A, Backman L, Jennings L, Levy M, Goldstein R, Gonwa T, Stone M, and **Klintmalm G.** HLA compatibility and liver transplant outcome: improved patient survival by HLA and crossmatching. *Trans Proc* 27(1):1186-8, 1995.
54. Mulligan D, Goldstein R, Crippin J, Abouljoud M, Levy M, Husberg B, Gonwa T, Foster B, Tillery G, and **Klintmalm G:** The use of anti-hepatitis C virus seropositive organs in liver transplantation. *Trans Proc* 27(1):1204-1205, 1995.

55. Fabia R, Levy M, Travis D, Goldstein M, Husberg B, and **Klntmalm G**: The effect of cyclosporine A pretreatment on porcine hepatic ischemia followed by reperfusion. *Surgical Forum XLVI*, 1995.
56. Hasse J, Blue L, Liepa G, Goldstein R, Jennings L, Mor E, Husberg B, Levy M, Gonwa T, and **Klntmalm G**: Early enteral nutrition support in patients undergoing liver transplantation. *Journal of Parenteral and Enteral Nutrition* 0148-0671/95/1906-0437, 1995.
57. **Klntmalm GBG**: Update on solid organ transplantation. *Dallas Medical Journal*: 222-225, June 1996.
58. Levy MF, Crippin JS, Abbasoglu O, Vodapally M, Goldstein RM, Husberg BS, Gonwa TA, and **Klntmalm GB**: Adenovirus infection of the human intestinal allograft: a case report. *Trans Proc*, 28(5):2786-2787, 1996.
59. Brooks BK, Levy MF, Jennings LW, Abbasoglu O, Vodapally M, Goldstein RM, Husberg BS, Gonwa TA, and **Klntmalm GB**. Influence of donor and recipient gender on the outcome of liver transplantation. *Transplant Proc* 29:475-476, 1997.
60. Jeyarajah DR and **Klntmalm GB**. Is liver transplantation indicated for cholangiocarcinoma? *J Hepatobiliary Pancreat Surg* 5(1):48-51, 1998.
61. Tong MJ, Terrault NA and **Klntmalm G**. Hepatitis B transplantation: special conditions. *Semin Liver Dis* 20 (Suppl 1):25-28, 2000. (review)
62. **Klntmalm GB**. International registry of liver tumors in liver transplantation. A registry update on hepatocellular carcinoma (HCC). *Zentralbl Chir* 125(7): 642-6, 2000.
63. Molmenti EP and **Klntmalm GB**. Hepatocellular cancer in liver transplantation. *J Hepatobiliary Pancreat Surg* 8:427-434, 2001.
64. Molmenti EP, Ramsay M, Ramsay K, Lynch K, Tillmann Hein HA, Molmenti H, Levy M, Goldstein RM, Ausloos K, East C, Fasola C, Jung G, Escobar J, and **Klntmalm GB**. Epoprostenol and nitric oxide therapy for severe pulmonary hypertension in liver transplantation. *Transplant Proc* 33(102): 1332, 2001.
65. Molmenti EP, Casey D, Coke C, Jennings L, Brooks B, Marubashi S., Molmenti H, Goldstein R, Levy M, Fasola C, Gonwa T, and **Klntmalm GB**. Correlation between intraoperative flows and hepatic artery strictures in liver transplantation. *Transplant Proc* 33(1-2): 1494, 2001.
66. Molmenti E, Casey D, Jennings L, Molmenti H, Jung G, Marubashi S, Sanchez E, Goldstein R, Levy M, Fasola C, Gonwa T, and **Klntmalm GB**. Correlation between

- intraoperative flows and hepatic artery strictures in liver transplantation. *Transplant Proc* 33(1-2): 1531, 2001.
67. Molmenti EP, Nagata D, Roden J, Squires R, Molmenti H, Casey D, Fasola C, Lopez MJ, Winick N, McPhail W, D'Amico L, Goldstein R, Levy M, Fasola C, Andersen J, and **Klintmalm G**. Incidence, management, and outcome of posttransplant lymphoproliferative disease in pediatric liver transplant recipients. *Transplant Proc* 33(1-2): 1727, 2001.
  68. Molmenti E, Nagata D, Roden J, Squires R, Molmenti H, Casey D, Prestidge C, McPhail W, Sanchez E, Goldstein R, Levy M, Fasola C, Andrews W, D'Amico L, Benser M, Emert L, Andersen J, and **Klintmalm G**. Pediatric liver transplantation for cystic fibrosis. *Transplant Proc* 33(1-2): 1738, 2001.
  69. Molmenti EP, Nagata D, Roden J, Squires R, Molmenti H, Casey D, Fasola C, Tomlinson G, Ratliff A, D'Amico L, Marubashi S, McCreight A, Jung GJ, Goldstein R, Levy M, Andrews W, McPhail W, Emert L, Andersen J, and **Klintmalm G**. Liver transplantation for hepatoblastoma in the pediatric population. *Transplant Proc* 33(1-2): 1749, 2001.
  70. Molmenti E, Casey D, Jennings L, Molmenti H, Jung G, Marubashi S, Sanchez E, Goldstein R, Levy M, Fasola C, Gonwa T, and **Klintmalm G**. Leading causes of death in the liver transplant population compared to the corresponding age-matched general US population. *Transplant Proc* 33(1-2):1531, 2001.
  71. Fasola CG, Netto GJ, Jennings LW, Christensen LL, Molmenti EP, Sanchez EQ, Levy MF, Goldstein RM, and **Klintmalm GB**. Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil. *Transplant Proc* 34(5):1563-64, 2002.
  72. Fasola CG, Netto GJ, Christensen LL, Molmenti EP, Sanchez EQ, Levy MF, Goldstein RM, and **Klintmalm GB**. Delay of hepatitis C recurrence in liver transplant recipients: impact of mycophenolate mofetil on transplant recipients with severe acute rejection or with renal dysfunction. *Transplant Proc* 34(5): 1561-2, 2002.
  73. **Klintmalm GB**. The history of organ transplantation in the Baylor Health Care System. *BUMC Proceedings* 17:23-34, 2004.

## BOOKS

1. Busuttil RW and **Klntmalm GB**, (eds). *Transplantation of the Liver*. W.B. Saunders Company, 1996.
2. **Klntmalm GB** and Levy MF, (eds). *Organ Procurement and Preservation*. Landes Bioscience, 1999.
3. Molmenti EP and **Klntmalm GB**. *Atlas of Liver Transplantation*. W.B. Saunders Company, 2002.
4. Busuttil RW and **Klntmalm GB**, (eds). *Transplantation of the Liver, Second Edition*. Elsevier, 2005.

## BOOK CHAPTERS

1. Iwatsuki S, Iwaki Y, **Klintmalm G**, Kano T, Krams AK, and Starzl TE: Lymphopheresis in organ transplantation: preliminary report. In: *Cytopheresis and Plasma Exchange: Clinical Indications*:219-226. Alan R. Liss, Inc., New York, 1982.
2. Starzl TE, Iwatsuki S, Bahnson HB, van Thiel DH, Hardesty R, Griffith B, Shaw Jr BW, **Klintmalm GBG**, and Porter KA: Cyclosporin A and steroids for liver and heart transplantation. In: *Cyclosporin A: Proceedings of an International Conference on Cyclosporin A*, 38:431-436. D.J.G White, ed. Elsevier Biomedical Press, Oxford, 1982.
3. Iwatsuki S, **Klintmalm GBG**, and Starzl TE: Liver transplantation. In: Rob & Smith's *Operative Surgery, 4th ed., Alimentary Tract and Abdominal Wall*. Part 2:508-519 Dudley H, Pories W, Carter D. (eds). Butterworth, England, 1983.
4. **Klintmalm G**: Clinical experience in scandinavia. *Immunotherapy and Renal Transplantation*. 4:10-14, Park Row Publishers, New York, 1986.
5. Detre KM, Belle SH, Carr MA, Gavalier JS, Kelsey SF, Wei YL, Gross CR, Hiatt JR, **Klintmalm G**, Payne WD, Van Thiel D, Wiesner RH, and Hoofnagle JH: "A report from the NIDDK liver transplantation database." *Clinical Transplants 1989*, Chapter 14 129-141, P. Terasaki, ed. UCLA Tissue Typing Laboratory, Los Angeles, California, 1990.
6. Goldstein RM, Solomon H, Holman MJ, Gibbs JF, Mor E, Morris CA, Husberg BS, Gonwa TA, and **Klintmalm GB**: Liver transplantation, 1990: a dallas perspective. *Clinical Transplants 1990*. Chapter 14123-133, P. Terasaki, ed. UCLA Tissue Typing Laboratory, Los Angeles, 1990.
7. Poplawski SC, **Klintmalm GB**, and Starzl, TE: Donor hepatectomy, Chapter 10, 67-75. *UNOS Organ Procurement, Preservation and Distribution in Transplantation*. Michael G. Phillips, ed. William Byrd Press: Richmond, Virginia, 1991.
8. Poplawski, SC, **Klintmalm GB**, and Starzl, TE: Donor en bloc hepatectomy, pancreatectomy, nephrectomy. Chapter 11, 77-78. *UNOS Organ Procurement, Preservation and Distribution in Transplantation*. Michael G. Phillips, ed. William Byrd Press: Richmond, Virginia, 1991.
9. **Klintmalm GB**, Husberg BS, and Starzl TE: "The organ transplanted patient--- immunological concepts and immunosuppression." *The Handbook of Transplantation Management*, Chapter 3, pp.72-109. Leonard Makowka, M.D., Ph.D., ed. R. G. Landes Company, Austin, 1992.

10. Levy M, Goldstein R, Husberg B, Gonwa T, Backman L, Abouljoud M, Mulligan D, and **Klintmalm G**: Baylor update: outcome analysis in liver transplantation. Terasaki, Cecka (eds). *Clinical Transplants 1993*, pp 161-173, UCLA Tissue Typing Laboratory, Los Angeles, California.
11. **Klintmalm G**: Liver transplantation in patients with tumors. In Maddrey WC, Sorrel MF (eds). 503-527, *Transplantation of the Liver*. Appleton & Lange, Norwalk, Connecticut, 1995.
12. Abouljoud MS, and **Klintmalm GBK**: Tacrolimus immunoprophylaxis and rescue therapy in liver transplantation. Lieberman R, Mukherjee A (eds). *Principles of Drug Development in Transplantation & Autoimmunity*, pp 191-195, R.G. Landes Company, 1996.
13. **Klintmalm GB** and Busuttil RW: The recipient hepatectomy and grafting. *Transplantation of the Liver*, Chapter 40, pp. 405-418. Edited by Ronald W. Busuttil and Goran B. Klintmalm. W.B. Saunders Publishing Company, 1996.
14. **Klintmalm GB** and Busuttil RW: Combined liver-kidney transplantation. *Transplantation of the Liver*, Chapter 51, pp. 514-517. Edited by Ronald W. Busuttil and Goran B. Klintmalm. W.B. Saunders Publishing Company, 1996.
15. Levy MF and **Klintmalm GB**: Postoperative management: adults. *Transplantation of the Liver*, Chapter 57, pp. 574-581. Edited by Ronald W. Busuttil and Goran B. Klintmalm. W.B. Saunders Publishing Company, 1996.
16. **Klintmalm GB**: Induction and maintenance of immunosuppression. *Transplantation of the Liver*, Chapter 72, pp. 741-753. Edited by Ronald W. Busuttil and Goran B. Klintmalm. W.B. Saunders Publishing Company, 1996.
17. Eytan Mor and **Klintmalm GB**: Preoperative predictors of outcome in liver transplantation: models for defining high-risk transplant recipients. *Transplantation of the Liver*, Chapter 79, pp. 815-823. Edited by Ronald W. Busuttil and Goran B. Klintmalm. W.B. Saunders Publishing Company, 1996.
18. Levy MF and **Klintmalm GB**: Long-term functional recovery and quality of life. *Transplantation of the Liver*, Chapter 81, pp. 835-840. Edited by Ronald W. Busuttil and Goran B. Klintmalm. W.B. Saunders Publishing Company, 1996.
19. Testa G and **Klintmalm GB**: Cyclosporine and tacrolimus: the mainstay of immunosuppressive therapy for solid organ transplantation. In: Keeffe EB, guest ed. *Clinics in Liver Disease: Liver Transplantation*. Philadelphia: W.B. Saunders Company; 1997, p 417-437.



20. **Klintmalm GB:** Tacrolimus. *Immunosuppression*. Edited by Leo C. Ginns, A. Benedict Cosimi, and Peter J. Morris. Blackwell Science, Malden, Massachusetts 1999.
21. Testa G and **Klintmalm GB:** Assessing suitability of the cadaver donor. *Organ Procurement & Preservation*, Chapter 4, pp. 47-62. Edited by Goran B. Klintmalm and Marlon F. Levy. Landes Bioscience, 1999.
22. Fasola CG and **Klintmalm GB:** Impact of immunosuppression in hepatitis C recurrence after liver transplantation: a controllable factor? *Current Opinion in Organ Transplantation*. Lippincott Williams & Wilkins, 2003.
23. **Klintmalm GB:** Transplant Surgery. *How We Care, Volume 2: Medical Specialties and Nursing*, Chapter 6, pp. 117-128. Edited by H. Lawrence Wilsey. Baylor Health Care System, 2004.
24. McKenna GJ, Sanchez EQ, Chinnakotla S, Randall HB, Dawson S, III, Jennings LW, Levy MF, Goldstein RM, and **Klintmalm GB:** The Baylor regional transplant institute: review of a twenty-year experience, *Clinical Transplants 2004*. UCLA Immunogenetics Center, Los Angeles, California, 2005.

## PUBLISHED ABSTRACTS

1. **Klntmalm GBG**, Klingensmith III WC, Iwatsuki S, Schroter GPJ, and Starzl TE: Tc-99m-DTPA and I-131-Hippuran findings in cyclosporin A nephrotoxicity in liver transplant recipients. Proc 28th Annual Meeting of Society of Nuclear Medicine. *J Nucl Med* 22: 37-38, 1981.
2. Collste H, Lundgren G, Wilczek H, **Klntmalm G**, Ringden O, Gunnarsson R, Ostman J, and Groth CG: Pancreas transplantation vid diabetes mellitus: tre patienter insulinfria sedan 8, 4 och 3 manader. *Hygea*: 170, 1982.
3. Nisell J, Gahrton G, **Klntmalm G**, and Lonnqvist B: Behandling av pure red cell anemi med cyclosporin A sv. lakaresallskapetets handlingar. *Hygea*: 170, 1982.
4. **Klntmalm GBG**: Indications and results of liver transplantation with particular emphasis on patients with portal hypertension. *Gastroenterologia e Endoscopia Digestiva*. 1986.
5. **Klntmalm G**: Liver transplantation 1986. *Gastroenterologica e Endoscopia Digestiva*. 1986.
6. Marengo-Rowe AJ, Leveson J, Larsen N, Williams P, and **Klntmalm G**: Provision of transfusion service support for a liver transplantation program: positive aspects. *SCABB Journal* 28/ 1: 3, 1987.
7. Marengo-Rowe AJ, Leveson J, Larsen N, Harrison M, Williams P, and **Klntmalm G**: Blood and blood component transfusion experience in an established liver transplantation program. *SCABB Journal* 28/ 1: 13, 1987.
8. **Klntmalm GBG**: Combined pancreatico-renal transplantation. 14th Annual Winter Nephrology Symposium, Jan 17-24, 1987.
9. Wiesner RH, Demetris J, Van Thiel DH, Belle S, Detre KM, **Klntmalm GB**, Hiatt J, and Payne J: Hepatic allograft rejection: incidence, timing of onset, and risk factors. National Institute of Health Transplant Database Study, American Association for the Study of Liver Diseases, Chicago (Oct) 1989.
10. **Klntmalm GB** and Gonwa TA: Liver Transplantation 1990: Experience from 300 patients and the effect of transplantation on renal function. Seventeenth Annual Winter Nephrology Symposium, 1990.
11. Han KH, Hollinger FB, Solomon H, **Klntmalm GBG**, Noonan Ca, Genta RM and Yoffe B: Simultaneous detection of HBV-related DNA and viral proteins in

paraffin-embedded liver tissue by in situ hybridization (ISH) and immunohistochemistry (IHC). *Hepatology* 14(4)2:65A, October 1991.

12. Yoffe B, Mearns M, Solomon H, **Klintmalm GBG** and Noonan CA: Detection of hepatitis B virus (HBV) DNA in liver and hepatocellular carcinoma (HCC) tissues by polymerase chain reaction (PCR) amplification. *Hepatology* 14(4)2:182A, October 1991.
13. **Klintmalm GB**: Posttransplant lymphoma formation. *Lymphoma Roundtable Newsletter*, 1991.
14. Levy M, Husberg B, Goldstein R, Backman L, McMillan R, Gibbs J, Gonwa T, and **Klintmalm G**: Diabetes mellitus and liver transplantation. *Hepatology* 16(4)2:50A, October, 1992.
15. Crippin J, Carlen S, Goldstein R, Husberg B, and **Klintmalm G**: Ductopenic rejection: increased risk in primary sclerosing cholangitis. *Hepatology* 16(4)2:276A, October, 1992.
16. Goldstein R, Watemberg I, Husberg B, Gonwa T, and **Klintmalm G**: Nonidentical blood group donors - a safe solution for patients with progressive deterioration. *Hepatology* 16(4)2: 280A, October, 1992.
17. Levy M, Crippin J, Gonwa T, Goldstein R, Husberg B, Backman L, McMillan R, Gibbs J, and **Klintmalm G**: Cytomegalovirus (CMV) Infections in Liver Transplant (Ltx) Recipients: Morbidity in the DHPG Era. *Hepatology* 16(4)2:282A, October, 1992.
18. Mor E, **Klintmalm G**, Gonwa T, Jennings L, Husberg B, and Goldstein R: Predictors of outcome in liver transplantation. *Hepatology* 16(4)2:285A, October, 1992.
19. Wilbanks S, Levy M, Jennings L, Gonwa T, Goldstein R, Husberg B, and **Klintmalm G**: Relationship between early cyclosporine A (CyA) blood levels and acute rejection in liver transplant recipients. *Hepatology* 18(4):345A, 1993.
20. Husberg B, Genyk Y, and **Klintmalm G**: A new rat model for studies of the ischemic injury after transplantation of fatty livers: improvement after postop treatment with prostaglandin (PGE<sub>1</sub>). *Hepatology* 18(4):334A, 1993.
21. Gonwa T, Distant D, Levy M, Goldstein R, Husberg B, and **Klintmalm G**: Impact of preoperative renal function on postoperative survival following orthotopic liver transplantation. *Hepatology* 18(4):68A, 1993.

22. Levy M, Jennings L, Goldstein R, Gonwa T, Husberg B, Backman L, Distant D, Renard T, Eisenstein C, and **Klintmalm G**: Quality of Life Changes Two Years After Liver Transplantation. *Hepatology* 18(4):67A, 1993.
23. Burton K, Alexander J, Goldstein R, Foster B, Crippin J, Tillery G, Husberg B, Levy M, and **Klintmalm G**: Should any patient who is hepatitis B surface antigen-positive be transplanted? *Hepatology* 18(4):70A, 1993.
24. Nightengale M, Crippin J, Foster B, Goldstein R, Levy M, Husberg B, and **Klintmalm G**: Recurrence of hepatitis B (HBV) following orthotopic liver transplantation (OLTx). *Hepatology* 18(4):339A, 1993.
25. Wiesner R, et al: The role of FK506 relative to other immunosuppressants. *Highlights brochure*, 1993.
26. Gonwa TA, Mor E, Jennings L, Goldstein R, Levy M, Husberg B, and **Klintmalm GB**: Predictors of survival and charge for patients undergoing liver transplant (OLTx) for chronic disease. *Hepatology* 18(4):332A, 1993.
27. Backman L, Nicar M, Levy M, Distant D, Eisenstein C, Renard T, Goldstein R, Husberg B, Gonwa T, and **Klintmalm G**: Chronic nephrotoxicity of FK506 after liver transplantation. *Trans Proc* 26(3):1803, 1994.
28. Backman L, Nicar M, Levy M, Distant D, Eisenstein C, Renard T, Goldstein R, Husberg B, Gonwa T, and **Klintmalm G**: Whole blood and plasma levels of FK506 after liver transplantation: Correlation with toxicity. *Trans Proc* 26(3):1804, 1994.
29. Kazachkov Y, Khaoustoy V, Yoffe B, Solomon H, **Klintmalm G**, and Tabor E: Hepatocellular carcinoma in the USA: Abnormalities fo the p53 tumor suppressor gene. *Hepatology* 20:364A, 1994.
30. Gerhardt TC, Goldstein RM, Mulligan DC, Levy MF, Husberg BS, Gonwa TA, and **Klintmalm GB**. Recidivism following liver transplantation for alcoholic cirrhosis. *Hepatology* 22(4):201A, 1995.
31. Gerhardt T, Goldstein R, Husberg B, Levy M, and **Klintmalm G**: Managing recidivism through evaluation of patient needs. *Hepatology* 24(Suppl 4):515A, 1996.
32. Netto G, Goldstein R, Do K, Stone M, Husberg B, Levy M, Jennings L, Tran M, and **Klintmalm G**. Evaluation of Prognostic Factors in Hepatocellular Carcinoma (HCC) Treated with Orthotopic Liver Transplantation (OLT). *Modern Pathology* 11(1):155A, 1998.

33. Netto G, **Klintmalm G**, and Albores-Saavedra J. Gallbladder Morphology in Liver Explants of Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cirrhosis (PBC). *Modern Pathology* 11(1):76A, 1998.
34. Brooks GK, Levy MF, Testa G, Obiekwe S, Jennings LW, Husberg BS, Goldstein RM, Gonwa TA, and **Klintmalm GB**. Surviving posttransplant lymphoma in the liver transplant recipient: Cause for optimism? *Transplantation* 65(12):S50, 1998.
35. Hasse JM, Levy MF, Hollander PA, Jennings LW, Gonwa TA, Goldstein RM, Husberg BS, and **Klintmalm GB**. Does diabetes mellitus influence liver transplant outcomes? *Transplantation* 65(12):S53, 1998.
36. Hasse JM, Testa G, Gonwa TA, Jennings LW, Levy MF, Goldstein RM, Husberg BS, and **Klintmalm GB**. Is pre-liver transplant obesity a risk factor for posttransplant metabolic complications? *Transplantation* 65(12):S53, 1998.
37. Hasse JM, Gonwa TA, Jennings LW, Goldstein RM, Levy MF, Husberg BS, and **Klintmalm GB**. Malnutrition affects liver transplant outcomes. *Transplantation* 65(12):S53, 1998.
38. Testa G, Gonwa TA, Husberg B, Goldstein RM, Levy MF, Brooks B, and **Klintmalm GB**. Kidney transplantation after liver transplantation: A single center experience. *Transplantation* 65(12):S54, 1998.
39. Testa G, Hasse JM, Jennings LW, Levy MF, Brkic B, Cook B, Obiekwe S, Husberg BS, Goldstein RM, Gonwa TA, and **Klintmalm GB**. Morbid obesity is not an independent risk factor for liver transplantation. *Transplantation* 66(8) Supp: S35, 1998.
40. Cowling T, Jung G, Molmenti EP, Goldstein RM, Gonwa TA, **Klintmalm GB**, and Levy MF. The influence of donor alcohol consumption on hepatic allograft function. *Transplantation* 67(7): Supp: S88, 1999.
41. Ramsay MAE, Molmenti E, Ramsay KJ, Lynch K, Hein HAT, Conkey A, Goldstein R, Levy M, and **Klintmalm G**. The efficacy of epoprostenol and nitric oxide therapy in reducing severe pulmonary hypertension and preserving right ventricular function following orthotopic liver transplantation. *Transplantation* 67(7): Supp: S245, 1999.
42. Cowling T, Jung G, Ernesto P, Molmenti EP, Goldstein RM, Gonwa TA, **Klintmalm GB**, and Levy MF. Social reintegration after liver transplantation for alcohol-related liver disease. *Transplantation* 67(7): Supp: S246, 1999.
43. Molmenti EP, Netto GJ, Crippin JS, Conkey AC, Hoover TC, Jennings LW, Jung GJ, Levy MF, Goldstein RM, Gonwa TA, and **Klintmalm GB**. Incidence and

- recurrence of autoimmune hepatitis in liver transplant recipients. *Liver Transpl Surg* 5(4): C-5, 1999.
44. Levy MF, Crippin JS, Sutton SW, Netto GJ, Jung GJ, Molmenti EP, Goldstein RM, Gonwa TA, **Klntmalm GB**, and Logan JS. Lack of pig to human transmission of the porcine endogenous retrovirus (PoERV) following extracorporeal hepatic support with transgenic (hCD55/hCD59) porcine livers. *Liver Transpl Surg* 5(4): C-8, 1999.
  45. Cowling T, Jung GJ, Molmenti EP, Goldstein RM, Gonwa TA, **Klntmalm GB**, and Levy MF. The influence of donor alcohol consumption on hepatic allograft function. *Liver Transpl Surg* 5(4): C-47, 1999.
  46. Cowling T, Jung GJ, Molmenti EP, Goldstein RM, Gonwa TA, **Klntmalm GB**, and Levy MF. Social reintegration after liver transplantation for alcohol-related liver disease. *Liver Transpl Surg* 5(4): C-47, 1999.
  47. Cowling T, Jung GJ, Molmenti EP, Goldstein RM, Gonwa TA, **Klntmalm GB**, and Levy MF. Liver transplant waiting list morbidity: A preliminary report. *Liver Transpl Surg* 5(4): C-50, 1999.
  48. Molmenti EP, Levy MF, Jung GJ, Jennings LW, Crippin JS, Conkey AC, Goldstein RM, Gonwa TA, and **Klntmalm GB**. Approaching half-life survival in liver transplantation. *Liver Transpl Surg* 5(4): C-51, 1999.
  49. Levy MF, Crippin JS, Sutton SW, Netto GJ, Jung GJ, Molmenti EP, Goldstein RM, Gonwa TA, Logan JS, and **Klntmalm GB**. Two patients successfully undergo liver transplantation following extracorporeal hepatic support with transgenic porcine livers. *Liver Transpl Surg* 5(4): C-57, 1999.
  50. Fasola CG, Netto GJ, Jennings LW, Gonwa TA, Goldstein RM, Levy MF, Molmenti EP, and **Klntmalm GB**. Does mofetil mycophenolate (MMF) delay hepatitis C recurrence in liver transplant patients? *Transplantation* 69(8):S120, April 2000.
  51. Smith DM, Agura ED, Levy MF, Molmenti EP, Goldstein RM, Baker JE, Osowski LD, McCormack JM, Collins RH, Stone MF, and **Klntmalm GB**. Liver transplant-associated graft versus host disease. *Transplantation* 69(8):S120, April 2000.
  52. Goldstein RM, Orr DW, Meyer RL, Derrick HC, Westmoreland MV, Levy MF, and **Klntmalm GB**. Treatment of hepatomas in cirrhotic patients with radiofrequency thermal ablation. *Transplantation* 69(8):S137, April 2000.
  53. Molmenti EP, Roodhouse TW, Huang H, Coke C, Levy MF, Jennings LW, Brooks BK, Conkey A, Johnson C, Sanchez EQ, Marubashi S, Jung G, Goldstein RM, Fasola CG, Gonwa TA, and **Klntmalm GB**. Intraoperative flows and postoperative

resistive index as predictors of hepatic artery and portal vein thrombosis in liver transplantation. *Transplantation* 69(8):S138, April 2000.

54. Molmenti EP, Roodhouse TW, Jaiswal K, Jennings LW, Sanchez EQ, Marubashi S, Jung G, Brooks BK, Conkey A, Mulligan D, Levy MF, Goldstein RM, and **Klntmalm GB**. Portal vein thrombendvenectomy in cases of organized portal vein thrombosis at the time of liver transplantation. *Transplantation* 69(8):S176, April 2000.
55. Gogel BM, Donohoe AL, Glastad KA, Crippin JS, Levy MF, **Klntmalm GB**, Kuhn JA, and McCarty TM. Screening for hepatocellular carcinoma in the multinodular cirrhotic liver. *Transplantation* 69(8):S214, April 2000.
56. Sanchez E, Marubashi S, Jung G, Goldstein RM, Molmenti EP, Fasola CG, Gonwa TA, Jennings LW, Conkey AC, Brooks BK, **Klntmalm GB**, and Levy MF. Lack of racial differences in quality of life improvements after liver transplantation. *Transplantation* 69(8):S216, April 2000.
57. Molmenti EP, Nagata D, Roden J, Squires RH, Fasola CG, Jung G, Marubashi S, Sanchez E, Levy MF, Goldstein RM, Andrews W, McPhail W, D'Amico L, Benser M, Emert L, Andersen J, and **Klntmalm GB**. Incidence, management, and outcome of posttransplant lymphoproliferative disease in pediatric liver recipients. *Transplantation* 69(8):S275, April 2000.
58. Gonwa TA, Fasola CG, Levy MF, Goldstein RM, Molmenti EP, and **Klntmalm GB**. Renal replacement therapy (RRT) and orthotopic liver transplantation (OLT): A negative predictor of survival. *Transplantation* 69(8):S311, April 2000.
59. Sanchez E, Marubashi S, Jung G, Levy MF, Goldstein RM, Molmenti EP, Fasola CG, Gonwa TA, Jennings LW, Conkey AC, Brooks BK, and **Klntmalm GB**. De novo tumors after liver transplantation occur in a set timeline. *Transplantation* 68(8):S392, April 2000.
60. Molmenti EP, Ramsay MA, Ramsay KJ, Lynch K, Tillmann-Hein HA, Conkey A, Coke C, Goldstein RM, Levy MF, Ausloos KA, Fasola CG, Marubashi S, Sanchez EQ, Jung G, East C, Escobar J, and **Klntmalm GB**. Epoprostenol and nitric oxide therapy for severe pulmonary hypertension in liver transplantation. *Transplantation* 69(8):S405, April 2000.
61. Rabkin JM, Kalayoglu M, **Klntmalm G**, Langnas AM, Levy GA, Mamelok RD, McDiarmid SV, McMaster P, Merion R, Wang W, and Wiesner RH. Efficacy of mycophenolate mofetil (MMF) in liver transplant recipients: Results of a randomized double blind comparative study with an analysis of the impact of hepatitis C. *Transplantation* 69(7):S118, April 2000.

62. Kim WR, Talwaker J, Malinchoc M, Crippin J, **Klntmalm G**, Ascher N, Rosen C, Wiesner R, and Dickson ER. Lower quality of life in liver transplant recipients with hepatitis C. *Transplantation* 69(8):S216, April 2000.
63. Goldstein R, Molmenti EP, Orr D, Meyer R, Derrick H, Westmoreland M, Levy M, and **Klntmalm G**. Treatment of hepatomas in cirrhotic patients with radiofrequency thermal ablation. *Liver Transplantation* 6(3): C-3, 2000.
64. Molmenti EP, Roodhouse T, Huang H, Coke C, Levy M, Jennings L, Brooks B, Conkey A, Johnson C, Sanchez E, Marubashi S, Jung G, Goldstein R, Fasola C, Gonwa T, and **Klntmalm G**. Intraoperative flows and postoperative resistive index as predictors of hepatic artery and portal vein thrombosis in liver transplantation. *Liver Transplantation* 6(3): C-5, 2000.
65. Molmenti EP, Roodhouse T, Jaiswal K, Jennings L, Sanchez E, Marubashi S, Jung G, Brooks B, Conkey A, Mulligan D, Levy M, Goldstein R, Fasola C, Gonwa T, and **Klntmalm G**. Portal vein thrombendvenectomy in cases of portal vein thrombosis at the time of liver transplantation. *Liver Transplantation* 6(3): C-5, 2000.
66. Gogel BM, Molmenti EP, Crippin JS, Levy MF, **Klntmalm GB**, Kuhn JA, McCarty TM, and Goldstein RM. Screening for hepatocellular carcinoma in the multinodular, cirrhotic liver. *Liver Transplantation* 6(3): C-8, 2000.
67. Molmenti EP, Ford K, Wenzel J, Donohoe A, Glastad K, Sanchez E, Marubashi S, Jung G, Goldstein R, Levy M, Fasola C, Gonwa T, and **Klntmalm G**. Primary biliary cirrhosis: MRI findings in 21 consecutive, pretransplant patients, and description of "MRI periportal halo" sign. *Liver Transplantation* 6(3): C-24; 2000.
68. Smith D, Molmenti EP, Agura E, Osowski L, McCormack J, Levy M, Goldstein R, Fichtel L, Collins R, Stone M, and **Klntmalm G**. Liver transplant associated graft versus host disease (GVHD). *Liver Transplantation* 6(3): C-27; 2000.
69. Fasola CG, Molmenti E, Netto GJ, Jennings LW, Gonwa TA, Goldstein RM, Levy MF, and **Klntmalm GB**. Does mofetil mycophenolate (MMF) delay hepatitis C (Hep C) recurrence in liver transplant patients (OLT)? *Liver Transplantation* 6(3): C-31, 2000.
70. Molmenti EP, Smith D, Agura E, Levy M, Goldstein R, Fasola C, Baker J, Gonwa T, McCormack J, Stone M, and **Klntmalm G**. Graft versus host disease in kidney transplantation. *Liver Transplantation* 6(3): C-43, 2000.
71. Molmenti EP, Fasola C, Roden J, Squires R, Nagata D, Jung G, Marubashi S, Sanchez E, Levy M, Goldstein R, Andrews W, McPhail W, D'Amico L, Benser M,



- Emert L, Aranda M, Andersen J, and **Klintmalm G**. Incidence, management, and outcome of posttransplant lymphoproliferative disease in pediatric liver transplant recipients. *Liver Transplantation* 6(3): C-52, 2000.
72. Cancemi MT, Cancemi ET, Ramsay KJ, Ramsay MAE, Hein HAT, Goldstein RM, Levy MF, Molmenti EP, Fasola CG, Jennings LW, Black RE, and **Klintmalm GB**. Prediction of high volume blood transfusion during orthotopic liver transplantation. *Liver Transplantation* 6(3): C-56, 2000.
73. Molmenti EP, Ramsay M, Ramsay K, Lynch K, Tillmann-Hein H, Conkey A, Coke C, Goldstein R, Levy M, Ausloos K, Fasola C, Marubashi S, Sanchez E, Jung G, East C, Escobar J, and **Klintmalm G**. Epoprostenol and nitric oxide therapy for severe pulmonary hypertension in liver transplantation. *Liver Transplantation* 6(3): C-56, 2000.
74. Martin P, Crippin JS, Goldstein RM, Artinian L, Veldhuisen PV, and **Klintmalm GB**, Busuttill R. Primary immunosuppressive agent does not affect hepatitis C recurrence rates following liver transplantation. *Hepatology* 32(4): Pt 2 of 2, October 2000.
75. Molmenti EP, Nagata D, Roden J, Squires R, Casey D, Prestridge C, McPhail W, Molmenti H, Sanchez EQ, Marubashi S, Jung GJ, and **Klintmalm GB**. Pediatric liver transplantation for cystic fibrosis. *Hepatology* 32(4) Pt 2 of 2:340A, October 2000.
76. Molmenti EP, Nagata D, Roden J, Squires R, Molmenti H, Casey D, Tomlinson G, Ratliff A, Sanchez EQ, Marubashi S, Jung GJ, and **Klintmalm GB**. Liver transplantation for hepatoblastoma in the pediatric population. *Hepatology* 32(4) Pt 2 of 2:342A, October 2000.
77. Fasola CG, Netto G, Jennings LW, Jung GJ, Marubashi S, Sanchez EQ, Molmenti EP, Gonwa TA, Goldstein RM, Levy MF, and **Klintmalm GB**. Initial clinical evidence that mofetil mycophenolate (MMF) antiviral effects may delay the recurrence of hepatitis C (Hep C) and reduce the incidence of CMV infection in hep C liver transplant recipients (OLT). *Hepatology* 32(4) Pt 2 of 2:290A, October 2000.
78. Fasola CG, Jennings LW, Jung G, Marubashi S, Sanchez EQ, Molmenti EP, Gonwa TA, Levy MF, Goldstein RM, and **Klintmalm GB**. Primary liver transplantation (OLT) and retransplantation (REOLT): Past and present outcomes. *Hepatology* 32(4) Pt 2 of 2:256A, October 2000.
79. Goldstein RM, Derrick HC, Orr DW, Meyer RL, Netto G, Levy MF, **Klintmalm GB**, and Westmoreland MV. Radiofrequency thermal ablation of primary and metastatic liver tumors. *Hepatology* 32(4) Pt 2 of 2:232A, October 2000.

80. Molmenti EP, Casey D, Jennings LW, Molmenti H, Sanchez EQ, Marubashi S, Jung GJ, Goldstein RM, Levy MF, Fasola CG, Gonwa TA, and **Klintmalm GB**. Time-staged causes of mortality after liver transplantation. *Hepatology* 32(4) Pt 2 of 2:254A, October 2000.
  
81. Molmenti EP, Casey D, Jennings LW, Brooks B, Sanchez EQ, Marubashi S, Jung GJ, Goldstein RM, Levy MF, Fasola CG, Gonwa TA, and **Klintmalm GB**. Intraoperative hepatic artery and portal vein flows and postoperative resistive index as predictors of hepatic artery strictures in liver transplantation. *Hepatology* 32(4) Pt 2 of 2:241A, October 2000.
  
82. Kim WR, Charlton M, Wiesner RH, Poterucha JJ, Rosen CB, Dickson ER, and **Klintmalm GB**. Patient and graft survival following hepatic retransplantation in patient with hepatitis C. *Hepatology* 32(4) Pt 2 of 2:257A, October 2000.
  
83. Kim WR, Wiesner RH, Therneau RM, Poterucha JJ, Rosen CB, and **Klintmalm GB**. Donor and recipient predictors of patient and graft survival following liver transplantation. *Hepatology* 32(4) Pt 2 of 2:253A, October 2000.
  
84. Netto G, Fasola C, Parker C, Mattison TL, Jennings L, Molmenti E, Levy M, Goldstein R, and **Klintmalm G**. Evaluation of the role of mofetil mycophenolate (MMF) in delaying progression of hepatitis C (HepC) recurrence following orthotopic liver transplantation (OLT). *Modern Pathology* 14(1):201A, 2001.
  
85. Netto G, Smith DM, Agura E, Molmenti E, Collins R, Levy M, Goldstein R, Dawson B, Domiati-Saad R, Stone M, and **Klintmalm G**. Risk factors for graft versus host disease (GVHD) following orthotopic liver transplantation (OLT). *Modern Pathology* 14(1):201A, 2001.
  
86. Molmenti EP, Ramsay M, Ramsay K, Lynch K, Tillmann Hein HA, Molmenti H, Levy M, Goldstein R, Ausloos K, East C, Fasola C, Jung G, Escobar J, and **Klintmalm G**. Epoprostenol and nitric oxide therapy for severe pulmonary hypertension in liver transplantation. *Transplant Proc* 33(2):1332, 2001.
  
87. Molmenti EP, Casey D, Coke C, Jennings L, Brooks B, Marubashi S, Molmenti H, Goldstein R, Levy M, Fasola C, Gonwa T, and **Klintmalm G**. Correlation between intraoperative flows and hepatic artery strictures in liver transplantation. *Transplant Proc* 33(2):1494, 2001.
  
88. Molmenti E, Casey D, Jennings L, Molmenti H, Jung G, Marubashi S, Sanchez E, Goldstein R, Levy M, Fasola C, Gonwa T, and **Klintmalm G**. Leading causes of

death in the liver transplant population compared to the corresponding age-matched general US population. *Transplant Proc* 33(2):1531, 2001.

89. Molmenti EP, Nagata D, Roden J, Squires R, Molmenti H, Casey D, Fasola C, Lopez MJ, Winick N, McPhail W, D'Amico R, Goldstein R, Levy M, Fasola C, Andersen J, and **Klntmalm G**. Incidence, management, and outcome of posttransplant lymphoproliferative disease in pediatric liver transplant recipients. *Transplant Proc* 33(2):1727, 2001.
90. Molmenti E, Nagata D, Roden J, Squires R, Molmenti H, Casey D, Prestidge C, McPhail W, Sanchez E, Goldstein R, Levy M, Fasola C, Andrews W, D'Amico L, Benser M, Emert L, Andersen J, and **Klntmalm G**. Pediatric liver transplantation for cystic fibrosis. *Transplant Proc* 33(2):1738, 2001.
91. Molmenti EP, Nagata D, Roden J, Squires R, Molmenti H, Casey D, Fasola C, Tomlinson G, Ratliff A, D'Amico L, Marubashi S, McCreight A, Jung GJ, R Goldstein, Levy M, Andrews W, McPhail W, Emert L, Andersen J, and **Klntmalm GB**. Liver transplantation for hepatoblastoma in the pediatric population. *Transplant Proc* 33(2):1749, 2001.
92. Gogel BM, Goldstein LM, Schoenvogel RC, Derrick HC, Westmoreland MV, Seiba M, Sanchez EQ, Marubashi S, Goldstein RM, Levy MF, Molmenti EP, Fasola CG, Gonwa TA, Christensen LL, and **Klntmalm GB**. Laparoscopic donor nephrectomy: A positive comparison with open procedures. *Am J Transplant* 1(Suppl 1):198, 2001.
93. Fasola CG, Netto GJ, Jennings LW, Christensen LL, Molmenti EP, Sanchez EQ, Marubashi S, Gogel BM, Gonwa TA, Goldstein RM, Levy MF, and **Klntmalm GB**. Optimal dosing of mycophenolate mofetil (MMF) is necessary to delay hepatitis C recurrence (hep CR) in liver transplant recipients (OLT). *Am J Transplant* 1(Suppl 1):202, 2001.
94. Fasola CG, Netto GJ, Jennings LW, Molmenti EP, Sanchez EQ, Marubashi S, Gogel BM, Weinstein JS, Gonwa TA, Goldstein RG, Levy MF, and **Klntmalm GB**. Hepatitis C recurrence (HCR) in liver transplant recipients (OLT): Patterns (PR) and early predictors (EP) of graft fibrosis (GF). *Am J Transplant* 1(Suppl 1):205, 2001.
95. Sanchez EQ, Byers D, Marubashi S, Gogel BM, Levy MF, Goldstein RM, Molmenti EP, Fasola CG, Gonwa TA, Tillery GW, Netto GJ, Watkins DL, Brooks BK, Christensen LL, and **Klntmalm GB**. Immunosuppressive effect on recurrence of primary biliary cirrhosis after liver transplantation. *Am J Transplant* 1(Suppl 1):207, 2001.

96. Gonwa TA, Mai ML, Melton LB, Hays SR, Levy MF, Goldstein RM, Molmenti EP, Fasola CG, and **Klntmalm GB**. End stage renal disease (ESRD) following orthotopic liver transplantation (OLT) utilizing calcineurin inhibitor (CNI) based immunotherapy: Risk of development and treatment. *Am J Transplant* 1(Suppl 1):265, 2001.
97. Molmenti EP, Ramsay MA, Ramsay KJ, Lynch K, Tillmann-Hein HA, Goldstein RM, Levy MF, Ausloos KA, Fasola CG, Marubashi S, Sanchez EQ, Gogel B, Escobar J, East C, and **Klntmalm GB**. Successful treatment of portopulmonary hypertension: Short term results and long term survival. *Am J Transplant* 1(Suppl 1):266, 2001.
98. Kim WR, Wiesner RH, Kamath PS, Malinchoc M, Kremers WK, Rosen CB, Dickson ER, and **Klntmalm GB**. Prediction of liver transplant outcome using the meld scale. *Am J Transplant* 1(Suppl 1):284, 2001.
99. Brooks BK, Diamond NG, Jennings LW, Sanchez EQ, Marubashi S, Gogel BM, Goldstein RM, Molmenti EP, Fasola CG, Gonwa TA, **Klntmalm GB**, and Levy MF. Incidence and impact of hepatic artery thrombosis in liver transplantation. *Am J Transplant* 1(Suppl 1):315, 2001.
100. Marubashi S, Sanchez EQ, Gogel BM, Jennings LW, Molmenti EP, Fasola CG, Goldstein RM, Levy MF, Brooks BK, Christensen LL, Gonwa TA, and **Klntmalm GB**. Orthotopic liver transplantation for fulminant hepatic failure. *Am J Transplant* 1(Suppl 1): 390, 2001.
101. First MR, West J, Aeder M, Danovitch G, **Klntmalm G**, Gorman K, Gordon J and Spinola K. Differences in patient and healthcare provider perceptions of immunosuppression-induced physical side effects. *Am J Transplant* 2 (Suppl 3): 404, 2002.
102. Onaca NN, Levy MF, Thomas MJ, Sanchez EQ, Brooks BK, Chinnakotla S, Fasola CG, Weinstein JS, Murray N, Goldstein RM, and **Klntmalm GB**: The pretransplant MELD score as a predictor of outcome after liver transplantation for chronic hepatitis C. *Am J Transplant* 2 (Suppl 3): 252, 2002.
103. Onaca N, Netto GJ, Morkowski J, Katabi N, Levy MF, Thomas MJ, Sanchez EQ, Weinstein JS, Murray N, Goldstein RM, and **Klntmalm GB**: Influence of steatosis in the liver allograft in the incidence of recurrent hepatitis C after liver transplantation. *Am J Transplant* 2 (Suppl 3): 429, 2002.
104. Sanchez EQ, Gonwa TA, Levy MF, Fasola CG, Goldstein RM, Chinnakotla S, Melton LB, Hays SR, Onaca N, Thomas M, and **Klntmalm GB**: Perioperative predictors of renal replacement therapy after orthotopic liver transplantation: Implications for MELD scoring. *Am J Transplant* 2 (Suppl 3): 299, 2002.

105. Fasola CG, Netto GJ, Christense LL, Weinstein J, Murray N, Thomas M, Onaca N, Sanchez EQ, Chinnakotla S, Levy MF, Goldstein RM, and **Klintmalm GB**: Evoluton of hepatitis C recurrence post liver transplantation in the last ten years: More aggressive recurrence in recent years? *Am J Transplant 2* (Suppl 3): 139, 2002.
106. Fasola CG, Netto G, Christensen L, Rakela J, Thomas M, Onaca N, Sanchez EQ, Chinnakotla S, Levy MF, Goldstein RM, and **Klintmalm GB**: The importance of HCV-RNA level determinations in early detection of aggressive hepatitis C recurrence post liver transplantation: The third month gap. *Am J Transplant 2* (Suppl 3): 164, 2002.
107. Fasola CG, Netto G, Christensen LL, Rakela J, Thomas M, Onaca N, Sanchez EQ, Chinnakotla S, Levy MF, Goldstein RM, and **Klintmalm GB**: Lower incidences of early hepatitis C-RNA levels and HCV recurrence post liver transplantation in patients induced with mycophenolate mofetil: A high-dose benefit. *Am J Transplant 2* (Suppl 3): 196, 2002.
108. Wiesner R, **Klintmalm G**, McDiarmid S, and the Rapamune Liver Transplant Study Group: Sirolimus immunotherapy results in reduced rates of acute rejection in de novo orthotopic liver transplant recipients. *Am J Transplant 2* (Suppl 3): 464, 2002.
109. Gonwa TA, Levey AS, Jennings LW, and **Klintmalm GB**. Comparison of calculated GFR to true GFR in calcineurin inhibitor (CNI) treated orthotopic liver transplant (OLT) recipients. *JASN* 13:371A, 2002.
110. Fasola CG, Netto GJ, Onaca N, Thomas M, Sanchez EQ, Chinnakotla S, Goldstein RM, Levy MF, Davis GL, and **Klintmalm GB**. A more severe hepatitis C recurrence (HCVR) post liver transplantation (OLT) observed in recent years may be explained by the unse of lower-dose corticosteroid (CS) maintenance protocols. *Hepatology* 38(4), Suppl 1:63A, 2003.
111. Bambha KM, Kim WR, Benson JT, Kamath PS, Dickson ER, and **Klintmalm GB**. Estimation of glomerular filtration rate in patients with end-stage liver disease: a new model superior to cockroft-gault. *Hepatology* 38(4), Suppl 1: 98A, 2003.
112. Arenas JI, Laskus T, Wilkinson J, Gallegos JF, Fasola CG, Adair D, Radowski M, Kibler KV, Douglas D, Williams, Netto G, Mulligan D, **Klintmalm G**, Rakela J, and Vargas HE. Rejection treatment modifies hcv quasispecies evolution after liver transplantation. *Hepatology* 38(4), Suppl 1: 115A, 2003.
113. Chinnakotla S, Levy M, Jennings L, Cowling T, Onaca N, Ueno T, Raofi V, Thomas M, Sanchez E, Dawson S, Randall H, Goldstein R, and **Klintmalm G**. What is the

- quality of life improvement (QOL) 10 years after liver transplantation (OLT)? *Am J Transplant* 3(Suppl 5):242, 2003.
114. Onaca N, Levy MF, Thomas MJ, Ueno T, Raofi V, Sanchez EQ, Chinnakotla S, Randall HB, Dawson S, Saracino G, Jennings LW, Goldstein RM, and **Klintmalm GB**. Liver disease etiology and pretransplant MELD scores – relationship with mortality in the first year posttransplant. *Am J Transplant* 3(Suppl 5):244, 2003.
  115. Fasola CG, Netto GJ, Thomas M, Onaca N, Sanchez EQ, Chinnakotla S, Goldstein RM, Levy MF, Davis GL, and **Klintmalm GB**. Corticosteroid (CS) maintenance and its impact in the progression of hepatitis C histologic recurrence (HHCVR) in liver transplant recipients (OLT) at one and two years (Y) post transplant (TX): a dose-dependent benefit? *Am J Transplant* 3(Suppl 5):294, 2003.
  116. Sanchez EQ, Onaca N, Thomas M, Ueno T, Raofi V, Goldstein RM, Levy MF, Chinnakotla S, Dawson Sh, Randall H, Saracino, and **Klintmalm GB**. Rapamune conversion in long-term liver transplant patients is effective in recovering renal function. *Am J Transplant* 3(Suppl 5):325, 2003.
  117. Sanchez EQ, Onaca N, Thomas M, Ueno T, Raofi V, Goldstein RM, Levy MF, Chinnakotla S, Dawson Sh, Randall H, Saracino G, and **Klintmalm GB**. Rapamycin use in liver transplantation: it is well tolerated. *Am J Transplant* 3(Suppl 5):373, 2003.
  118. Chinnakotla S, Goldstein R, Onaca N, Ueno T, Raofi V, Thomas M, Jennings L, Sanchez E, Dawson S, Randall H, Levy M, and **Klintmalm G**. Causes of mortality in 344 adult liver transplant (OLT) recipients who survived for more than 10 years. *Am J Transplant* 3(Suppl 5):379, 2003.
  119. Cibrik DM, Jensik S, Meier-Kriesche H-U, Bresnahan B, and Lieberman B for the Myfortic-US01 Renal Transplant Study Group. Enteric-coated mycophenolate sodium in combination with optimized neoral dosing, basiliximab, and steroids results in good efficacy and renal function in renal transplant recipients in the first 6 months. *Am J Transplant* 4(Suppl 8):218, 2004.
  120. Alloway R for the Tacrolimus Modified Release Kidney Conversion Study Group. Conversion of stable kidney transplant recipients from a twice daily Prograf based regimen to a once daily modified release tacrolimus based regimen. *Am J Transplant* 4(Suppl 8):230, 2004.
  121. Grazi GL, Levy G, Wu Y, Marotta P, Boillot O, San Juan F, Samuel D, Muehlbacher F, and Fillamil F, on behalf of LIS2T Study Group. 12-Month follow-up data from a randomized, multicentre, prospective study of cyclosporine C2 monitoring versus tacrolimus in liver transplantation (LIS2T). *Am J Transplant* 4(Suppl 8):268, 2004.

122. Florman S for the Tacrolimus Modified Release Liver Conversion Study Group. Conversion of stable liver transplant recipients from a twice daily Prograf based regimen to a once daily modified release tacrolimus based regimen. *Am J Transplant* 4(Suppl 8):268, 2004.
123. Fasola CG, Netto GJ, Sanchez EQ, Chinnakotla S, Levy MF, Goldstein RM, and **Klntmalm GB**. Hepatitis C recurrence (HCVR) in liver transplant recipients (OLT) under bycophenolate mofetil (MMF) immunosuppression (IS): a long-term follow up. *Am J Transplant* 4(Suppl 8):356, 2004.
124. Fasola CG, **Klntmalm GB**, and Hepatitis C Three Study Group. Multicenter randomized hepatitis C (HCV) three trial post liver transplantation (OLT): a preliminary report. *Am J Transplant* 4(Suppl 8):410, 2004.
125. Sanchez EQ, Gonwa TA, Martin AP, Ueno T, Onaca N, Randall HB, Dawson S, Chinnakotla S, Levy MF, Goldstein RM, Mai ML, Hays SR, Melton LB, and **Klntmalm GB**. Predictive model for renal replacement therapy (RRT) following orthotopic liver transplantation (OLT) based on MELD, Creatinine, BUN, ICU length of stay. *Am J Transplant* 4(Suppl 8):492, 2004.
126. Ueno T, Jones G, Martin A, Sanchez E, Chinnakotla S, Dawson S, Randall H, Onaca N, Goldstein R, Levy M, and **Klntmalm G**. Artery stenting for hepatic artery stenosis in liver transplantation. *Am J Transplant* 4(Suppl 8):504, 2004.
127. Cowling T, Jennings LW, Ueno T, Martin P, Sanchez EQ, Chinnakotla S, Randall H, Dawson S, Goldstein RM, **Klntmalm GB**, and Levy MF. Model for end-stage liver disease scores do not predict liver transplantation waiting list morbidity. *Am J Transplant* 4(Suppl 8):516, 2004.
128. Martin AP, Goldstein RG, Netto G, Katabi N, Ueno T, Onaca N, Sanchez EQ, Chinnakotla S, Dawson S, Randall H, Levy MF, and **Klntmalm GB**. Radiofrequency ablation of liver tumors before liver transplantation - a clinical and histological examination. *Am J Transplant* 4(Suppl 8):539, 2004
129. Sanchez ES, Martin AP, Ikegami T, Uemura T, Narasimhan G, Chinnakotla S, Randall HB, McKenna GJ, Levy MF, Goldstein RM, Saracino G, and **Klntmalm GB**. Comparison of immunosuppression regimen and advanced donor age effect in hepatitis c patients in two chronologic eras. *Am J Transplant* 5 (Suppl 11): 177, 2005.
130. Samuel D, Levy G, Villamil F, Sanjuan F, Grazi G, Muehlbacher F, Otto G, Jones R, Tanaka K, and **Klntmalm G** on behalf of the LIS2T Study Group. Does the choice of calcineurin inhibitor influence the time to histological recurrence of hepatitis c post-transplant? *Am J Transplant* 5 (Suppl 11): 179, 2005.
131. Washburn KK, Teperman LW, Heffron TG, Douglas DD, Katz E, Fasola CG, and **Klntmalm GB** for Hepatitis C Three Study Group. Pharmacokinetics and

- pharmacodynamics of 3-dose Daclizumab in liver transplant recipients with hepatitis c. *Am J Transplant* 5 (Suppl 11): 179, 2005.
132. Cibrik D, Jensik S, Bresnahan B, Whelchel J, and **Klintmalm G** for the ERL2405-US01 Study Group. Safety and efficacy of EC-MPS in combination with Simulect and neoral in de novo renal transplant high-risk recipients. *Am J Transplant* 5 (Suppl 11): 190, 2005.
  133. Buell JF, Koffron AJ, Rudich SM, Koehler A, Thomas MJ, Abecassis, **Klintmalm G**, and Goldstein R. Histologic response to radiogrequency ablation in transplant recipients. *Am J Transplant* 5 (Suppl 11): 234-35, 2005.
  134. Onaca N, Davis GL, Jennings LW, Goldstein RM, and **Klintmalm GB**. Improvement of results of liver transplantation for hepatocellular carcinoma. *Am J Transplant* 5 (Suppl 11): 235, 2005.
  135. Washburn K, Harper A, **Klintmalm G**, Goss J, and Halff G. Regional sharing for status 1 candidates: reduction in waitlist mortality. *Am J Transplant* 5 (Suppl 11): 263, 2005.
  136. Fasola CG, Heffron TG, Sher L, Douglas DD, Brown R, Ham J, Teperman L, Roberts J, Charlton M, Baliga P, Pruett T, Koneru B, Pomfret E, Abecassis M, and **Klintmalm GB**. Multicenter randomized hepatitis c (HCV) three trial post liver transplantation (OLT): A one-year follow up report. *Am J Transplant* 5 (Suppl 11): 276, 2005.
  137. Gallegos-Orozco JF, Vargas HE, Eckhoff DE, and Hepatitis C III Study Group. Hepatitis C hypervariable region 1 quasispecies behavior after liver transplantation: a preliminary report from the hepatitis C III trial. *Am J Transplant* 5 (Suppl 11): 278, 2005.
  138. Uemura T, Sanchez EQ, Martin AP, Ikegami T, Narasimhan G, McKenna GJ, Chinnakotla S, Dawson III S, Randall HB, Levy MF, Goldstein RM, and **Klintmalm GB**. Clinical characteristics of primary nonfunction in liver transplantation. *Am J Transplant* 5 (Suppl 11): 332, 2005.
  139. Smith DM, Domiati-Saad R, Netto G, Agura ED, Chinnakotla S, and **Klintmalm GB**. The development of graft versus host disease following liver transplantation: patterns of lymphocyte chimerism. *Am J Transplant* 5 (Suppl 11): 335, 2005.
  140. McKenna GJ, Sanchez EQ, Chinnakotla S, Randall HB, Dawson III S, Jennings LW, Martin AP, Ikegami T, Uemura T, Narasimhan G, Levy MF, Goldstein RM, and **Klintmalm GB**. Incidence and outcome of acute cellular rejection without liver enzyme elevation. *Am J Transplant* 5 (Suppl 11): 375, 2005.



141. Levy MF, Jennings LW, Sanchez EQ, Chinnakotla S, Dawson III S, Randall H, McKenna G, Goldstein RM, and **Klntmalm GB**. Deceased donor vessels as hepatic artery conduits. *Am J Transplant* 5 (Suppl 11): 490, 2005.
142. Biggins S, Kim WR, Saab S, Balan V, Schiano T, Benson J, Therneau T, Kremers W, Wiesner R, Kamath P, Terrault N, and **Klntmalm G**. MELDS: incorporation of the serum sodium concentration into MELD: and evidence-based proposal. *Am J Transplant* 5 (Suppl 11): 564, 2005.
143. **Klntmalm GB**. The outcome of neoadjuvant therapy for hepatocellular carcinoma in liver transplantation. A registry report. *Am J Transplant* 5 (Suppl 11): 575, 2005.
144. Fasola C, Heffron T, Sher L, Douglas D, Brown R, Ham J, Teperman L, Eckhoff D, Washburn K, Millis M, Roberts J, Charlton M, Baliga P, Pruett T, Baliga B, Pomfret E, Abecassis M, and **Klntmalm G**. Multicenter randomized hepatitis C (HCV) three trial post liver transplantation (OLT): a one-year follow up report. *Hepatology* 42(4) (Suppl 1): 199A, 2005.
145. Washburn K, Teperman L, Heffron T, Douglas D, Katz E, Fasola CG, and **Klntmalm G**. Pharmacokinetics and pharmacodynamics of 3-dose Daclizumab in liver transplant recipients with hepatitis C. *Hepatology* 42(4) (Suppl 1): 326-27A, 2005.
146. Benson J, Kim WR, Biggins S, Therneau T, Kremers W, Gores G, Rosen C, and **Klntmalm G**. Outcome of liver transplantation in patients with hyponatremia. *Hepatology* 42(4) (Suppl 1): 328A, 2005.
147. Ikegami T, Sanchez EQ, Martin AP, Uemura T, Narasimhan G, Chinnakotla S, Dawson S, McKenna GJ, Randall HB, Goldstein RG, Levy MF, and **Klntmalm GB**. The clinical impact of preservation injury on outcome after liver transplantation. *Hepatology* 42(4) (Suppl 1): 331-32A, 2005.

## PRESENTATIONS

1. Valek TR, Paulsen AW, Blessing WS, Johnson DD, Parks RI, Pyron JT, Ramsay M, Simpson BR, Swygert T, Walling P, Husberg BS, and **Klntmalm GB**: Hemodynamic of patients undergoing orthotopic liver transplantation. European Congress of Anesthesiologists, Sept. 1986.
2. Demetris J, Belle S, Hart J, Lewin K, Ludwig J, Snover D, Tillery W, and LTD Database: Reliability of pathology findings for post-orthotopic liver transplant biopsies. (Poster) XII International Congress of the Transplantation Society, 1988.
3. Howard TK, **Klntmalm GB**, Cofer JB, Husberg BS, Goldstein RM, and Gonwa TA: Does preservation injury predispose to rejection in the hepatic transplant recipient? Presented in poster form for American Society of Transplant Physicians, 1989.
4. Takaoka F, Brown MR, Paulsen AW, Ramsay MAE, and **Klntmalm GB**: Adult respiratory distress syndrome following orthotopic liver transplantation. Annual Meeting of American Society of Anesthesiologists, October 1989.
5. Mor E, **Klntmalm GB**, Gonwa Ta, Solomon H, Holman M, Gibbs J, Goldstein R, and Husberg BS: The effect of operative blood transfusion on rejection, infection, graft and patient survivals in 205 orthotopic liver transplants. Presented in poster form at European Society for Organ Transplantation, Maastricht, The Netherlands, 1991.
6. Mora NP, **Klntmalm GB**, Gonwa TA, Goldstein R, and Husberg BS: The impact of the different infections (SEV INF) on the outcome of liver transplantation (LTX): A Study of 150 patients. Presented in poster form at European Society for Organ Transplantation, Maastricht, The Netherlands, 1991.
7. Levy M, Backman L, Husberg B, Goldstein R, McMillan R, Gibbs J, Gonwa T, Holman M, and **Klntmalm G**: De Novo malignancy following liver transplantation: A single center study. XIVth International Congress of the Transplantation Society, Paris, France, August, 1992. (poster presentation)
8. Levy MF, Husberg BS, Goldstein RM, Backman L, McMillan RW, Gibbs JF, Gonwa TA, and **Klntmalm GB**. Diabetes mellitus and liver transplantation. 43<sup>rd</sup> Annual Meeting of the American Association for the Study of Liver Diseases, Chicago, Illinois, October 1992. (poster presentation)
9. Willard S, Gillespie A, Holman M, Tillery W, Stone Marvin, and **Klntmalm G**: Neoadjuvant Chemotherapy and Orthotopic Liver Transplant for Unresectable Hepatocellular Carcinoma. American Society of Transplant Surgeons presentation, 1993.

10. Nikaein A, Collins R, Anastasi J, Terstappen L, **Klintmalm G**, Fay J, and Stone M: Graft Versus Host disease following liver transplantation is mediated by donor-derived lymphocytes. American Society of Transplant Physicians presentation, 1993.
11. Renard T, Goldstein R, Backman L, Eisenstein C, Distant D, Levy M, Husberg B, Gonwa T, and **Klintmalm G**: ABO Incompatible Liver Transplantation in the Emergent Setting as Bridge to Future Transplantation. American Society of Transplant Physicians presentation, 1993.
12. Distant D, Backman L, Eisenstein C, Renard T, Levy M, Goldstein R, Husberg B, Gonwa T, and **Klintmalm G**: Outcome of Liver Transplantation in Elderly Recipients: An Analysis of 559 Patients. American Society of Transplant Physicians presentation, 1993.
13. Blue L, Hasse J, Levy M, Jennings L, Goldstein R, Gonwa T, Husberg B, and **Klintmalm G**: Effect of Obesity on Clinical Outcomes in Liver Transplantation. American Society of Transplant Physicians presentation, 1993.
14. Distant D, Gonwa T, Jennings L, Backman L, Eisenstein C, Renard T, Levy M, Goldstein R, Husberg B, and **Klintmalm G**: Long-term Renal Function after Liver Transplantation: An Analysis of 600 Patients on Cyclosporine or FK506 Immunosuppression. American Society of Transplant Physicians presentation, 1993.
15. Levy M, Crippin J, Gonwa T, Backman L, Renard T, Eisenstein C, Distant D, Goldstein R, Husberg B, and **Klintmalm G**: Cytomegalovirus (CMV) infections in liver transplant (LTx) recipients: Morbidity in the DHPG era. American Society of Transplant Physicians presentation, 1993.
16. Backman L, Nicar M, Distant D, Eisenstein C, Renard T, Levy M, Husberg B, Goldstein R, Gonwa T, and **Klintmalm G**: Whole blood and plasma levels of FK506 in liver transplant recipients: Correlation to clinical events and side effects. American Society of Transplant Physicians presentation, 1993.
17. Backman L, Nicar M, Distant D, Eisenstein C, Renard T, Levy M, Husberg B, Goldstein R, Gonwa T, and **Klintmalm G**: Nephrotoxicity of FK506 in liver transplant recipients. American Society of Transplant Physicians presentation, 1993.
18. **Klintmalm G**: US multi-center prospective randomized trial comparing FK506 to cyclosporine after liver transplantation: Primary outcome analysis. American Society of Transplant Surgeons presentation, 1993.
19. Gonwa T, **Klintmalm G**, et al: Effect of FK506 and Cyclosporine (CyA) on renal function following liver transplantation: Results from the U.S. Multicenter Trial. XVth World Congress of the Transplantation Society, Kyoto, Japan, August/September 1994.

20. Mulligan D, Goldstein R, Crippin J, Abouljoud M, Levy M, Husberg B, Gonwa T, Foster B, and **Klintmalm G**: The use of anti-hepatitis C virus seropositive organs in liver transplantation. XVth World Congress of the Transplantation Society, Kyoto, Japan, August/September 1994.
21. Nikaein A, Backman L, Jennings L, Levy M, Goldstein R, Gonwa T, Stone M, and **Klintmalm G**: HLA compatibility and liver transplant outcome: Improved patient survival by HLA and crossmatching. XVth World Congress of the Transplantation Society, Kyoto, Japan, August/September 1994.
22. Abouljoud M, Levy M, and **Klintmalm G**: Hyperlipidemia after liver transplantation: Long-term results of the FK506/Cyclosporine A U.S. Multi-Center Trial. XVth World Congress of the Transplantation Society, Kyoto, Japan, 1994.
23. Backman L, **Klintmalm G**, and U.S. FK506 Multicenter Study Group: Whole blood and plasma levels of FK506 after liver transplantation: Results from the U.S. Multicenter Trial. XVth World Congress of the Transplantation Society, Kyoto, Japan, August/September 1994.
24. Levy M, Jennings L, Abouljoud M, Mulligan D, Goldstein R, Husberg B, Gonwa T, and **Klintmalm G**: Quality of life improvements one, two, and five years after liver transplantation. XVth World Congress of the Transplantation Society, Kyoto, Japan, August/September 1994.
25. Forde C, Levy M, Jennings L, Mulligan D, Abouljoud M, Goldstein R, Husberg B, Gonwa T, and **Klintmalm G**: Efficacy of DHPG/Acyclovir prophylaxis against cytomegalovirus (CMV) infection in liver transplantation (OLTx). XVth World Congress of the Transplantation Society, Kyoto, Japan, August/September 1994.
26. Hasse J, Blue L, Goldstein R, Liepa G, Jennings L, Mor E, Husberg B, Levy M, Gonwa T, and **Klintmalm G**: Early nutrition support via enteral route in patients undergoing orthotopic liver transplantation. XVth World Congress of the Transplantation Society, Kyoto, Japan, August/September 1994.
27. Collins R, **Klintmalm G**, Terstappen L, Solano M, Stone M, and Nikaein A: Graft versus host disease following liver transplantation may resist or result in the development of tolerance. XVth World Congress of the Transplantation Society, Kyoto, Japan, August/September 1994.
28. Mulligan DC, Levy MF, Schreimann KD, Morphew CA, Abouljoud MS, Goldstein RM, Husberg BS, Gonwa TA, and **Klintmalm GB**. The Fate of Liver Offers to a Single Transplant Center: A Study of 543 cases. American Association for the Study of Liver Diseases, Chicago, IL, November 1994.

29. Mulligan DC, Aguanno JA, Goldstein RM, Holmberg SB, Levy MF, Husberg BS, Gonwa TA, and **Klintmalm GB**. Whole Blood Monitoring for FK506 Immunosuppression in Liver Transplantation: Imx vs Enzyme Immunoassay (EIA). The American Society of Transplant Physicians, 14<sup>th</sup> Annual Scientific Meeting, Chicago, IL, May 1995. (poster presentation)
30. Mulligan DC, Goldstein RM, Crippin JS, Holmberg SB, Levy MF, Husberg BS, Gonwa TA, and **Klintmalm GB**. Outcome of anti-hepatitis C virus seropositive organs in patients following liver transplantation. American Society of Transplant Surgeons, 21<sup>st</sup> Annual Scientific Meeting, Chicago, IL, May 1995.
31. Mulligan DC, Goldstein RM, Levy MF, Jennings L, Holmberg SB, Husberg BS, Gonwa TA, Brooks BA, Smith SJ, and **Klintmalm GB**. Hepatitis C Viral Infection in Liver Transplantation: Effect of Cyclosporine A vs. FK506. The American Society of Transplant Physicians, 14<sup>th</sup> Annual Scientific Meeting, Chicago, IL, May 1995.
32. Levy MF, Backman L, Busuttil RW, Kelley SD, Roberts J, Goldstein RM, Husberg BS, Gonwa TA, and **Klintmalm GB**. Final Report of an Open-Labeled Multicenter Prospective Randomized Controlled Trial of Prostaglandin E<sub>1</sub> Use in Liver Transplantation. XVI International Congress of the Transplantation Society, Barcelona, Spain, August 1996. (oral presentation)
33. **Klintmalm G**, Ramanan J, and Jennings L. International Registry of Hepatic Tumors in Liver Transplantation: Current Treatments and Overall Results. XVI International Congress of the Transplantation Society, Barcelona, Spain, August 1996. (oral presentation)
34. Brooks B, Levy MF, Abbasoglu O, Vodapally M, Jennings L, Goldstein RM, Husberg BS, Gonwa TA, and **Klintmalm GB**. Influence of Donor and Recipient Gender on the Outcome of Liver Transplantation. XVI International Congress of the Transplantation Society, Barcelona, Spain, August 1996. (oral presentation)
35. Abbasoglu O, Levy MF, Vodapally M, Goldstein RM, Husberg BS, Gonwa TA, and **Klintmalm GB**. Patency of the Revised Hepatic Artery After Liver Transplantation. XVI International Congress of the Transplantation Society, Barcelona, Spain, August 1996. (poster presentation)
36. Gerhardt TC, Levy MF, Goldstein RM, Abbasoglu O, Testa G, Jeyarajah R, Husberg BS, Gonwa TA, and **Klintmalm GB**. Employment/Volunteerism among adults undergoing liver transplantation for Laennec's cirrhosis. NIDDK and NIAAA of the National Institutes of Health Conference, Liver Transplantation for Alcoholic Liver Disease, Bethesda, Maryland, December 1996. (poster presentation)

37. Gerhardt TC, Goldstein RM, Levy MF, Husberg BS, Abbasoglu O, Testa G, Jeyarajah R, Gonwa TA, and **Klintmalm GB**. Alcohol use among patients transplanted for alcoholic cirrhosis. NIDDK and NIAAA of the National Institutes of Health, Liver Transplantation for Alcoholic Liver Disease, Bethesda, Maryland, December 1996. (poster presentation)
38. Levy MF, Gerhardt TC, Jennings L, Abbasoglu O, Testa G, Jeyarajah R, Goldstein RM, Husberg BS, Gonwa TA, and **Klintmalm GB**. Comparing quality of life following liver transplantation for Laennec's vs. non-Laennec's patients. NIDDK and NIAAA of the National Institutes of Health, Liver Transplantation for Alcoholic Liver Disease, Bethesda, Maryland, December 1996. (poster presentation)
39. Kim W, Malinchoc M, Therneau T, Crippin J, **Klintmalm G**, Krom R, Wiesner R, and Dickson E: Mayo Risk Score and Outcome of Liver Transplantation in Primary Biliary Cirrhosis: A Report from the Second Decade. Annual Meeting during Digestive Disease Week presentation, 1997.
40. Gerhardt TC, Goldstein RM, Levy MF, Husberg BS, Testa G, Abbasoglu O, Jeyarajah R, Gonwa TA, and **Klintmalm GB**. Alcohol use among patients transplant for alcoholic cirrhosis. Presented in poster form for American Society of Transplant Physicians, 16th Annual Scientific Meeting, Chicago, Illinois, 1997.
41. Crews KA, Levy MF, Jenevein B, Noel BL, Jeyarajah DR, Testa G, Abbasoglu O, Goldstein RM, Husberg BS, Gonwa TA, and **Klintmalm GB**: Neurologic death following liver transplantation. Presented in poster form for American Society of Transplant Physicians, 16<sup>th</sup> Annual Scientific Meeting, Chicago, Illinois, 1997.
42. Testa G, Crippin J, Abbasoglu O, Goldstein RM, Husberg BS, Jeyarajah DR, Levy MF, and **Klintmalm GB**: Does recurrent autoimmune hepatitis after liver transplant have an impact on patient and graft survival? American Society of Transplant Physicians, 16<sup>th</sup> Annual Scientific Meeting, Chicago, Illinois, 1997. (oral presentation)
43. Jeyarajah DR, Gonwa TA, McBride M, Abbasoglu O, Goldstein RM, Husberg BS, Levy MF, Testa G, and **Klintmalm GB**: Does preoperative creatinine (Scr) affect outcome after orthotopic liver transplantation? (OLTx)? American Society of Transplant Physicians presentation, 16<sup>th</sup> Annual Scientific Meeting, Chicago, Illinois, 1997. (oral presentation)
44. Jeyarajah DR, Gonwa TA, McBride M, Abbasoglu O, Goldstein RM, Husberg BS, Levy MF, Testa G, and **Klintmalm GB**: Hepatorenal syndrome (HRS): Why are combined liver kidney transplants still being done? American Society of Transplant Physicians presentation, 1997. (oral presentation)

45. Abbasoglu O, Levy MF, Brkic B, Testa G, Jeyarajah DR, Goldstein RM, Husberg BS, Gonwa TA, and **Klintmalm GB**: 10 Years of liver transplantation: An evolving understanding of late graft loss. American Society of Transplant Physicians presentation, 1997. (oral presentation)
46. Goldstein R, Baker J, **Klintmalm G**, Levy MF, and Husberg B: Anti-platelet therapy and liver transplantation for budd-chiari syndrome associated with myeloproliferative disorders. Presented in poster form for American Society of Transplant Surgeons, 1997.
47. Testa G, Goldstein RM, Abbasoglu O, Jeyarajah DR, Brooks BK, Levy MR, Husberg BS, Gonwa TA, and **Klintmalm GB**. Long-term outcome of patients transplanted with livers from hepatitis C positive donors. American Society of Transplant Surgeons presentation, 1997. (oral presentation)
48. Abbasoglu O, Levy MF, Jeyarajah DR, Testa G, Brkic BS, Jennings LW, Goldstein RM, Husberg BS, Gonwa TA, and **Klintmalm GB**: Does intraoperative hepatic artery flow predict post liver transplant arterial complications? Presented in poster form for American Society of Transplant Surgeons, 1997.
49. Goldstein RM, Baker J, Testa G, Jennings LW, Brooks BK, Levy MF, Orr D, Netto G, Husberg BS, and **Klintmalm GB**: Total hepatectomy and liver transplantation for hepatocellular carcinoma. A single center experience with 72 patients. American Society of Transplant Surgeons presentation, 1997. (oral presentation)
50. Levy M, Ramsay MAE, GreenL, Ramsay KJ, Meng J, Hein HAT, and **Klintmalm GB**. Readmission to ICU following OLT: Etiology and predictability. Liver Transplantation and Surgery 3(5):C-40,1997. (oral presentation)
51. Jeyarajah DR, Netto GJ, Lee SP, Abbasoglu O, Testa G, Goldstein RM, Husberg BS, Levy MF, Tillery GW, Gonwa TA, Crippin JS, and **Klintmalm GB**. Defining recurrent primary sclerosing cholangitis (PSC): Is chronic rejection part of the disease process? Liver Transplantation and Surgery 3(5):C-43, 1997. (oral presentation)
52. Levy M, Ramsay NAE, Greene L, Ramsay KJ, Meng J, Hein HAT, and **Klintmalm GB**. Readmission to ICU following OLT: Etiology and predictability. Fourth Congress International Liver Transplantation Society, Seattle, WA, October 1997. (oral presentation)
53. Jeyarajah DR, Netto GJ, Lee SP, Abbasoglu O, Testa G, Goldstein RM, Husberg BS, Levy MF, Tillery GW, Gonwa TA, Crippin JS, and **Klintmalm GB**. Defining recurrent primary sclerosing cholangitis (PSC): Is chronic rejection part of the disease process?

Fourth Congress International Liver Transplantation Society, Seattle, WA, October 1997. (oral presentation)

54. Testa G, Goldstein R, Brkic B, Jennings L, Brooks B, Levy M, Husberg B, and **Klntmalm G**. Is there an effect of immunosuppression given during the first 6 months on recurrence of hepatitis C in patients who survive more than 2 years? The International Congress on Immunosuppression, Orlando, FL, December 1997. (poster presentation)
55. Wiesner RH, U.S. FK506 Liver Transplant Study Group: A Long-Term Comparison of Tacrolimus (FK506) and Cyclosporine in Liver Transplantation: Results of the U.S. Multicenter, Randomized Trial. The International Congress on Immunosuppression, Orlando, FL, December 1997. (oral presentation)
56. Lake JR, U.S. FK506 Liver Transplant Study Group: Outcomes of Hepatitis C Virus Infected Liver Transplant Recipients Comparing Tacrolimus Versus Cyclosporine-Based Immunosuppression. The International Congress on Immunosuppression, Orlando, FL, December 1997. (poster presentation)
57. So S, U.S. FK506 Liver Transplant Study Group: Linear Growth in Children After Cadaveric Liver Transplantation on Longterm Tacrolimus Therapy. The International Congress on Immunosuppression, Orlando, FL, December 1997. (poster presentation)
58. Merion RM, **Klntmalm GBG**, McDiarmid SV, Weisner RH, Roberts JP, Schwartz ME, and Nicholls AJ. Pharmacokinetics of Intravenous and Oral Mycophenolate Mofetil (MMF) in Liver Allograft Recipients. American Society of Transplant Physicians, 16<sup>th</sup> Annual Meeting, May 1997.
59. Netto G, Goldstein R, Do K, Stone M, Husberg B, Levy M, Jennings L, Tran M, and **Klntmalm G**. Evaluation of Prognostic Factors in Hepatocellular Carcinoma (HCC) Treated with Orthotopic Liver Transplantation (OLT). United States and Canadian Academy of Pathology, Inc., 87<sup>th</sup> Annual Meeting, February – March 1998. (poster presentation)
60. Netto G, **Klntmalm G**, and Albores-Saavedra J. Gallbladder Morphology in Liver Explants of Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis. United States and Canadian Academy of Pathology, Inc., 87<sup>th</sup> Annual Meeting, February – March 1998. (poster presentation)
61. **Klntmalm GBK**. Tumor Characteristics Impact on Outcome After Liver Transplantation for Hepatocellular Carcinoma: A Registry Report. American Surgical Association, 118<sup>th</sup> Annual Meeting, Palm Beach, FL April 1998. (oral presentation)



62. Brooks BK, Levy MF, Testa G, Obiekwe S, Jennings LW, Husberg BS, Goldstein RM, Gonwa TA, and **Klntmalm GB**. Surviving postransplant lymphoma in the liver transplant recipient: Cause for optimism? American Society of Transplant Physicians, 17<sup>th</sup> Annual Meeting, Chicago, IL, May 1998. (poster presentation)
63. Hasse JM, Levy MF, Hollander PA, Jennings LW, Gonwa TA, Goldstein RM, Husberg BS, and **Klntmalm GB**. Does diabetes mellitus influence liver transplant outcomes? American Society of Transplant Physicians, 17<sup>th</sup> Annual Meeting, Chicago, IL, May 1998. (poster presentation)
64. Hasse JM, Testa G, Gonwa TA, Jennings LW, Levy MF, Goldstein RM, Husberg BS, and **Klntmalm GB**. Is pre-liver transplant obesity a risk factor for posttransplant metabolic complications? American Society of Transplant Physicians, 17<sup>th</sup> Annual Meeting, Chicago, IL, May 1998. (poster presentation)
65. Hasse JM, Gonwa TA, Jennings LW, Goldstein RM, Levy MF, Husberg BS, and **Klntmalm GB**. Malnutrition affects liver transplant outcomes. American Society of Transplant Physicians, 17<sup>th</sup> Annual Meeting, Chicago, IL, May 1998. (poster presentation)
66. Testa G, Gonwa TA, Husberg B, Goldstein RM, Levy MF, Brooks B, and **Klntmalm GB**. Kidney transplantation after liver transplantation: A single center experience. American Society of Transplant Physicians, 17<sup>th</sup> Annual Meeting, Chicago, IL, May 1998. (poster presentation)
67. Testa G, Hasse JM, Jennings LW, Levy MF, Brkic B, Cook B, Obiekwe S, Husberg BS, Goldstein RM, Gonwa TA, and **Klntmalm GB**. Morbid obesity is not an independent risk factor for liver transplantation. American Society of Transplant Surgeons, 24<sup>th</sup> Annual Scientific Meeting, Chicago, IL, May 1998. (poster presentation)
68. Testa G, Goldstein RM, Brooks BK, Levy MF, Husberg BS, Gonwa TA, and **Klntmalm GB**. Long-term outcome of patients transplanted with livers from hepatitis C positive donors. The Transplantation Society, XVII World Congress, Montreal, July 1998. (oral presentation)
69. Brooks BK, Levy MF, Testa G, Obiekwe S, Jennings LW, Husberg BS, Goldstein RM, Gonwa TA, and **Klntmalm GB**. Surviving posttransplant lymphoma in the liver transplant recipient: Cause for optimism? The Transplantation Society, XVII World Congress, Montreal, July 1998. (poster presentation)
70. Scholz T, Solberg R, Gallimore MJ, Okkenhaug C, Videm V, Mathisen O, Mollnes TE, Bergan A, Soreide O, **Klntmalm GB**, and Aasen AO. The significance of heparinized perfusion circuits in activation of humoral defense systems in an in vitro model for OLT. The Transplantation Society, XVII World Congress, Montreal, July 1998. (poster presentation)

71. **Klintmalm GB**, Levy MF, Goldstein RM, and Husberg BS. Tumor characteristics impact on outcome after liver transplantation for hepatocellular carcinoma: A registry report. The Transplantation Society, XVII World Congress, Montreal, July 1998. (oral presentation)
72. Levy MF, Crippin J, Sutton S, Weinstein J, Testa G, Obiekwe S, Goldstein RM, Husberg GS, Gonwa TA, Logan J, and **Klintmalm GB**. Successful transgenic porcine liver perfusion as a bridge to human liver transplantation. The Transplantation Society, XVII World Congress, Montreal, July 1998. (oral presentation)
73. Abbasoglu O, Levy MF, Brkic B, Testa G, Obiekwe S, Goldstein RM, Husberg BS, Gonwa TA, and **Klintmalm GB**. 10 Years of liver transplantation: An evolving understanding of late graft loss. The Transplantation Society, XVII World Congress, Montreal, July 1998. (poster presentation)
74. Testa G, Crippin J, Abbasoglu O, Goldstein RM, Husberg BS, Obiekwe S, Levy MF, and **Klintmalm GB**. Does recurrent autoimmune hepatitis after liver transplant have an impact on patient and graft survival? The Transplantation Society, XVII World Congress, Montreal, July 1998. (poster presentation)
75. Kim WR, Wiesner RH, Therneau TM, Malinchoc M, Krom RAF, Evans RW, Dickson ER, Crippin JS, **Klintmalm GBG**, Rakela J, and Starzl TE. Liver transplantation for primary sclerosing cholangitis in the 90's: Patient survival and resource utilization. American Association for the Study of Liver Diseases, 49<sup>th</sup> Annual Meeting, Chicago, IL, November 1998. (oral presentation)
76. Molmenti EP, Netto GJ, Crippin JS, Conkey AC, Hoover TX, Jennings LW, Jung GJ, Levy MF, Goldstein RM, Gonwa TA, and **Klintmalm GB**. Incidence and recurrence of autoimmune hepatitis in liver transplant recipients. American Society of Transplant Surgeons, 25<sup>th</sup> Annual Scientific Meeting, Chicago, IL, May 1999. (poster presentation)
77. Molmenti EP, Levy MF, Jung GJ, Jennings LW, Crippin JS, Conkey AC, Goldstein RM, Gonwa TA, and **Klintmalm GB**. Outcome 10-years after liver transplantation. American Society of Transplant Surgeons, 25<sup>th</sup> Annual Scientific Meeting, Chicago, IL, May 1999. (oral presentation)
78. Levy MF, Crippin JS, Sutton SW, Netto GJ, Jung GJ, Molmenti EP, Goldstein RG, Gonwa TA, **Klintmalm GB**, and Logan JS. Two patients undergo liver allotransplantation (OLT<sub>x</sub>) following extracorporeal hepatic support with transgenic (hCD55/hCD59) porcine livers: Clinical results and lack of pig to human transmission of the porcine endogenous retrovirus (PoERV). American Society of Transplant Surgeons, 25<sup>th</sup> Annual Scientific Meeting, Chicago, IL, May 1999. (oral presentation)

79. Cowling T, Jung G, Molmenti EP, Goldstein RM, Gonwa TA, **Klintmalm GB**, and Levy MF. The influence of donor alcohol consumption on hepatic allograft function. American Society of Transplantation, 18<sup>th</sup> Annual Scientific Meeting, Chicago, IL, May 1999. (poster presentation)
80. Cowling T, Jung G, Molmenti EP, Goldstein RM, Gonwa TA, **Klintmalm GB**, and Levy MF. Social reintegration after liver transplantation for alcohol-related liver disease. American Society of Transplantation, 18<sup>th</sup> Annual Scientific Meeting, Chicago, IL, May 1999. (oral presentation)
81. Ramsay MAE, Molmenti E, Ramsay KJ, Lynch K, Hein HAT, Conkey A, Goldstein R, Levy M, and **Klintmalm G**. The efficacy of Epoprostenol and nitric oxide therapy in reducing severe pulmonary hypertension and preserving right ventricular function following orthotopic liver transplantation. American Society of Transplantation, 18<sup>th</sup> Annual Scientific Meeting, Chicago, IL, May 1999. (oral presentation)
82. Levy MF, Crippin JS, Sutton SW, Netto GJ, Jung GJ, Molmenti EP, Goldstein RM, Gonwa TA, and **Klintmalm GB**, Logan JS. Lack of pig to human transmission of the porcine endogenous retrovirus (PoERV) following extracorporeal hepatic support with transgenic (hCD55/hCD59) porcine livers. International Liver Transplantation Society, Pittsburgh, PA, August 1999. (oral presentation)
83. Levy MF, Crippin JS, Sutton SW, Netto GJ, Jung GJ, Molmenti EP, Goldstein RM, Gonwa TA, Logan JS, and **Klintmalm GB**. Two patients successfully undergo liver transplantation following extracorporeal hepatic support with transgenic porcine livers. International Liver Transplantation Society, Pittsburgh, PA, August 1999. (poster presentation)
84. Molmenti EP, Netto GJ, Crippin JS, Conkey AC, Hoover TC, Jennings LW, Jung GJ, Levy MF, Goldstein RM, Gonwa TA, and **Klintmalm GB**. Incidence and recurrence of autoimmune hepatitis in liver transplant recipients. International Liver Transplantation Society, Pittsburgh, PA, August 1999. (oral presentation)
85. Molmenti EP, Levy MF, Jung GJ, Jennings LW, Crippin JS, Conkey AC, Goldstein RM, Gonwa TA, and **Klintmalm GB**. Approaching half-life survival in liver transplantation. International Liver Transplantation Society, Pittsburgh, PA, August 1999. (poster presentation)
86. Cowling T, Jung GJ, Molmenti EP, Goldstein RM, Gonwa TA, **Klintmalm GB**, and Levy MF. Liver transplant waiting list morbidity: a preliminary report. International Liver Transplantation Society, Pittsburgh, PA, August 1999. (poster presentation)

87. Cowling T, Jung GJ, Molmenti EP, Goldstein RM, Gonwa TA, **Klintmalm GB**, and Levy MF. The influence of donor alcohol consumption on hepatic allograft function. International Liver Transplantation Society, Pittsburgh, PA, August 1999. (poster presentation)
88. Cowling T, Jung GJ, Molmenti EP, Goldstein RM, Gonwa TA, **Klintmalm GB**, and Levy MF. Social reintegration after liver transplantation for alcohol-related liver disease. International Liver Transplantation Society, Pittsburgh, PA, August 1999. (poster presentation)
89. Levy MF, Crippin JS, Sutton SW, Netto GJ, Jung GJ, Molmenti EP, Goldstein RM, Gonwa TA, Logan JS, and **Klintmalm GB**. Lack of pig to human transmission of the porcine endogenous retrovirus (PoERV) following extracorporeal hepatic support with transgenic (hCD55/hCD59) porcine livers. The 5<sup>th</sup> Congress of the International Xenotransplantation Association, Nagoya, Japan, October 1999. (oral presentation)
90. Levy MF, Crippin JS, Sutton SW, Netto GJ, Jung GJ, Molmenti EP, Goldstein RM, Gonwa TA, Logan JS, and **Klintmalm GB**. Two patients successfully undergo liver transplantation following extracorporeal hepatic support with transgenic porcine livers. The 5<sup>th</sup> Congress of the International Xenotransplantation Association, Nagoya, Japan, October 1999. (oral presentation)
91. Cowling T, Jung GJ, Molmenti EP, Goldstein RM, Gonwa TA, **Klintmalm GB**, and Levy MF. Liver transplant waiting list morbidity: A preliminary report. Association for Academic Surgery, 33rd Annual Meeting, Philadelphia, PA, November 1999. (poster presentation)
92. Sanchez E, Marubashi S, Jung G, Levy MF, Goldstein RM, Molmenti EP, Fasola CG, Gonwa TA, Jennings LW, Conkey AC, Brooks B, and **Klintmalm GB**. De novo tumors after liver transplantation occur in a set timeline. American Society of Transplant Surgeons and American Society of Transplantation. Transplant 2000 Joint Meeting, Chicago, IL, May 2000. (poster presentation)
93. Fasola CG, Netto GJ, Jennings LW, Gonwa TA, Goldstein RM, Levy MF, Molmenti EP, and **Klintmalm GB**. Does mofetil mycophenolate (MMF) delay hepatitis C recurrence in liver transplant patients? American Society of Transplant Surgeons and American Society of Transplantation. Transplant 2000 Joint Meeting, Chicago, IL, May 2000. (oral presentation)
94. Rabkin JM, Kalayoglu M, **Klintmalm G**, Langnas AM, Levy GA, Mamelok RD, McDiarmid SV, McMaster P, Merion R, Wang W, and Wiesner RH. Efficacy of mycophenolate (MMF) in liver transplant recipients: Results of a randomized double blind comparative study with an analysis of the impact of hepatitis C. American Society of Transplant Surgeons and American Society of Transplantation. Transplant 2000 Joint Meeting, Chicago, IL, May 2000. (oral presentation)

95. Molmenti EP, Ramsay MA, Ramsay KJ, Lynch K, Tillmann-Hein HA, Conkey A, Coke C, Goldstein RM, Levy MF, Ausloos KA, Fasola CG, Marubashi S, Sanchez EQ, Jung G, East C, Escobar J, and **Klntmalm GB**. Epoprostenol and nitric oxide therapy for severe pulmonary hypertension in liver transplantation. American Society of Transplant Surgeons and American Society of Transplantation. Transplant 2000 Joint Meeting, Chicago, IL, May 2000. (oral presentation)
96. Molmenti EP, Nagata D, Roden J, Squires RH, Fasola CG, Jung G, Marubashi S, Sanchez E, Levy MF, Goldstein RM, Andrews W, McPhail W, D'Amico L, Benser M, Emert L, Andersen J, and **Klntmalm GB**. Incidence, management, and outcome of posttransplant lymphoproliferative disease in pediatric liver recipients. American Society of Transplant Surgeons and American Society of Transplantation. Transplant 2000 Joint Meeting, Chicago, IL, May 2000. (oral presentation)
97. Molmenti EP, Roodhouse TW, Hunag H, Coke C, Levy MF, Jennings LW, Brooks BK, Conkey A, Johnson C, Sanchez EQ, Marubashi S, Jung G, Goldstein RM, Fasola CG, Gonwa TA, and **Klntmalm GB**. Intraoperative flows and postoperative resistive index as predictors of hepatic artery and portal vein thrombosis in liver transplantation. American Society of Transplant Surgeons and American Society of Transplantation. Transplant 2000 Joint Meeting, Chicago, IL, May 2000. (oral presentation)
98. Sanchez E, Marubashi S, Jung G, Goldstein RM, Molmenti EP, Fasola CG, Gonwa TA, Jennings LW, Conkey AC, Brooks BK, **Klntmalm GB**, and Levy MF. Lack of racial differences in quality of life improvements after liver transplantation. American Society of Transplant Surgeons and American Society of Transplantation. Transplant 2000 Joint Meeting, Chicago, IL, May 2000. (poster presentation)
99. Smith D, Agura E, Osowski L, McCormack J, Levy M, Molmenti E, Goldstein R, Fichtel L, Collins R, Stone M, and **Klntmalm G**. Liver transplant associated graft versus host disease (GVHD). American Society of Transplant Surgeons and American Society of Transplantation. Transplant 2000 Joint Meeting, Chicago, IL, May 2000. (oral presentation)
100. Molmenti EP, Roodhouse TW, Jaiswal K, Jennings LW, Sanchez EQ, Marubashi S, Jung G, Brooks BK, Conkey A, Mulligan D, Levy MF, Goldstein RM, and **Klntmalm GB**. Portal vein thrombendvenectomy in cases of organized portal vein thrombosis at the time of liver transplantation. American Society of Transplant Surgeons and American Society of Transplantation. Transplant 2000 Joint Meeting, Chicago, IL, May 2000. (poster presentation)

101. Gonwa T, Fasola CG, Levy MF, Goldstein RM, Molmenti EP, and **Klintmalm GB**. Renal replacement therapy (RRT) and orthotopic liver transplantation (OLT): A negative predictor of survival. American Society of Transplant Surgeons and American Society of Transplantation. Transplant 2000 Joint Meeting, Chicago, IL, May 2000. (poster presentation)
102. Gogel BM, Donohoe AL, Glastad KA, Crippin JS, Levy MF, **Klintmalm GB**, Kuhn JA, McCarty TM, and Goldstein RM. Screening for hepatocellular carcinoma in the multinodular, cirrhotic liver. American Society of Transplant Surgeons and American Society of Transplantation. Transplant 2000 Joint Meeting, Chicago, IL, May 2000. (poster presentation)
103. Goldstein RM, Orr DW, Meyer RL, Derrick HC, Westmoreland MV, Levy MF, and **Klintmalm GB**. Treatment of hepatomas in cirrhotic patients with radiofrequency thermal ablation. American Society of Transplant Surgeons and American Society of Transplantation. Transplant 2000 Joint Meeting, Chicago, IL, May 2000. (oral presentation)
104. Fasola CG, Molmenti E, Netto GJ, Jennings LW, Gonwa TA, Goldstein RM, Levy MF, and **Klintmalm GK**. Does mofetil mycophenolate (MMF) delay hepatitis C (hep C) recurrence in liver transplant patients (OLT)? Sixth Congress of the International Liver Transplantation Society, Buenos Aires, Argentina, June 2000. (oral presentation)
105. Molmenti EP, Ramsay M, Ramsay K, Lynch K, Tillmann-Hein H, Conkey A, Coke C, Goldstein R, Levy M, Ausloos K, Fasola C, Marubashi S, Sanchez E, Jung G, East C, Escobar J, and **Klintmalm G**. Epoprostenol and nitric oxide therapy for severe pulmonary hypertension in liver transplantation. Sixth Congress of the International Liver Transplantation Society, Buenos Aires, Argentina, June 2000. (poster presentation)
106. Molmenti EP, Smith D, Agura E, Levy M, Goldstein R, Fasola C, Baker J, Gonwa T, McCormack J, Stone M, and **Klintmalm G**. Graft versus host disease in kidney transplantation. Sixth Congress of the International Liver Transplantation Society, Buenos Aires, Argentina, June 2000.
107. Molmenti EP, Fasola C, Roden J, Squires R, Nagata D, Jung G, Marubashi S, Sanchez E, Levy M, Goldstein R, Andrews W, McPhail W, D'Amico L, Benser M, Emert L, Aranda M, Andersen J, and **Klintmalm G**. Incidence, management, and outcome of posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Sixth Congress of the International Liver Transplantation Society, Buenos Aires, Argentina, June 2000. (poster presentation)
108. Molmenti EP, Roodhouse T, Huang H, Coke C, Levy M, Jennings L, Brooks B, Conkey A, Johnson C, Sanchez E, Marubashi S, Jung G, Goldstein R, Fasola C, Gonwa T, and **Klintmalm G**. Intraoperative flows and postoperative resistive index as predictors of

- hepatic artery and portal vein thrombosis in liver transplantation. Sixth Congress of the International Liver Transplantation Society, Buenos Aires, Argentina, June 2000. (oral presentation)
109. Smith D, Molmenti EP, Agura E, Osowski L, McCormack J, Levy M, Goldstein R, Fichtel L, Collins R, Stone M, and **Klintmalm G**. Liver transplant associated graft versus host disease (GVHD). Sixth Congress of the International Liver Transplantation Society, Buenos Aires, Argentina, June 2000. (oral presentation)
  110. Molmenti EP, Roodhouse T, Jaiswal K, Jennings L, Sanchez E, Marubashi S, Jung G, Brooks B, Conkey A, Mulligan D, Levy M, Goldstein R, Fasola C, Gonwa T, and **Klintmalm G**. Portal vein thrombendvenectomy in cases of portal vein thrombosis at the time of liver transplantation. Sixth Congress of the International Liver Transplantation Society, Buenos Aires, Argentina, June 2000. (oral presentation)
  111. Molmenti EP, Ford K, Wenzel J, Donohoe A, Glastad K, Sanchez E, Marubashi S, Jung G, Goldstein R, Levy M, Fasola C, Gonwa T, and **Klintmalm G**. Primary biliary cirrhosis: MRI findings in 21 consecutive, pretransplant patients, and description of "MRI periportal halo" sign. Sixth Congress of the International Liver Transplantation Society, Buenos Aires, Argentina, June 2000. (poster presentation)
  112. **Klintmalm G** for the Mycophenolate Liver Transplant Study Investigators. Safety, efficacy and pharmacokinetics of mycophenolate mofetil in liver transplantation: Results of a multicenter, randomized, double blind trial. Sixth Congress of the International Liver Transplantation Society, Buenos Aires, Argentina, June 2000. (oral presentation)
  113. Gogel BM, Molmenti EP, Crippin JS, Levy MF, **Klintmalm GB**, Kuhn JA, McCarty TM, and Goldstein RM. Screening for hepatocellular carcinoma in the multinodular, cirrhotic liver. Sixth Congress of the International Liver Transplantation Society, Buenos Aires, Argentina, June 2000. (poster presentation)
  114. Molmenti EP, Orr D, Meyer R, Derrick H, Westmoreland M, Levy M, and **Klintmalm G**. Treatment of hepatomas in cirrhotic patients with radiofrequency thermal ablation. Sixth Congress of the International Liver Transplantation Society, Buenos Aires, Argentina, June 2000. (oral presentation)
  115. Cancemi MT, Cancemi ET, Ramsay KJ, Ramsay MAE, Hein HAT, Goldstein RM, Levy MF, Molmenti EP, Fasola CG, Jennings LW, Black RE, and **Klintmalm GB**. Prediction of high volume blood transfusion during orthotopic liver transplantation. Sixth Congress of the International Liver Transplantation Society, Buenos Aires, Argentina, June 2000 (poster presentation)
  116. Molmenti E, Nagata D, Roden J, Squires R, Casey D, Prestidge C, McPhail W, Molmenti H, Sanchez E, Goldstein R, Levy M, Fasola C, Andrews W, D'Amico L,

- Benser M, Emert L., Andersen J, and **Klintmalm G**. Pediatric liver transplantation for cystic fibrosis. First Congress of the International Pediatric Transplant Association, Venice, Italy, August 2000. (oral presentation)
117. Molmenti EP, Roden J, Squires R, Jennings L, Fasola C, Molmenti H, Casey D, Nagata D, McPhail W, D'Amico L, Goldstein R, Levy M, Andrews W, Emert L, Aranda M, Andersen J, and **Klintmalm G**. Mortality in the pediatric liver transplant population according to age groups. First Congress of the International Pediatric Transplant Association, Venice, Italy, August 2000. (poster presentation)
118. Molmenti EP, Roden J, Squires R, Jennings L, Molmenti H, Casey D, Nagata D, D'Amico L, McPhail W, Sanchez E, Goldstein R, Levy M, Fasola C, Andrews W, Emert L, Andersen J, and **Klintmalm G**. Patient and graft survival after liver transplantation in the pediatric population. First Congress of the International Pediatric Transplant Association, Venice, Italy, August 2000. (poster presentation)
119. Molmenti EP, Roden J, Squires R, Jennings L, Molmenti H, Casey D, Nagata D, McPhail W, D'Amico L, Goldstein R, Levy M, Fasola C, Andrews W, Emert L, Aranda M, Andersen J, and **Klintmalm G**. Mortality in the pediatric liver transplant population. First Congress of the International Pediatric Transplant Association, Venice, Italy, August 2000. (poster presentation)
120. Casey D, Molmenti E, Peterson T, Creech M, Bashes V, Roden J, Squires R, Jung G, McPhail W, D'Amico L, Andersen J, Goldstein R, Levy M, Fasola C, Gonwa T, and **Klintmalm G**. Unusually high incidence of HTLV I-II among young female organ donors in the peripartum period without risk history. First Congress of the International Pediatric Transplant Association, Venice, Italy, August 2000. (poster presentation)
121. Molmenti E, Nagata D, Roden J, Squires R, Casey D, Tomlinson G, Ratliff A, D'Amico L, Molmenti H, Marubashi S, Goldstein R, Levy M, Fasola C, Andrews W, McPhail W, Emert L, Andersen J, and **Klintmalm G**. Liver transplantation for hepatoblastoma in the pediatric population. First Congress of the International Pediatric Transplant Association, Venice, Italy, August 2000. (poster presentation)
122. Molmenti EP, Ramsay M, Ramsay K, Lynch K, Tillmann-Hein H, Conkey A, Goldstein R, Levy M, Ausloos K, Fasola C, Jung G, Escobar J, and **Klintmalm G**. Epoprosterenol and nitric oxide therapy for severe pulmonary hypertension in liver transplantation. XVIII International Congress of the Transplantation Society, Rome, Italy, August 2000. (oral presentation)
123. Molmenti EP, Nagata D, Roden J, Squires R, Casey D, Winick N, McPhail W, D'Amico L, Molmenti H, Marubashi S, Goldstein R, Levy M, Fasola C, Aranda M, Andersen J, and **Klintmalm G**. Incidence, management, and outcome of posttransplant



lymphoproliferative disease in pediatric liver transplant recipients. XVIII International Congress of the Transplantation Society, Rome, Italy, August 2000. (oral presentation)

124. Sanchez E, Marubashi S, Jung G, Goldstein RM, Molmenti EP, Fasola C, Gonwa TA, Jennings L, Conkey AC, Brooks BK, Levy MF, and **Klintmalm GB**. De novo tumors after liver transplant occur in a set timeline. XVIII International Congress of the Transplantation Society, Rome, Italy, August 2000. (poster presentation)
125. Goldstein R, Orr D, Meyer R, Derrick H, Westmoreland M, Levy M, and **Klintmalm G**. Treatment of hepatomas in cirrhotic patients with radiofrequency thermal ablation. XVIII International Congress of the Transplantation Society, Rome, Italy, August 2000. (poster presentation)
126. Molmenti E, Nagata D, Roden J, Squires R, Casey D, Prestidge C, McPhail W, Molmenti H, Sanchez E, Goldstein R, Levy M, Fasola C, Andrews W, D'Amico L, Benser M, Emert L, Andersen J, and **Klintmalm G**. Pediatric liver transplantation for cystic fibrosis. XVIII International Congress of the Transplantation Society, Rome, Italy, August 2000. (poster presentation)
127. Molmenti E, Casey D, Jennings L, Jung G, Marubashi S, Sanchez E, Goldstein R, Levy M, Fasola C, Gonwa T, and **Klintmalm G**. Leading causes of death in the liver transplant population compared to the corresponding age-matched general U.S. population. XVIII International Congress of the Transplantation Society, Rome, Italy, August 2000. (poster presentation)
128. Molmenti E, Nagata D, Roden J, Squires R, Casey D, Tomlinson G, Ratliff A, D'Amico L, Molmenti H, Marubashi S, Goldstein R, Levy M, Fasola C, Andrews W, McPhail W, Emert L, Andersen J, and **Klintmalm G**. Liver transplantation for hepatoblastoma in the pediatric population. XVIII International Congress of the Transplantation Society, Rome, Italy, August 2000. (poster presentation)
129. Molmenti E, Roodhouse T, Huang H, Coke C, Casey D, Levy M, Jennings L, Brooks B, Conkey A, Johnson C, Sanchez E, Goldstein R, Fasola C, Gonwa T, and **Klintmalm G**. Correlation between intraoperative flows and hepatic artery and portal vein thrombosis in liver transplantation. XVIII International Congress of the Transplantation Society, Rome, Italy, August 2000. (poster presentation)
130. Gonwa T, Fasola C, Molmenti E, Levy M, Goldstein R, and **Klintmalm G**. Liver transplant and renal replacement therapy: the role of CVVHD. XVIII International Congress of the Transplantation Society, Rome, Italy, August 2000. (poster presentation)
131. Sanchez E, Marubashi S, Jung G, Goldstein RM, Molmenti EP, Fasola C, Gonwa TA, Jennings L, Conkey AC, Brooks BK, **Klintmalm GB**, and Levy MF. Lack of racial

- differences in quality of life improvements after liver transplantation. XVIII International Congress of the Transplantation Society, Rome, Italy, August 2000. (poster presentation)
132. McMaster P, Wiesner R, Rabkin J, **Klintmalm G**, Langnas A, McDiarmid S, Merion R, Kalayoglu M, Levy G, Freeman R, Bismuth H, Roberts J, Neuhaus P, and Navarro M. Efficacy and safety of mycophenolate mofetil (MMF) after liver transplantation (OLT): Results of a double-blind randomized trial. XVIII International Congress of the Transplantation Society, Rome, Italy, August 2000. (oral presentation)
  133. Goldstein RM, Derrick HC, Orr DW, Meyer RL, Netto G, Levy MF, **Klintmalm GB**, and Westmoreland MV. Radiofrequency thermal ablation of primary and metastatic liver tumors. American Association for the Study of Liver Diseases, 51<sup>st</sup> Annual Meeting, Dallas, Texas, October 2000. (oral presentation)
  134. Molmenti EP, Nagata D, Roden J, Squires R, Casey D, Prestidge C, McPhail W, Fasola CG, Jung GJ, Marubashi S, Sanchez EQ, Gogel B, Goldstein RM, Lopez J, Andrews W, D'Amico L, Benser M, Moisa G, Andersen J, and **Klintmalm GB**. Pediatric Liver Transplantation for Cystic Fibrosis. American Association for the Study of Liver Diseases, 51<sup>st</sup> Annual Meeting, Dallas, Texas, October 2000. (poster presentation)
  135. Molmenti EP, Nagata D, Roden J, Squires R, Casey D, Tomlinson G, Ratliff A, D'Amico L, Fasola CG, Jung GJ, Marubashi S, Sanchez EQ, Gogel B, Goldstein RM, Andrews W, McPhail W, Lopez J, Moisa G, Andersen J, and **Klintmalm GB**. Liver transplantation for hepatoblastoma in the pediatric population. American Association for the Study of Liver Diseases, 51<sup>st</sup> Annual Meeting, Dallas, Texas, October 2000. (poster presentation)
  136. Molmenti EP, Casey D, Jennings LW, Brooks B, Jung GJ, Marubashi S, Sanchez EQ, Gogel B, Goldstein, Levy MF, Fasola CG, Gonwa TA, and **Klintmalm GB**. Intraoperative hepatic artery and portal vein flows and postoperative resistive index as predictors of hepatic artery strictures in liver transplantation. American Association for the Study of Liver Diseases, 51<sup>st</sup> Annual Meeting, Dallas, Texas, October 2000. (poster presentation)
  137. Molmenti EP, Casey D, Jennings LW, Molmenti H, Sanchez EQ, Marubashi S, Jung GJ, Gogel B, Goldstein RM, Levy MF, Fasola CG, Gonwa TA, and **Klintmalm GB**. Time-staged causes of mortality after liver transplantation. American Association for the Study of Liver Diseases, 51<sup>st</sup> Annual Meeting, Dallas, Texas, October 2000. (poster presentation)
  138. Fasola CG, Netto G, Jennings LW, Jung GJ, Marubashi S, Sanchez EQ, Molmenti EP, Gonwa TA, Goldstein RM, Levy MF, and **Klintmalm GB**. Initial clinical evidence that mofetil mycophenolate's (MMF) antiviral effects may delay the recurrence of hepatitis C (hep C) and reduce the incidence of CMV infection in hep C liver transplant

- recipients (OLT). American Association for the Study of Liver Diseases, 51<sup>st</sup> Annual Meeting, Dallas, Texas, October 2000. (poster presentation)
139. Fasola C, Jennings LW, Jung G, Marubashi S, Sanchez EQ, Molmenti EP, Gonwa TA, Levy MF, Goldstein RM, and **Klntmalm GB**. Primary liver transplantation (OLT) and retransplantation (ReOLT): past and present outcomes. American Association for the Study of Liver Diseases, 51<sup>st</sup> Annual Meeting, Dallas, Texas, October 2000. (poster presentation)
140. **Klntmalm, Goran** and Bruix, Jody, moderators. Topic: Pretransplant treatment of hepatocellular cancer in an era of increase waiting time: What are the best options? AASLD/Transplant Course entitled "Advances and Controversies in Liver Transplant." AASLD Annual Meeting, Dallas, Texas, October, 27, 2000.
141. Kim WR, Wiesner RH, Therneau TM, Poterucha JJ, Rosen CB, **Klntmalm GB**, and Dickson ER. Donor and Recipient Predictors of Patient and Graft Survival Following Liver Transplantation. American Association for the Study of Liver Disease, 51<sup>st</sup> Annual Meeting, Dallas, Texas, October 2000. (poster presentation)
142. Kim WR, Charlton MR, Wiesner RH, Poterucha JJ, Rosen CB, Dickson ER, and **Klntmalm GB**. Patient and graft survival following hepatic retransplantation in patients with hepatitis C. American Association for the Study of Liver Disease, 51<sup>st</sup> Annual Meeting, Dallas, Texas, October 2000. (poster presentation)
143. Martin Paul, Crippin JS, Goldstein RM, Artinian L, Veldhuisen PV, **Klntmalm GB**, and Busuttil RW. Primary immunosuppressive agent does not affect hepatitis C recurrence rates following liver transplantation. American Association for the Study of Liver Disease, 51<sup>st</sup> Annual Meeting, Dallas, Texas, October 2000. (poster presentation)
144. Netto G, Fasola C, Parker C, Mattison TL, Jennings L, Molmenti, Levy M, Goldstein R, and **Klntmalm G**. Evaluation of the role of mofetil mycophenolate (MMF) in delaying progression of hepatitis C (HepC) recurrence following orthotopic liver transplantation (OLT). United States and Canadian Academy of Pathology Annual Meeting, Atlanta, GA, March 2001. (poster presentation)
145. Netto G, Smith DM, Agura E, Molmenti E, Collins R, Levy M, Goldstein R, Dawson B, Domiati-Saad R, Stone M, and **Klntmalm G**. Risk factors for graft versus host disease (GVHD) following orthotopic liver transplantation (OLT). United States and Canadian Academy of Pathology Annual Meeting, Atlanta, GA, March 2001. (poster presentation)
146. Molmenti EP, Marubashi S, Sanchez E, Gogel B, Jennings L, Brooks B, Goldstein R, Levy M, Fasola C, Gonwa T, and **Klntmalm G**. Correlation between intraoperative

- flows and hepatic artery strictures in liver transplantation. 3<sup>rd</sup> Americas Congress, American Hepato-Pancreato-Biliary Association, February 2001. (poster presentation)
147. Molmenti EP, Ramsay M, Ramsay K, Lynch K, Tillmann-Hein H, Marubashi S, Sanchez E, Gogel B, Goldstein R, Levy M, Ausloos K, Fasola C, East C, Escobar J, and **Klintmalm G**. Epoprostenol and nitric oxide therapy for severe pulmonary hypertension in liver transplantation. 3<sup>rd</sup> Americas Congress, American Hepato-Pancreato-Biliary Association, February 2001. (poster presentation)
148. Molmenti EP, Nagata D, Roden J, Squires R, Molmenti H, Winick N, Fasola C, D'Amico L, Marubashi S, Sanchez E, Gogel B, Goldstein R, Levy M, Andersen J, and **Klintmalm G**. Incidence, management, and outcome of posttransplant lymphoproliferative disease in pediatric liver transplant recipients. 3<sup>rd</sup> Americas Congress, American Hepato-Pancreato-Biliary Association, February 2001. (poster presentation)
149. Molmenti EP, Roodhouse T, Levy M, Jennings L, Brooks B, Johnson C, Marubashi S, Sanchez E, Gogel B, Goldstein R, Fasola C, Gonwa T, and **Klintmalm G**. Intraoperative flows and postoperative resistive index as predictors of hepatic artery and portal vein thrombosis in liver transplantation. 3<sup>rd</sup> Americas Congress, American Hepato-Pancreato-Biliary Association, February 2001. (oral presentation)
150. Molmenti E, Nagata D, Roden J, Squires R, Molmenti H, Tomlinson G, Ratliff A, Fasola C, D'Amico L, Marubashi S, Sanchez E, Gogel B, Goldstein R, Levy M, Andrews W, Andersen J, and **Klintmalm G**. Liver transplantation for hepatoblastoma in the pediatric population. 3<sup>rd</sup> Americas Congress, American Hepato-Pancreato-Biliary Association, February 2001. (poster presentation)
151. Molmenti EP, Nagata D, Roden J, Squires R, Molmenti H, Prestridge C, Fasola C, Marubashi S, Sanchez E, Gogel B, Goldstein R, Levy M, Andrews W, D'Amico L, Andersen J, and **Klintmalm G**. Pediatric liver transplantation for cystic fibrosis. 3<sup>rd</sup> Americas Congress, American Hepato-Pancreato-Biliary Association, February 2001. (poster presentation)
152. Molmenti EP, Roodhouse T, Molmenti H, Jaiswal K, Marubashi S, Sanchez E, Gogel B, Levy M, Goldstein R, Fasola C, Mulligan D, Gonwa T, and **Klintmalm G**. Thrombendvenectomy for organized portal vein thrombosis at the time of liver transplantation. 3<sup>rd</sup> Americas Congress, American Hepato-Pancreato-Biliary Association, February 2001. (poster presentation)
153. Fasola CG, Netto GJ, Jennings LW, Christensen LL, Molmenti EP, Sanchez EQ, Marubashi S, Gogel BM, Gonwa TA, Goldstein RM, Levy MF, and **Klintmalm GB**. Optimal dosing of mycophenolate mofetil (MMF) is necessary to delay hepatitis C recurrence (hep CR) in liver transplant recipients (OLT). The American Society of

Transplant Surgeons and the American Society of Transplantation, Transplant 2001 Joint Meeting, Chicago, IL, May 2001. (poster presentation)

154. Fasola CG, Netto GJ, Jennings LW, Molmenti EP, Sanchez EQ, Marubashi S, Gogel BM, Weinstein JS, Gonwa TA, Goldstein RM, Levy MF, and **Klntmalm GB**. Hepatitis C recurrence (HCR) in liver transplant recipients (OLT): Patterns (PR) and early predictors (EP) of graft fibrosis (GF). The American Society of Transplant Surgeons and the American Society of Transplantation, Transplant 2001 Joint Meeting, Chicago, IL, May 2001. (poster presentation)
155. Gonwa TA, Mai ML, Melton LB, Hays SR, Levy MF, Goldstein RG, Molmenti EP, Fasola CG, and **Klntmalm GB**. End stage renal disease (ESRD) following orthotopic liver transplantation (OLT) utilizing calcineurin inhibitor (CNI) based immunotherapy: Risk of development and treatment. The American Society of Transplant Surgeons and the American Society of Transplantation, Transplant 2001 Joint Meeting, Chicago, IL, May 2001. (oral presentation)
156. Marubashi S, Sanchez EO, Gogel BM, Jennings LW, Molmenti EP, Fasola CG, Goldstein RM, Levy MF, Brooks BK, Christensen LL, Gonwa TA, and **Klntmalm GB**. Orthotopic liver transplantation for fulminant hepatic failure. The American Society of Transplant Surgeons and the American Society of Transplantation, Transplant 2001 Joint Meeting, Chicago, IL, May 2001. (oral presentation)
157. Brooks BK, Diamond NG, Jennings LW, Sanchez EQ, Marubashi S, Gogel BM, Goldstein RM, Molmenti EP, Fasola CG, Gonwa TA, **Klntmalm GB**, and Levy MF. Incidence and impact of hepatic artery thrombosis in liver transplantation. The American Society of Transplant Surgeons and the American Society of Transplantation, Transplant 2001 Joint Meeting, Chicago, IL, May 2001. (poster presentation)
158. Gogel BM, Goldstein LM, Schoenvogel RC, Derrick HC, Westmoreland MV, Seiba M, Sanchez EQ, Marubashi S, Goldstein RM, Levy MF, Molmenti EP, Fasola CG, Gonwa TA, Christensen LL, and **Klntmalm GB**. Laparoscopic donor nephrectomy: A positive comparison with open procedures. The American Society of Transplant Surgeons and the American Society of Transplantation, Transplant 2001 Joint Meeting, Chicago, IL, May 2001. (poster presentation)
159. Sanchez EQ, Byers D, Marubashi S, Gogel BM, Levy MF, Goldstein RM, Molmenti EP, Fasola CG, Gonwa TA, Tillery GW, Netto GJ, Watkins DL, Brooks BK, Christensen LL, and **Klntmalm GB**. Immunosuppressive effect on recurrence of primary biliary cirrhosis after liver transplantation. The American Society of Transplant Surgeons and the American Society of Transplantation, Transplant 2001 Joint Meeting, Chicago, IL, May 2001. (poster presentation)

160. Molmenti EP, Ramsay MA, Ramsay KJ, Lynch K, Tillmann-Hein HA, Goldstein RM, Levy MF, Ausloos KA, Fasola CG, Marubashi S, Sanchez EQ, Gogel B, Escobar J, East C, and **Klintmalm GB**. Successful treatment of portopulmonary hypertension: Short term results and long term survival. The American Society of Transplant Surgeons and the American Society of Transplantation, Transplant 2001 Joint Meeting, Chicago, IL, May 2001. (oral presentation)
161. Kim WR, Wiesner RH, Kamath PS, Malinchoc M, Kremers WK, Rosen CB, Dickson ER, and **Klintmalm GB**. Prediction of liver transplant outcome using the MELD scale. The American Society of Transplant Surgeons and the American Society of Transplantation, Transplant 2001 Joint Meeting, Chicago, IL, May 2001. (oral presentation)
162. Dullye LJ, Ramsay MA, Black RE, Jones CC, Molmenti EP, **Klintmalm GB**, and Tillman Hein HA. The impact of an increased cardiac output post-reperfusion on the survival of liver transplant patients. The Joint Meeting of the ILTS, ELTA and LICAGE, Berlin, Germany, July 2001. (oral presentation)
163. Dullye LJ, Ramsay MA, Black RE, Jones CC, Molmenti EP, **Klintmalm GB**, and Tillmann Hein HA. Factors associated with development of severely increased cardiac output following orthotopic liver transplantation. The Joint Meeting of the ILTS, ELTA and LICAGE, Berlin, Germany, July 2001. (poster presentation)
164. Molmenti EP, Ramsay MA, Ramsay KJ, Lynch K, Tillmann Hein HA, Goldstein RM, Levy MF, Ausloos KA, Fasola CG, Marubashi S, Sanchez EQ, Gogel B, Escobar J, East C, and **Klintmalm GB**. Successful treatment of portopulmonary hypertension: short-term results and long-term survival. The Joint Meeting of the ILTS, ELTA and LICAGE, Berlin, Germany, July 2001. (poster presentation)
165. Kim WR, Wiesner RH, Kamath PS, Kremers WK, Rosen CB, Dickson ER, Weinstein JS, and **Klintmalm GB**. Prediction of liver transplant outcome using the MELD scale. The Joint Meeting of the ILTS, ELTA and LICAGE, Berlin, Germany, July 2001. (poster presentation)
166. Fasola CG, Netto GJ, Jennings LW, Molmenti EP, Gonwa TA, Goldstein RM, Levy MF, and **Klintmalm GB**. Hepatitis C recurrence (HCR) in liver transplant recipients (OLT): patterns (PR) and early predictors (EP) of graft fibrosis (GF). The Joint Meeting of the ILTS, ELTA and LICAGE, Berlin, Germany, July 2001. (poster presentation)
167. Fasola CG, Netto GJ, Christensen LL, Molmenti EP, Gonwa TA, Goldstein RM, Levy MF, and **Klintmalm GB**. Natural history of recurrence of hepatitis C (HEP CR) in liver

- transplant recipients (OLT) under mycophenolate mofetil (MMF) immunosuppression (IS). The Joint Meeting of the ILTS, ELTA and LICAGE, Berlin, Germany, July 2001. (poster presentation)
168. Fasola CG, Netto GJ, Christensen LL, Molmenti EP, Gonwa TA, Goldstein RM, Levy MF, and **Klintmalm GB**. Optimal dosing of mycophenolate mofetil (MMF) is necessary to delay hepatitis C recurrence (HEP CR) in liver transplant recipients (OLT). The Joint Meeting of the ILTS, ELTA and LICAGE, Berlin, Germany, July 2001. (poster presentation)
  169. Molmenti EP, Roden J, Squires R, Molmenti H, Fasola CG, Nagata D, Lopez MJ, D'Amico L, Prestidge C, Marubashi S, Sanchez EQ, Gogel B, Goldstein RM, Levy MF, Andrews W, Andersen J, and **Klintmalm GB**. Liver Transplantation for cholestasis associated with cystic fibrosis in the pediatric population. The Joint Meeting of the ILTS, ELTA and LICAGE, Berlin, Germany, July 2001. (poster presentation)
  170. Molmenti EP, Roden J, Squires R, Molmenti H, Fasola CG, Nagata D, D'Amico L, Lopez MJ, Tomlinson G, Ratliff A, Wilkinson K, Marubashi S, Sanchez EQ, Gogel BM, Goldstein RM, Levy MF, Andrews W, Andersen J, and **Klintmalm GB**. Treatment of unresectable hepatoblastoma with liver transplantation in the pediatric population. The Joint Meeting of the ILTS, ELTA and LICAGE, Berlin, Germany, July 2001. (oral presentation)
  171. Fasola CG, Christensen LL, Buxton CM, Molmenti EP, Gonwa TA, Goldstein RM, Levy MF, and **Klintmalm GB**. Importance of the timely use of sirolimus (SRL) pharmacokinetics (PKT) to further decrease the incidence of acute cellular rejection (ACR) in liver transplant recipients (OLT). The Joint Meeting of the ILTS, ELTA and LICAGE, Berlin, Germany, July 2001. (oral presentation)
  172. Molmenti EP, Smith DM, Jennings LW, Fasola CG, Marubashi S, Sanchez EQ, Gogel BM, Goldstein RG, Levy MF, **Klintmalm GB**. Significance of positive T and/or B cell cytotoxic crossmatch in whole graft liver transplantation. The Joint Meeting of the ILTS, ELTA and LICAGE, Berlin, Germany, July 2001. (oral presentation)
  173. First MR, Peters T, West J, Aeder M, Danovitch G, **Klintmalm G**, Gorman K, Gordon J and Spinola K. Differences in patient and healthcare provider perceptions of immunosuppression-induced physical side effects. American Transplant Congress, Washington, DC, April/May 2002. (poster presentation)
  174. Onaca NN, Levy MF, Thomas MJ, Sanchez EQ, Brooks BK, Chinnakotla S, Fasola CG, Weinstein JS, Murray N, Goldstein RM, and **Klintmalm GB**: The pretransplant MELD score as a predictor of outcome after liver transplantation for chronic hepatitis C. American Transplant Congress, Washington, D.C., April/May 2002 (oral presentation)
  175. Onaca N, Netto GJ, Morkowski J, Katabi N, Levy MF, Thomas MJ, Sanchez EQ, Weinstein JS, Murray N, Goldstein RM, and **Klintmalm GB**: Influence of steatosis in

- the liver allograft in the incidence of recurrent hepatitis C after liver transplantation. American Transplant Congress, Washington, D.C., April/May 2002 (poster presentation)
176. Sanchez EQ, Gonwa TA, Levy MF, Fasola CG, Goldstein RM, Chinnakotla S, Melton LB, Hays SR, Onaca N, Thomas M, and **Klintmalm GB**: Perioperative predictors of renal replacement therapy after orthotopic liver transplantation: Implications for MELD scoring. American Transplant Congress, Washington, D.C., April/May 2002 (poster presentation)
  177. Fasola CG, Netto GJ, Christense LL, Weinstein J, Murray N, Thomas M, Onaca N, Sanchez EQ, Chinnakotla S, Levy MF, Goldstein RM, and **Klintmalm GB**: Evolution of hepatitis C recurrence post liver transplantation in the last ten years: More aggressive recurrence in recent years? American Transplant Congress, Washington, D.C., April/May 2002 (oral presentation)
  178. Fasola CG, Netto G, Christensen L, Rakela J, Thomas M, Onaca N, Sanchez EQ, Chinnakotla S, Levy MF, Goldstein RM, and **Klintmalm GB**: The importance of HCV-RNA level determinations in early detection of aggressive hepatitis C recurrence post liver transplantation: The third month gap. American Transplant Congress, Washington, D.C., April/May 2002 (oral presentation)
  179. Fasola CG, Netto G, Christensen LL, Rakela J, Thomas M, Onaca N, Sanchez EQ, Chinnakotla S, Levy MF, Goldstein RM, and **Klintmalm GB**: Lower incidences of early hepatitis C-RNA levels and HCV recurrence post liver transplantation in patients induced with mycophenolate mofetil: A high-dose benefit. American Transplant Congress, Washington, D.C., April/May 2002 (poster presentation)
  180. Jones CC, Knorpp HC, Ramsay MA, Emmett M, Tillmann-Hein HA, and **Klintmalm GB**: Fenoldopam infusion may provide renal protection during orthotopic liver transplantation. International Liver Transplantation Society 2002 Annual Meeting, Chicago, IL, June 13-15, 2002 (poster presentation)
  181. Wiesner R, **Klintmalm G**, McDiarmid S, Neuhaus, and the Rapamune Liver Transplant Study Group. Sirolimus decreases acute rejection rates in de novo orthotopic liver transplant recipients. International Liver Transplantation Society 2002 Annual Meeting, Chicago, IL, June 13-15, 2002. (oral presentation)
  182. **Klintmalm GB** and Molmenti EP. Hepatocellular carcinoma in 790 patients. A report from the international tumor registry. International Liver Transplantation Society 2002 Annual Meeting, Chicago, IL, June 13-15, 2002 (oral presentation)
  183. Sanchez EQ, Gonwa TA, Levy MF, Fasola CG, Goldstein RM, Chinnakotla S, Melton LB, Hays SR, Onaca N, Thomas M, and **Klintmalm GB**. Perioperative predictors of renal replacement therapy after orthotopic liver transplantation: implications for meld



scoring. International Liver Transplantation Society 2002 Annual Meeting, Chicago, IL, June 13-15, 2002 (poster presentation)

184. Fasola CG, Netto G, Christensen LL, Rakela J, Thomas M, Onaca N, Sanchez EQ, Chinnakotla S, Levy MF, Goldstein RM, and **Klntmalm GB**. Lower incidences of early hepatitis C (HCV) - RNA levels and HCV recurrence (R) post liver transplantation (OLT) in patients induced with mycophenolate mofetil (MMF): a high-dose benefit. International Liver Transplantation Society 2002 Annual Meeting, Chicago, IL, June 13-15, 2002 (poster presentation)
185. Fasola CG, Netto G, Christensen L, Rakela J, Thomas M, Onaca N, Sanchez E, Chinnakotla S, Levy M, Goldstein R, and **Klntmalm G**. Evolution of hepatitis C recurrence (HCVR) post liver transplantation (OLT) in the last ten years: more aggressive recurrence in recent years? International Liver Transplantation Society 2002 Annual Meeting, Chicago, IL, June 13-15, 2002 (poster presentation)
186. Fasola CG, Netto G, Christensen LL, Rakela J, Thomas M, Onaca N, Sanchez EQ, Chinnakotla S, Levy MF, Goldstein RM, and **Klntmalm GB**. The importance of HCV-RNA level determinations in early detection of aggressive hepatitis C recurrence (HCVR) post liver transplantation (OLT): the third month gap. International Liver Transplantation Society 2002 Annual Meeting, Chicago, IL, June 13-15, 2002 (poster presentation)
187. Sullivan SO, Jennings LW, Goldstein RM, and **Klntmalm GB**. The international tumor registry going web. International Liver Transplantation Society 2002 Annual Meeting, Chicago, IL, June 13-15, 2002 (poster presentation)
188. Molmenti EP, Molmenti H, Weinstein J, Fasola CG, Elliott EE, Orr D, Blum J, Savino D, Goldstein RM, Levy MF, and **Klntmalm GB**. Association between liver transplantation, breast cancer, and ovarian cancer. International Liver Transplantation Society 2002 Annual Meeting, Chicago, IL, June 13-15, 2002 (poster presentation)
189. Onaca NN, Levy MF, Thomas MJ, Sanchez EQ, Brooks BB, Chinnakotla S, Fasola CG, Weinstein JW, Murray NG, Goldstein RM, and **Klntmalm GB**. A correlation between pre-transplant meld score and mortality in the first two years posttransplant. International Liver Transplantation Society 2002 Annual Meeting, Chicago, IL, June 13-15, 2002 (oral presentation)
190. **Klntmalm GB**. Impact of age on donor selection and recipient outcome. XIX International Congress of The Transplantation Society, Miami, FL, August 25-30, 2002 (oral presentation)

191. **Klntmalm GB** and Molmenti EP. Hepatocellular carcinoma in 790 patients. A report from the international tumor registry. XIX International Congress of The Transplantation Society, Miami, FL, August 25-30, 2002 (oral presentation)
192. Fasola CG, Netto G, Christensen L, Rakela J, Thomas M, Onaca N, Sanchez E, Chinnakotla S, Levy M, Goldstein R, and **Klntmalm G**. Lower incidences of early hepatitis C (HCV)-RNA levels and HCV recurrence (R) post liver transplantation (OLT) in patients induced with mycophenolate mofetil (MMF): a high-dose benefit. XIX International Congress of The Transplantation Society, Miami, FL, August 25-30, 2002 (oral presentation)
193. Fasola CG, Netto GJ, Christensen LL, Rakela J, Thomas MJ, Onaca N, Sanchez EQ, Chinnakotla S, Levy MF, Goldstein RM, and **Klntmalm GB**. The importance of HCV-RNA level determinations in early detection of aggressive hepatitis C recurrence (HCVR) post liver transplantation (OLT): the third month gap. XIX International Congress of The Transplantation Society, Miami, FL, August 25-30, 2002 (poster presentation)
194. Onaca N, Levy M, Orr D, Sanchez E, Chinnakotla S, Fasola C, Thomas M, Ueno T, Goldstein R, and **Klntmalm GB**. A single center experience with liver transplantation for rare hepatic tumors. ASTS Winter Symposium, Miami, FL, Jan. 24-26, 2003 (poster presentation)
195. Onaca N, Levy MF, Orr, DW, Sanchez EQ, Fasola CG, Chinnakotla S, Thomas MJ, Murray NG, Weinstein JS, Goldstein RM and **Klntmalm GB**. Adriamycin monotherapy can induce hepatotoxicity after liver transplantation for HCC. ASTS Winter Symposium, Miami, FL, Jan. 24-26, 2003 (poster presentation)
196. Goldstein R...and **Klntmalm GB**. Efficacy of radio frequency ablation as a bridge to transplantation in cirrhotics with hepatomas in 27 patients with explant pathology. ASTS Winter Symposium, Miami, FL, Jan. 24-26, 2003 (poster presentation)
197. Netto G...and **Klntmalm GB**. Evaluation of the effectiveness of radio frequency ablation of hepatocellular carcinoma (HCC) prior to liver transplantation. ASTS Winter Symposium, Miami, FL, Jan. 24-26, 2003 (poster presentation)
198. Onaca N, Levy MF, Thomas MJ, Ueno T, Raofi V, Sanchez EQ, Chinnakotla S, Randall, HB, Dawson S, Saracino G, Jennings LW, Goldstein RM, and **Klntmalm GB**. Liver disease etiology and pretransplant MELD scores relationship with mortality in the first year posttransplant. American Transplant Congress, Washington, DC, May 30-June 4, 2003 (poster presentation)
199. Sanchez EQ, Onaca N, Thomas M, Ueno T, Raofi V, Goldstein RM, Levy MF, Chinnakotla S, Dawson S, Randall H, Saracino G, and **Klntmalm GB**. Rapamune

conversion in long-term liver transplant patients is effective in recovering renal function. American Transplant Congress, Washington, DC, May 30-June 4, 2003 (oral presentation)

200. Sanchez EQ, Onaca N, Thomas M, Ueno T, Raofi V, Goldstein RM, Levy MF, Chinnakotla S, Dawson Sh, Randall H, Saracino G, and **Klntmalm GB**. Rapamycin use in liver transplantation: it is well tolerated. American Transplant Congress, Washington, DC, May 30-June 4, 2003 (poster presentation)
201. Chinnakotla S, Goldstein R, Onaca N, Ueno T, Raofi V, Thomas M, Jennings L, Sanchez E, Dawson Sh, Randall H, Levy M, **Klntmalm G**. Causes of mortality in 344 adult liver transplant (OLT) recipinets who survived for more than 10 years. American Transplant Congress, Washington, DC, May 30-June 4, 2003 (poster presentation)
202. Chinnakotla, Levy M, Jennings L, Cowling T, Onaca N, Ueno T, Raofi V, Thomas M, Sanchez S, Dawson Sh, Randall H, Goldstein, and **Klntmalm G**. What is the quality of life improvement (QOL) 10 years after liver transplantation (OLT). American Transplant Congress, Washington, DC, May 30-June 4, 2003 (poster presentation)
203. Fasola CG, Netto GJ, Thomas M, Onaca N, Sanchez EQ, Chinnakotla S, Goldstein RM, Levy MF, Davis GL, and **Klntmalm GB**. Corticosteroid (CS) maintenance and its impact in the progression of hepatitis C histologic recurrence (HHCVR) in liver transplant recipients (OLT) at one and two years (Y) post transplant (tx): a dose-dependent benefit? American Transplant Congress, Washington, DC, May 30-June 4, 2003 (oral presentation)
204. Onaca N, Levy MF, Fasola CG, Thomas MJ, Ueno T, Raofi V, Sanchez EQ, Chinnakotla S, Randall HB, Dawson S, Saracino G, Jennings LW, Goldstein RM, and **Klntmalm GB**. Liver disease etiology and pretransplant MELD scores: a relationship with mortality in the first year posttransplant. Ninth Annual International Liver Transplant Society Congress, Barcelona, Spain, June 18-21, 2003 (oral presentation)
205. Onaca N, Levy MF, Fasola CG, Thomas MJ, Ueno T, Raofi V, Sanchez EQ, Chinnakotla S, Dawson S, Randall HB, Goldstein RM, and **Klntmalm GB**. Primary liver transplantation and retransplantation: an outcome comparison based on the pretransplant MELD score. Ninth Annual International Liver Transplant Society Congress, Barcelona, Spain, June 18-21, 2003 (poster presentation)
206. Thomas MJ, Levy MF, Goldstein R, Sanchez EQ, Chinnakotla S, Onaca N, and **Klntmalm GB**. Health-related quality of Life after liver transplantation: effects of post-transplantation diabetes. Ninth Annual International Liver Transplant Society Congress, Barcelona, Spain, June 18-21, 2003 (oral presentation)

207. Blankenship J, Husain S, Heitman J, and the cryptococcal collaborative transplant study group. Temperature sensitive phenotypic characteristics and resistance to calcineurin-inhibitors (CsA or FK) in *C. neoformans*: correlation with tissue tropism in transplant recipients. Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 14-17, 2003 (poster presentation)
208. Levy M, Argaw T, Wilson C, Brooks J, Chapman L, Logan J, and **Klintmalm GB**. Lack of PoErv detection in health care workers exposed to transgenic porcine liver extracorporeal support experiments. VII International Xenotransplantation Congress 2003, Glasgow, Scotland, September 30 – October 4, 2003 (poster presentation)
209. Barri YM, Rice K, Melton LB, Hays S, Saracino G, and **Klintmalm G**. The impact of early versus late ARF post-liver transplantation on renal and patient outcome: a controlled comparative study. American Society of Nephrologists 36<sup>th</sup> Annual Meeting & Scientific Exposition, San Diego, CA, November 2003 (poster presentation)
210. Barri YM, Melton LB, Rice K, Saracino G, Zayas C, Hays S, and **Klintmalm G**. The impact of acute renal failure following orthotopic-liver transplantation on long-term outcome: a controlled study. American Society of Nephrologists 36<sup>th</sup> Annual Meeting & Scientific Exposition, San Diego, CA, November 2003 (poster presentation)
211. Barri YM, Hays S, Melton LB, Rice K, Zayas C, Saracino G, and **Klintmalm G**. Early versus late ARF post-liver transplantation: different spectrum and etiology. American Society of Nephrologists 36<sup>th</sup> Annual Meeting & Scientific Exposition, San Diego, CA, November 2003 (poster presentation)
212. Sanchez E, Ueno T, Martin A, Onaca N, Chinnakotla S, Randall H, Dawson S, Goldstein R, Levy M, and **Klintmalm G**. T-Tube free biliary anastomosis in liver transplantation is safe. American Society of Transplant Surgeons 4<sup>th</sup> Annual State of the Art Winter Symposium, Scottsdale, AZ, January 2004 (poster presentation)
213. Onaca N, Sanchez EQ, Chinnakotla S, Martin PA, Ueno T, Randall H, Dawson S, Levy MF, Goldstein RM, and **Klintmalm GB**. Cadaveric orthotopic auxiliary split liver transplantation and kidney transplantation: a therapeutic alternative for renal failure from primary hyperoxaluria. American Society of Transplant Surgeons 4<sup>th</sup> Annual State of the Art Winter Symposium, Scottsdale, AZ, January 2004 (poster presentation)
214. Sanchez EQ, Gonwa TA, Martin AP, Ueno T, Onaca N, Randall HB, Dawson S, Chinnakotla S, Levy MF, Goldstein RM, Mai ML, Hays SR, Melton LB, and **Klintmalm GB**. Predictive model for renal replacement therapy (RRT) following orthotopic liver transplantation (OLT) based on MELD, Creatinine, BUN, ICU length of stay. American Transplant Congress, Boston, MA, May 14-19, 2004 (poster presentation)
215. Grazi GL, Levy G, Wu Y, Marotta P, Boillot O, San Juan F, Samuel D, Muehlbacher F, and Fillamil F, on behalf of LIS2T Study Group. 12-Month follow-up data from a randomized, multicentre, prospective study of cyclosporine C2 monitoring versus

tacrolimus in liver transplantation (LIS2T). American Transplant Congress, Boston, MA, May 14-19, 2004 (oral presentation)

216. Cibrik DM, Jensik S, Meier-Kriesche H-U, Bresnahan B, and Lieberman B for the Myfortic-US01 Renal Transplant Study Group. Enteric-coated mycophenolate sodium in combination with optimized neoral dosing, basiliximab, and steroids results in good efficacy and renal function in renal transplant recipients in the first 6 months. American Transplant Congress, Boston, MA, May 14-19, 2004 (poster presentation)
217. Florman S for the Tacrolimus Modified Release Liver Conversion Study Group. Conversion of stable liver transplant recipients from a twice daily Prograf based regimen to a once daily modified release tacrolimus based regimen. American Transplant Congress, Boston, MA, May 14-19, 2004 (oral presentation)
218. Alloway R for the Tacrolimus Modified Release Kidney Conversion Study Group. Conversion of stable kidney transplant recipients from a twice daily Prograf based regimen to a once daily modified release tacrolimus based regimen. American Transplant Congress, Boston, MA, May 14-19, 2004 (poster presentation)
219. Fasola CG, Netto GJ, Sanchez EQ, Chinnakotla S, Levy MF, Goldstein RM, and **Klintermalm GB**. Hepatitis C recurrence (HCVR) in liver transplant recipients (OLT) under bycophenolate mofetil (MMF) immunosuppression (IS): a long-term follow up. American Transplant Congress, Boston, MA, May 14-19, 2004 (poster presentation)
220. Fasola CG, **Klintermalm GB**, and Hepatitis C Three Study Group. Multicenter randomized hepatitis C (HCV) three trial post liver transplantation (OLT): a preliminary report. American Transplant Congress, Boston, MA, May 14-19, 2004 (oral presentation)
221. Martin AP, Goldstein RG, Netto G, Katabi N, Ueno T, Onaca N, Sanchez EQ, Chinnakotla S, Dawson S, Randall H, Levy MF, and **Klintermalm GB**. Radiofrequency ablation of liver tumors before liver transplantation – a clinical and histological examination. American Transplant Congress, Boston, MA, May 14-19, 2004 (oral presentation)
222. Ueno T, Jones G, Martin A, Sanchez E, Chinnakotla S, Dawson S, Randall H, Onaca N, Goldstein R, Levy M, and **Klintermalm G**. Artery stenting for hepatic artery stenosis in liver transplantation. American Transplant Congress, Boston, MA, May 14-19, 2004 (poster presentation)
223. Cowling T, Jennings LW, Ueno T, Martin P, Sanchez EQ, Chinnakotla S, Randall H, Dawson S, Goldstein RM, **Klintermalm GB**, and Levy MF. Model for end-stage liver disease scores do not predict liver transplantation waiting list morbidity. American Transplant Congress, Boston, MA, May 14-19, 2004 (poster presentation)

224. Onaca N, Naziruddin B, Harris M, Hornaday N, Peterson T, Sanchez E, Chinnakotla S, Dawson S, Randall H, Goldstein R, **Klntmalm G**, and Levy M. Analysis of factors leading to suboptimal use of deceased donor pancreata in the era of ilet cell transplantation. XX International Congress of the Transplantation Society, Vienna, Austria, September 5-10, 2004 (poster presentation)
225. Sanchez E, Fasola C, Onaca N, Ueno T, Martin A, Chinnakotla S, Randall H, Dawson S, Levy M, Goldstein R, Saracino G, and **Klntmalm G**. Donor age over 50 is not associated with increased hepatitis C recurrence after liver transplant: a comparison of two eras in a large single institution experience. XX International Congress of the Transplantation Society, Vienna, Austria, September 5-10, 2004 (poster presentation)
226. Martin A, Goldstein R, Katabi N, Netto G, Altrabulsi B, Ikegami T, Ueno T, Onaca N, Sanchez E, **Klntmalm G**, Chinnakotla S, Dawson S, Randall H, and Levy M. Radiofrequency thermal ablation of liver tumors before liver transplant – a clinical and histological examination. XX International Congress of the Transplantation Society, Vienna, Austria, September 5-10, 2004 (oral presentation)
227. Fasola CG, Heffron TG, Sher L, Douglas DD, Brown R, Ham J, Tepterman L, Hanaway M, Eckhoff D, Millis M, Roberts J, Charlton M, Baliga P, Pruett T, Koneru B, Pomfret E, Abecassis M, and **Klntmalm GB**. Multicenter Randomized Hepatitis C (HCV) Three Trial Post Liver Transplantation (OLT): a 90-day report. AASLD 59<sup>th</sup> Annual The Liver Meeting, Boston, MA, Oct. 29 – Nov. 2, 2004 (oral presentation)
228. Cibrik D, Jensik S, Bresnahan B, Whelchel J, and **Klntmalm G** for the ERL2405-US01 Study Group. Safety and efficacy of Myfortic in combination with Simulect and neoral in de novo renal transplant high-risk recipients. ASN 37<sup>th</sup> Annual Meeting and Scientific Exposition 2005 (poster presentation)
229. Sanchez ES, Martin AP, Ikegami T, Uemura T, Narasimhan G, Chinnakotla S, Randall HB, McKenna GJ, Levy MF, Goldstein RM, Saracino G, and **Klntmalm GB**. Comparison of immunosuppression regimen and advanced donor age effect in hepatitis c patients in two chronologic eras. 2005 American Transplant Congress, Seattle, Washington, May 21-25, 2005 (poster presentation)
230. Samuel D, Levy G, Villamil F, Sanjuan F, Grazi G, Muehlbacher F, Otto G, Jones R, Tanaka K, and **Klntmalm G** on behalf of the LIS2T Study Group. Does the choice of calcineurin inhibitor influence the time to histological recurrence of hepatitis c post-transplant? 2005 American Transplant Congress, Seattle, Washington, May 21-25, 2005 (poster presentation)

231. Washburn KK, Teperman LW, Heffron TG, Douglas DD, Katz E, Fasola CG, and **Klintmalm GB** for Hepatitis C Three Study Group. Pharmacokinetics and pharmacodynamics of 3-dose Daclizumab in liver transplant recipients with hepatitis c. 2005 American Transplant Congress, Seattle, Washington, May 21-25, 2005 (poster presentation)
232. Cibrik D, Jensik S, Bresnahan B, Whelchel J, and **Klintmalm G** for the ERL2405-US01 Study Group. Safety and efficacy of EC-MPS in combination with Simulect and neoral in de novo renal transplant high-risk recipients. 2005 American Transplant Congress, Seattle, Washington, May 21-25, 2005 (poster presentation)
233. Buell JF, Koffron AJ, Rudich SM, Koehler A, Thomas MJ, Abecassis, **Klintmalm G**, and Goldstein R. Histologic response to radiogrequency ablation in transplant recipients. 2005 American Transplant Congress, Seattle, Washington, May 21-25, 2005 (poster presentation)
234. Onaca N, Davis GL, Jennings LW, Goldstein RM, and **Klintmalm GB**. Improvement of results of liver transplantation for hepatocellular carcinoma. 2005 American Transplant Congress, Seattle, Washington, May 21-25, 2005 (poster presentation)
235. Washburn K, Harper A, **Klintmalm G**, Goss J, and Half G. Regional sharing for status 1 candidates: reduction in waitlist mortality. 2005 American Transplant Congress, Seattle, Washington, May 21-25, 2005 (oral presentation)
236. Fasola CG, Heffron TG, Sher L, Douglas DD, Brown R, Ham J, Teperman L, Roberts J, Charlton M, Baliga P, Pruett T, Koneru B, Pomfret E, Abecassis M, and **Klintmalm GB**. Multicenter randomized hepatitis c (HCV) three trial post liver transplantation (OLT): A one-year follow up report. 2005 American Transplant Congress, Seattle, Washington, May 21-25, 2005 (oral presentation)
237. Uemura T, Sanchez EQ, Martin AP, Ikegami T, Narasimhan G, McKenna GJ, Chinnakotla S, Dawson III S, Randall HB, Levy MF, Goldstein RM, and **Klintmalm GB**. Clinical characteristics of primary nonfunction in liver transplantation. 2005 American Transplant Congress, Seattle, Washington, May 21-25, 2005 (poster presentation)
238. Smith DM, Domiati-Saad R, Netto G, Agura ED, Chinnakotla S, and **Klintmalm GB**. The development of graft versus host disease following liver transplantation: patterns of lymphocyte chimerism. 2005 American Transplant Congress, Seattle, Washington, May 21-25, 2005 (poster presentation)
239. McKenna GJ, Sanchez EQ, Chinnakotla S, Randall HB, Dawson III S, Jennings LW, Martin AP, Ikegami T, Uemura T, Narasimhan G, Levy MF, Goldstein RM, and

- Klintmalm GB.** Incidence and outcome of acute cellular rejection without liver enzyme elevation. 2005 American Transplant Congress, Seattle, Washington, May 21-25, 2005 (oral presentation)
240. Levy MF, Jennings LW, Sanchez EQ, Chinnakotla S, Dawson III S, Randall H, McKenna G, Goldstein RM, and **Klintmalm GB.** Deceased donor vessels as hepatic artery conduits. 2005 American Transplant Congress, Seattle, Washington, May 21-25, 2005 (poster presentation)
241. Biggins S, Kim WR, Saab S, Balan V, Schiano T, Benson J, Therneau T, Kremers W, Wiesner R, Kamath P, Terrault N, and **Klintmalm G.** MELDS: incorporation of the serum sodium concentration into MELD: and evidence-based proposal. 2005 American Transplant Congress, Seattle, Washington, May 21-25, 2005 (oral presentation)
242. **Klintmalm GB.** The outcome of neoadjuvant therapy for hepatocellular carcinoma in liver transplantation. A registry report. 2005 American Transplant Congress, Seattle, Washington, May 21-25, 2005 (oral presentation)
243. Gallegos-Orozco JF, Vargas HE, Eckhoff DE, and Hepatitis C III Study Group. Hepatitis C hypervariable region 1 quasispecies behavior after liver transplantation: a preliminary report from the hepatitis C III trial. 2005 American Transplant Congress, Seattle, Washington, May 21-25, 2005 (oral presentation)
244. Onaca N, Goldstein RM, Jennings LW, Davis GL, and **Klintmalm GB.** Indications for liver transplantation for hepatocellular carcinoma could be expanded. ILTS 11<sup>th</sup> Annual International Congress, Los Angeles, CA, July 20-23, 2005 (oral presentation)
245. Onaca N, Davis GL, Jennings LW, Goldstein RM, and **Klintmalm GB.** Improvement of results of liver transplantation for hepatocellular carcinoma. ILTS 11<sup>th</sup> Annual International Congress, Los Angeles, CA, July 20-23, 2005 (poster presentation)
246. Chinnakotla S, Feller J, Narasimhan G, Uemura T, Ikegami T, Martin AP, Jennings LW, Bursac N, Sanchez EQ, Randall HB, Dawson S, III, Levy MF, Goldstein RM, and **Klintmalm GB.** Rapamycin, Cyclosporine-based immunosuppression for patients with hepatocellular carcinoma (HCC). ILTS 11<sup>th</sup> Annual International Congress, Los Angeles, CA, July 20-23, 2005 (oral presentation)
247. Uemura T, Sanchez EQ, Martin AP, Ikegami T, Narasimhan G, Chinnakotla S, Dawson S, III, McKenna GJ, Randall HB, Goldstein RM, Levy MF, and **Klintmalm GB.** Successful combined liver and kidney transplant for COACH syndrome and five-year follow-up. ILTS 11<sup>th</sup> Annual International Congress, Los Angeles, CA, July 20-23, 2005 (poster presentation)
248. Fasola C, Heffron T, Sher L, Douglas D, Brown R, Ham J, Teperman L, Eckhoff D, Washburn K, Millis M, Roberts J, Charlton M, Baliga P, Pruett T, Baliga B, Pomfret E,



- Abecassis M, and **Klintmalm G**. Multicenter randomized hepatitis C (HCV) three trial post liver transplantation (OLT): a one-year follow up report. ILTS 11<sup>th</sup> Annual International Congress, Los Angeles, CA, July 20-23, 2005 (oral presentation)
249. Washburn K, Teperman L, Heffron T, Douglas D, Katz E, Fasola CG, and **Klintmalm G**. Pharmacokinetics and pharmacodynamics of 3-dose Daclizumab in liver transplant recipients with hepatitis C. ILTS 11<sup>th</sup> Annual International Congress, Los Angeles, CA, July 20-23, 2005 (oral presentation)
250. Fasola C, Heffron T, Sher L, Douglas D, Brown R, Ham J, Teperman L, Eckhoff D, Washburn K, Millis M, Roberts J, Charlton M, Baliga P, Pruett T, Baliga B, Pomfret E, Abecassis M, and **Klintmalm G**. Multicenter randomized hepatitis C (HCV) three trial post liver transplantation (OLT): a one-year follow up report. AASLD The Liver Meeting, San Francisco, CA, Nov. 11-15, 2005 (oral presentation)
251. Washburn K, Teperman L, Heffron T, Douglas D, Katz E, Fasola CG, and **Klintmalm G**. Pharmacokinetics and pharmacodynamics of 3-dose Daclizumab in liver transplant recipients with hepatitis C. AASLD The Liver Meeting, San Francisco, CA, Nov. 11-15, 2005 (poster presentation)
252. Benson J, Kim WR, Biggins S, Therneau T, Kremers W, Gores G, Rosen C, and **Klintmalm G**. Outcome of liver transplantation in patients with hyponatremia. AASLD The Liver Meeting, San Francisco, CA, Nov. 11-15, 2005 (poster presentation).
253. Ikegami T, Sanchez EQ, Martin AP, Uemura T, Narasimhan G, Chinnakotla S, Dawson S, McKenna GJ, Randall HB, Goldstein RG, Levy MF, and **Klintmalm GB**. The clinical impact of preservation injury on outcome after liver transplantation. AASLD The Liver Meeting, San Francisco, CA, Nov. 11-15, 2005 (poster presentation)
254. Chinnakotla S, Smith DM, Domiati-Saad R, Agura ED, Watkins DL, Netto GJ, Uemura T, Narasimhan G, Masannat O, McKenna GJ, Randall HB, Sanchez EQ, Levy MF, Goldstein RG, and **Klintmalm GB**. Acute graft versus host disease after liver transplantation: role withdrawal of immunosuppression in therapeutic management. World Transplant Congress, Boston, MA, July 22-26, 2006 (oral presentation)
255. Barri YM, Jennings LJ, Melton LB, **Klintmalm G**, and Levy M. Donor CVA is more predictive of graft survival compared to other variables in expanded criteria donors. World Transplant Congress, Boston, MA, July 22-26, 2006 (oral presentation)
256. Fasola CG, Hepatitis C Three Group, and **Klintmalm GB**. Multicenter randomized hepatitis C (HCV) - three trial post liver transplantation (OLT): two-year interim report. World Transplant Congress, Boston, MA, July 22-26, 2006 (oral presentation)
257. Chaussabel D, Glaser C, Monnet L, Shen J, Lanier A, Johnson D, Randall H, Ramilo O, Pascual V, Fay J, **Klintmalm G**, Banchereau J, and Palucka AK. Blood leukocytes from liver transplant recipients and patients with metastatic melanoma display a

common transcriptional signature of immunosuppression. World Transplant Congress, Boston, MA, July 22-26, 2006 (poster presentation)

258. McKenna GJ, Sanchez EQ, Randall HB, Chinnakotla S, Uemura T, Narasimhan G, Masannat O, Dempster J, Derrick HC, Levy MF, **Klintmalm GB**, and Goldstein RG. Impact of liver transplant for hepatocellular carcinoma in the era of radiofrequency thermal ablation. World Transplant Congress, Boston, MA, July 22-26, 2006 (oral presentation)
259. Chinnakotla S, Goldstein RM, Orr D, Davis GL, Narasimhan G, Uemura T, Masannat O, Jennings LW, McKenna GJ, Randall HB, Sanchez EQ, Levy MF, and **Klintmalm GB**. Pattern of recurrence of hepatocellular carcinoma after liver transplantation. World Transplant Congress, Boston, MA, July 22-26, 2006 (oral presentation)
260. Chinnakotla S, Ashfaq M, Davis GL, Narasimhan G, Uemura T, Masannat O, Sanchez EQ, Randall HB, McKenna GJ, Goldstein RM, Levy MF, Ramsay M, and **Klintmalm GB**. Liver transplantation in patients with severe portopulmonary hypertension. World Transplant Congress, Boston, MA, July 22-26, 2006 (oral presentation)
261. Barri YM, Sanchez EQ, Jennings L, Melton LB, Levy M, and **Klintmalm G**. Acute renal failure (ARF) requiring renal replacement therapy (RRT) post-liver transplantation: a controlled study. World Transplant Congress, Boston, MA, July 22-26, 2006 (poster presentation)
262. Barri YM, Sanchez E, Melton LB, Jennings L, Levy M, and **Klintmalm G**. How can we define clinically relevant acute renal failure post-liver transplantation? World Transplant Congress, Boston, MA, July 22-26, 2006 (poster presentation)
263. Barri YM, Sanchez EQ, Jennings L, Melton LB, Levy M, and **Klintmalm G**. ARF is associated with higher incidence of CKD, ESRD, and reduced graft and patient survival post-liver transplant. World Transplant Congress, Boston, MA, July 22-26, 2006 (poster presentation)
264. Steinberg S, Jain A, Campbell P, **Klintmalm GB**, Jevnikar A, Aspeslet LJ, Foster RT, Freitag DG, Huizinga RB, Kneteman N, and Yatscoff RW. ISA247: A novel calcineurin inhibitor - high efficacy and promising safety profiles. World Transplant Congress, Boston, MA, July 22-26, 2006 (poster presentation)
265. Brielmaier BD, Chinnakotla S, Franklin MT, Uemura T, Narasimhan G, Masannat O, Sloan LM, Sutker WL, McKenna GJ, Randall HB, Sanchez EQ, Levy MF, Goldstein RM, and **Klintmalm GB**. Invasive fungal infections following liver transplantation: analysis of 2656 patients transplanted at a single center. World Transplant Congress, Boston, MA, July 22-26, 2006 (oral presentation)

266. Brielmaier BD, Chinnakotla S, Franklin MT, Uemura T, Narasimhan G, Masannat O, Sloan LM, Sutker WL, McKenna GJ, Randall HB, Sanchez EQ, Levy MF, Goldstein RM, and **Klntmalm GB**. Fungal infection prophylaxis in liver transplant recipients: the role of low-dose amphotericin B. World Transplant Congress, Boston, MA, July 22-26, 2006 (oral presentation)
267. Chinnakotla S, Goldstein RM, Orr D, Davis GL, Narasimhan G, Uemura T, Masannat O, Jennings LW, McKenna GJ, Randall HB, Sanchez EQ, Levy MF, and Klntmalm GB. Analysis of outcomes of liver transplantation for hepatocellular carcinoma over two decades. A single center experience. World Transplant Congress, Boston, MA, July 22-26, 2006 (poster presentation)

## WHITE PAPERS AND CONSENSUS STATEMENTS

1. **Klintmalm, GB** (conference participant). A National Kidney Foundation White Paper: Drug Substitution in Transplantation published in American Journal of Kidney Diseases 33(2):389-397, February 1999.
2. **Klintmalm, GB** (conference participant at the National Conference on the Live Organ Donor, Kansas City, Missouri, June 1-2, 2000). The Authors of the Live Organ Donor Consensus Group. Consensus Statement on the Live Organ Donor published in Journal of the American Medical Association 284(22):2919-2926, December 13, 2000.

## AWARDS & CITATIONS for PUBLICATIONS

1. James H. Nakano Citation from The National Center for Infectious Diseases of the Centers for Disease Control and Prevention for an outstanding scientific paper published in 2005 to Srinivasan A, Burton EC, Kuehnert MJ, Rupprecht C, Sutker WL, Ksiazek TG, Paddock CD, Guarner J, Shieh WJ, Goldsmith C, Hanlon CA, Zoretic J, Fischbach B, Niezgoda M, El-Feky WH, Orciari L, Sanchez EQ, Likos A, **Klintmalm GB**, Cardo D, Leduc J, Chamberland ME, Jernigan DB, Zaki SR; Rabies in Transplant Recipients Investigation Team. Transmission of rabies virus from an organ donor to four transplant recipients. *N Engl J Med* 2005; 352:1103-11.